[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxAk-8DjVXEevoVA8urNEawIt-zbOl734RhWiR9YF1Ac":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":21,"truncated":22,"activeTrials":23,"phase3Count":24,"totalEnrollment":25,"activePrograms":26,"nonDrugCount":27,"topConditions":28,"upcomingReadouts":53,"phaseBuckets":64,"rows":71},"Abbott",[6,4,7,8,9,10,11,12,13,14,15,16,17,18,19,20],"Abbott Medical Devices","Abbott RDx Cardiometabolic","Abbott Diabetes Care","Abbott Nutrition","Abbott Molecular","Abbott Transfusion Medicine","Abbott Rapid Dx","Abbott Diagnostics Division","Abbott Medical Optics","Abbott Biologicals","Abbott Research Group","Abbott Products","Abbott Point of Care","Abbott Rapid Diagnostics Jena GmbH","Abbott (Ukraine)",1202,false,84,205,808938,2,852,[29,32,35,38,41,44,47,50],{"name":30,"count":31},"Heart Failure",89,{"name":33,"count":34},"Coronary Artery Disease",72,{"name":36,"count":37},"Atrial Fibrillation",35,{"name":39,"count":40},"Rheumatoid Arthritis",33,{"name":42,"count":43},"Coronary Disease",28,{"name":45,"count":46},"Bradycardia",25,{"name":48,"count":49},"Diabetes Mellitus",24,{"name":51,"count":52},"Coronary Artery Stenosis",23,[54,59],{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06952296","Study of the Effectiveness of Dydrogesterone in the Treatment of Endometriosis-related Pain","2026-06-30","Dydrogesterone",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04226547","Amplatzer Amulet LAAO vs. NOAC","2029-01","Non-Vitamin K Oral Antagonists",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,107,131,273,365,452,525,582,638,674,715,748,770,792,820,846,884,908,926,944,962,980,1005,1023,1052,1078,1096,1119,1137,1162,1180,1198,1222,1247,1265,1283,1397,1482,1521,1568,1618,1663,1716,1761,1804,1838,1864,1899,1932,1967,1989,2013,2042,2064,2095,2117,2139,2171,2203,2230,2257,2291,2313,2349,2380,2398,2416,2440,2463,2481,2504,2522,2547,2574,2592,2610,2628,2646,2670,2694,2712,2730,2748,2766,2784,2802,2820,2843,2867,2890,2908,2930,2948,2966,2984,3009,3027,3045,3063,3087,3105,3123,3141,3163,3184,3207,3229,3255,3273,3291,3317,3335,3353,3377,3395,3420,3438,3462,3480,3498,3521,3547,3565,3583,3609,3627,3650,3673,3700,3718,3744,3762,3780,3798,3821,3847,3871,3892,3915,3941,3959,3977,4000,4018,4036,4087,4142,4194,4216,4238,4272,4304,4326,4354,4386,4416,4449,4473,4491,4509,4527,4551,4569,4591,4612,4636,4654,4677,4700,4718,4736,4758,4781,4799,4823,4841,4866,4884,4906,4924,4946,4970,4988,5006,5024,5047,5065,5089,5107,5154,5202,5243,5278,5304,5340,5379,5406,5434,5463,5481,5506,5524,5545,5567,5589,5612,5630,5652,5673,5695,5717,5741,5759,5782,5800,5824,5846,5864,5886,5907,5925,5943,5964,5987,6381,6500,6550,6607,6663,6685,6721,6752,6780,6802,6827,6849,6873,6896,6918,6942,6964,6986,7008,7029,7053,7075,7098,7116,7134,7152,7175],{"intervention":58,"totalTrials":26,"cells":73},{"EARLY_PHASE1":74,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":94,"NA":96},{"trials":75,"activeCount":76},[],0,{"trials":78,"activeCount":76},[],{"trials":80,"activeCount":76},[],{"trials":82,"activeCount":76},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NCT00193674","Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage","COMPLETED",[68],"2009-07","2003-09",71,[92],"Recurrent Miscarriage",[58],{"trials":95,"activeCount":76},[],{"trials":97,"activeCount":106,"soonestReadout":57},[98],{"nctId":55,"briefTitle":56,"status":99,"phases":100,"primaryCompletion":57,"completion":57,"start":101,"enrollment":102,"conditions":103,"interventions":105},"NOT_YET_RECRUITING",[],"2025-04",250,[104],"Endometriosis",[58],1,{"intervention":63,"totalTrials":106,"cells":108},{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":117,"NA":119},{"trials":110,"activeCount":76},[],{"trials":112,"activeCount":76},[],{"trials":114,"activeCount":76},[],{"trials":116,"activeCount":76},[],{"trials":118,"activeCount":76},[],{"trials":120,"activeCount":106,"soonestReadout":62},[121],{"nctId":60,"briefTitle":61,"status":122,"phases":123,"primaryCompletion":62,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":130},"ACTIVE_NOT_RECRUITING",[70],"2031-04","2020-07-07",2650,[36,128,129],"Stroke","Bleeding",[63],{"intervention":132,"totalTrials":133,"cells":134},"paricalcitol",14,{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":192,"PHASE4":233,"NA":271},{"trials":136,"activeCount":76},[],{"trials":138,"activeCount":76},[],{"trials":140,"activeCount":76},[141,153,162,174,183],{"nctId":142,"briefTitle":143,"status":86,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":151},"NCT00990704","Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism",[67],"2010-05","2009-10",47,[149,150],"Secondary Hyperparathyroidism","Hemodialysis",[132,152],"maxacalcitol",{"nctId":154,"briefTitle":155,"status":86,"phases":156,"primaryCompletion":157,"start":158,"enrollment":46,"conditions":159,"interventions":161},"NCT00646932","Paricalcitol Injection Phase II Trial",[67],"2007-02","2005-11",[160],"Chronic Kidney Disease",[132,132,132,132],{"nctId":163,"briefTitle":164,"status":86,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"NCT00667576","Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis",[67],"2009-03","2008-04",153,[170,149],"Chronic Kidney Disease on Hemodialysis",[172,173],"Maxacalcitol","Paricalcitol",{"nctId":175,"briefTitle":176,"status":86,"phases":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT00053378","A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects",[67],"2002-01",45,[181],"Hypocalcemia",[132],{"nctId":184,"briefTitle":185,"status":86,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":191},"NCT00701805","Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)",[67],"2009-12","2008-07",107,[149,150],[173],{"trials":193,"activeCount":76},[194,203,212,218,227],{"nctId":195,"briefTitle":196,"status":86,"phases":197,"start":198,"enrollment":199,"conditions":200,"interventions":202},"NCT00048451","Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)",[68],"2002-02",68,[201],"Renal Insufficiency, Chronic",[132],{"nctId":204,"briefTitle":205,"status":86,"phases":206,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":211},"NCT01071070","Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease",[68],"2010-11","2009-11",216,[160],[132],{"nctId":213,"briefTitle":214,"status":86,"phases":215,"start":198,"enrollment":199,"conditions":216,"interventions":217},"NCT00048438","Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)",[68],[201],[132],{"nctId":219,"briefTitle":220,"status":86,"phases":221,"primaryCompletion":222,"start":178,"enrollment":223,"conditions":224,"interventions":226},"NCT00646035","A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis",[68],"2002-11",75,[225],"End Stage Renal Disease",[132],{"nctId":228,"briefTitle":229,"status":86,"phases":230,"start":198,"enrollment":199,"conditions":231,"interventions":232},"NCT00048516","Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)",[68],[201],[132],{"trials":234,"activeCount":76},[235,241,250,260],{"nctId":236,"briefTitle":237,"status":86,"phases":238,"start":178,"enrollment":43,"conditions":239,"interventions":240},"NCT00053547","Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis",[69],[149,225],[132],{"nctId":242,"briefTitle":243,"status":86,"phases":244,"primaryCompletion":245,"completion":245,"start":208,"enrollment":246,"conditions":247,"interventions":248},"NCT00977080","Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D",[69],"2011-05",272,[160,149,150],[173,249],"Cinacalcet",{"nctId":251,"briefTitle":252,"status":86,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},"NCT00537979","Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis",[69],"2010-07","2007-09",147,[149,258],"Dialysis",[173,173],{"nctId":261,"briefTitle":262,"status":263,"phases":264,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},"NCT00664430","Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects","TERMINATED",[69],"2009-06","2009-01",13,[149,258],[270,173],"Calcitriol",{"trials":272,"activeCount":76},[],{"intervention":274,"totalTrials":275,"cells":276},"Divalproex Sodium",9,{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":283,"PHASE4":353,"NA":363},{"trials":278,"activeCount":76},[],{"trials":280,"activeCount":76},[],{"trials":282,"activeCount":76},[],{"trials":284,"activeCount":76},[285,294,304,313,322,330,338,346],{"nctId":286,"briefTitle":287,"status":86,"phases":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT00060905","An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania\u002FBipolar Disorder",[68],"2003-01",370,[292],"Bipolar Disorder",[274],{"nctId":295,"briefTitle":296,"status":86,"phases":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT00195741","The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents",[68],"2003-05",300,[301],"Migraine",[303],"divalproex sodium",{"nctId":305,"briefTitle":306,"status":86,"phases":307,"start":308,"enrollment":309,"conditions":310,"interventions":312},"NCT00102713","A Study for Treatment of Partial Seizures in Children",[68],"2005-02",50,[311],"Partial Seizures",[274],{"nctId":314,"briefTitle":315,"status":86,"phases":316,"start":317,"enrollment":318,"conditions":319,"interventions":321},"NCT00195754","A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.",[68],"2004-07",114,[320],"Migraines",[303],{"nctId":323,"briefTitle":324,"status":86,"phases":325,"start":317,"enrollment":326,"conditions":327,"interventions":329},"NCT00195767","Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents",[68],150,[328],"Bipolar I Disorder, Manic or Mixed",[303],{"nctId":331,"briefTitle":332,"status":86,"phases":333,"start":308,"enrollment":334,"conditions":335,"interventions":337},"NCT00195780","A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents",[68],227,[336],"Bipolar I Disorder",[274],{"nctId":339,"briefTitle":340,"status":263,"phases":341,"start":342,"enrollment":299,"conditions":343,"interventions":345},"NCT00067431","A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children",[68],"2003-07",[344],"Partial Seizure Disorder",[274],{"nctId":347,"briefTitle":348,"status":86,"phases":349,"start":308,"enrollment":350,"conditions":351,"interventions":352},"NCT00195806","Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine",[68],315,[301],[303],{"trials":354,"activeCount":76},[355],{"nctId":356,"briefTitle":357,"status":263,"phases":358,"start":342,"enrollment":359,"conditions":360,"interventions":361},"NCT00071253","Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness",[69],180,[292],[274,274,362],"Olanzapine",{"trials":364,"activeCount":76},[],{"intervention":366,"totalTrials":367,"cells":368},"cefdinir",8,{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":387,"NA":450},{"trials":370,"activeCount":76},[],{"trials":372,"activeCount":76},[],{"trials":374,"activeCount":76},[],{"trials":376,"activeCount":76},[377],{"nctId":378,"briefTitle":379,"status":86,"phases":380,"primaryCompletion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},"NCT00645203","Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media",[67,68],"2003-04","2002-07",447,[385],"Acute Otitis Media",[366],{"trials":388,"activeCount":76},[389,399,409,418,426,433,440],{"nctId":390,"briefTitle":391,"status":86,"phases":392,"primaryCompletion":393,"start":394,"enrollment":395,"conditions":396,"interventions":397},"NCT00645112","A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media",[69],"2004-01","2003-11",357,[385],[366,398],"azithromycin",{"nctId":400,"briefTitle":401,"status":86,"phases":402,"primaryCompletion":403,"start":394,"enrollment":404,"conditions":405,"interventions":407},"NCT00645073","Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis",[69],"2004-03",271,[406],"Acute Bacterial Sinusitis",[366,408],"levofloxacin",{"nctId":410,"briefTitle":411,"status":86,"phases":412,"primaryCompletion":289,"start":289,"enrollment":413,"conditions":414,"interventions":416},"NCT00644891","Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications",[69],158,[415],"Healthy",[366,417],"amoxicillin",{"nctId":419,"briefTitle":420,"status":86,"phases":421,"primaryCompletion":381,"start":422,"enrollment":423,"conditions":424,"interventions":425},"NCT00644943","A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin\u002FClavulanate in Pediatric Subjects With Acute Otitis Media",[69],"2003-02",425,[385],[366,417],{"nctId":427,"briefTitle":428,"status":86,"phases":429,"primaryCompletion":422,"start":289,"enrollment":430,"conditions":431,"interventions":432},"NCT00645125","A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications",[69],154,[415],[366,417],{"nctId":434,"briefTitle":435,"status":86,"phases":436,"primaryCompletion":289,"start":289,"enrollment":437,"conditions":438,"interventions":439},"NCT00644774","A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications",[69],157,[415],[366,398],{"nctId":441,"briefTitle":442,"status":86,"phases":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT00234949","A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections",[69],"2005-03",380,[447],"Mild to Moderate Uncomplicated Skin and Skin Structure Infections",[366,449],"cephalexin",{"trials":451,"activeCount":76},[],{"intervention":453,"totalTrials":454,"cells":455},"Zemplar",6,{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":473,"PHASE4":484,"NA":523},{"trials":457,"activeCount":76},[],{"trials":459,"activeCount":76},[],{"trials":461,"activeCount":76},[462],{"nctId":463,"briefTitle":464,"status":86,"phases":465,"primaryCompletion":265,"completion":265,"start":466,"enrollment":467,"conditions":468,"interventions":470},"NCT00421733","The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors",[67],"2006-12",281,[469,160],"Diabetic Nephropathy",[471,472],"Zemplar (paricalcitol )","Zemplar (paricalcitol)",{"trials":474,"activeCount":76},[475],{"nctId":476,"briefTitle":477,"status":86,"phases":478,"start":479,"enrollment":480,"conditions":481,"interventions":483},"NCT00091975","Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis",[68],"2004-08",78,[482],"Kidney Disease",[453],{"trials":485,"activeCount":76},[486,495,504,515],{"nctId":487,"briefTitle":488,"status":263,"phases":489,"start":381,"enrollment":490,"conditions":491,"interventions":493},"NCT00062699","Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w\u002F Stage V Chronic Kidney Disease on Hemodialysis",[69],2200,[492],"End-Stage Kidney Disease",[453,494],"Calcijex",{"nctId":496,"briefTitle":497,"status":86,"phases":498,"start":499,"enrollment":500,"conditions":501,"interventions":503},"NCT00091481","Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis",[69],"2003-06",201,[502],"Kidney Failure, Chronic",[453],{"nctId":505,"briefTitle":506,"status":86,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":514},"NCT00891813","Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH\u002F100 as Initial Dose",[69],"2010-09","2009-05",100,[149,201,512,150,513],"Parathyroid Hormone","Hypercalcemia",[453],{"nctId":516,"briefTitle":517,"status":86,"phases":518,"start":519,"enrollment":520,"conditions":521,"interventions":522},"NCT00073710","Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium",[69],"2004-09",30,[149,160],[453,494],{"trials":524,"activeCount":76},[],{"intervention":526,"totalTrials":527,"cells":528},"methotrexate",5,{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":563,"NA":580},{"trials":530,"activeCount":76},[],{"trials":532,"activeCount":76},[],{"trials":534,"activeCount":76},[],{"trials":536,"activeCount":76},[537,547,555],{"nctId":538,"briefTitle":539,"status":86,"phases":540,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT00234936","Quality of Life Study With Adalimumab in Rheumatoid Arthritis",[68],"2003-12",200,[39],[545,546],"Adalimumab","Methotrexate",{"nctId":548,"briefTitle":549,"status":86,"phases":550,"start":342,"enrollment":551,"conditions":552,"interventions":553},"NCT00235859","Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate",[68],128,[39],[554,526],"adalimumab",{"nctId":556,"briefTitle":557,"status":86,"phases":558,"start":559,"enrollment":560,"conditions":561,"interventions":562},"NCT00234845","Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis",[68],"2003-03",148,[39],[554,526],{"trials":564,"activeCount":76},[565,573],{"nctId":566,"briefTitle":567,"status":263,"phases":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT00233558","Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis",[69],"2005-06",160,[39],[554,526],{"nctId":574,"briefTitle":575,"status":86,"phases":576,"primaryCompletion":254,"completion":254,"start":466,"enrollment":577,"conditions":578,"interventions":579},"NCT00420927","Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis",[69],1032,[39],[554,526],{"trials":581,"activeCount":76},[],{"intervention":583,"totalTrials":584,"cells":585},"trandolapril\u002Fverapamil",4,{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":594,"NA":636},{"trials":587,"activeCount":76},[],{"trials":589,"activeCount":76},[],{"trials":591,"activeCount":76},[],{"trials":593,"activeCount":76},[],{"trials":595,"activeCount":76},[596,606,615,626],{"nctId":597,"briefTitle":598,"status":86,"phases":599,"primaryCompletion":444,"start":393,"enrollment":395,"conditions":600,"interventions":604},"NCT00234871","Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)",[69],[601,602,603],"Hypertension","Diabetes","Proteinuria",[583,605],"Lotrel",{"nctId":607,"briefTitle":608,"status":86,"phases":609,"primaryCompletion":610,"start":611,"enrollment":612,"conditions":613,"interventions":614},"NCT00235001","Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension",[69],"2006-11","2004-06",120,[601],[583],{"nctId":616,"briefTitle":617,"status":86,"phases":618,"primaryCompletion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT00235014","A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)",[69],"2006-01","1997-03",1204,[601,602],[624,583,625],"trandolapril","verapamil",{"nctId":627,"briefTitle":628,"status":86,"phases":629,"primaryCompletion":630,"start":403,"enrollment":631,"conditions":632,"interventions":634},"NCT00234858","Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)",[69],"2006-04",280,[601,633],"Metabolic Syndrome",[583,635],"(Hyzaar) losartan\u002Fhydrochlorothiazide",{"trials":637,"activeCount":76},[],{"intervention":417,"totalTrials":584,"cells":639},{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":658,"NA":672},{"trials":641,"activeCount":76},[],{"trials":643,"activeCount":76},[],{"trials":645,"activeCount":76},[],{"trials":647,"activeCount":76},[648],{"nctId":649,"briefTitle":650,"status":86,"phases":651,"primaryCompletion":403,"start":298,"enrollment":652,"conditions":653,"interventions":655},"NCT00644553","Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis",[68],437,[654],"Acute Bacterial Sinusitis (ABS)",[656,657],"Clarithromycin","Amoxicillin",{"trials":659,"activeCount":76},[660,664,668],{"nctId":410,"briefTitle":411,"status":86,"phases":661,"primaryCompletion":289,"start":289,"enrollment":413,"conditions":662,"interventions":663},[69],[415],[366,417],{"nctId":419,"briefTitle":420,"status":86,"phases":665,"primaryCompletion":381,"start":422,"enrollment":423,"conditions":666,"interventions":667},[69],[385],[366,417],{"nctId":427,"briefTitle":428,"status":86,"phases":669,"primaryCompletion":422,"start":289,"enrollment":430,"conditions":670,"interventions":671},[69],[415],[366,417],{"trials":673,"activeCount":76},[],{"intervention":675,"totalTrials":676,"cells":677},"Humira",3,{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":693,"PHASE4":704,"NA":713},{"trials":679,"activeCount":76},[],{"trials":681,"activeCount":76},[],{"trials":683,"activeCount":76},[684],{"nctId":685,"briefTitle":686,"status":687,"phases":688,"start":689,"enrollment":246,"conditions":690,"interventions":692},"NCT00512863","A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma","WITHDRAWN",[67],"2007-08",[691],"Asthma",[675],{"trials":694,"activeCount":76},[695],{"nctId":696,"briefTitle":697,"status":86,"phases":698,"primaryCompletion":699,"start":255,"enrollment":700,"conditions":701,"interventions":703},"NCT00513370","A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis",[68],"2008-09",203,[702],"Psoriasis",[675],{"trials":705,"activeCount":76},[706],{"nctId":707,"briefTitle":708,"status":263,"phases":709,"primaryCompletion":710,"completion":710,"start":610,"enrollment":133,"conditions":711,"interventions":712},"NCT00761514","Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira",[69],"2008-08",[39],[675],{"trials":714,"activeCount":76},[],{"intervention":716,"totalTrials":26,"cells":717},"Creon",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":746},{"trials":719,"activeCount":76},[],{"trials":721,"activeCount":76},[],{"trials":723,"activeCount":76},[],{"trials":725,"activeCount":76},[],{"trials":727,"activeCount":76},[728,737],{"nctId":729,"briefTitle":730,"status":687,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":76,"conditions":734,"interventions":736},"NCT02009410","A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2",[69],"2014-08","2013-11",[735],"Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2",[716],{"nctId":738,"briefTitle":739,"status":86,"phases":740,"primaryCompletion":741,"completion":741,"start":167,"enrollment":742,"conditions":743,"interventions":745},"NCT00535756","Creon After Pancreatic Surgery",[69],"2011-06",58,[744],"Pancreatic Insufficiency",[716],{"trials":747,"activeCount":76},[],{"intervention":494,"totalTrials":26,"cells":749},{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":768},{"trials":751,"activeCount":76},[],{"trials":753,"activeCount":76},[],{"trials":755,"activeCount":76},[],{"trials":757,"activeCount":76},[],{"trials":759,"activeCount":76},[760,764],{"nctId":487,"briefTitle":488,"status":263,"phases":761,"start":381,"enrollment":490,"conditions":762,"interventions":763},[69],[492],[453,494],{"nctId":516,"briefTitle":517,"status":86,"phases":765,"start":519,"enrollment":520,"conditions":766,"interventions":767},[69],[149,160],[453,494],{"trials":769,"activeCount":76},[],{"intervention":398,"totalTrials":26,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":780,"NA":790},{"trials":773,"activeCount":76},[],{"trials":775,"activeCount":76},[],{"trials":777,"activeCount":76},[],{"trials":779,"activeCount":76},[],{"trials":781,"activeCount":76},[782,786],{"nctId":390,"briefTitle":391,"status":86,"phases":783,"primaryCompletion":393,"start":394,"enrollment":395,"conditions":784,"interventions":785},[69],[385],[366,398],{"nctId":434,"briefTitle":435,"status":86,"phases":787,"primaryCompletion":289,"start":289,"enrollment":437,"conditions":788,"interventions":789},[69],[415],[366,398],{"trials":791,"activeCount":76},[],{"intervention":362,"totalTrials":26,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":810,"PHASE4":812,"NA":818},{"trials":795,"activeCount":76},[],{"trials":797,"activeCount":76},[],{"trials":799,"activeCount":76},[800],{"nctId":801,"briefTitle":802,"status":86,"phases":803,"start":342,"enrollment":804,"conditions":805,"interventions":807},"NCT00073164","Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia",[67],400,[806],"Schizophrenia",[808,362,809],"Divalproex Sodium Extended-Release","Risperidone",{"trials":811,"activeCount":76},[],{"trials":813,"activeCount":76},[814],{"nctId":356,"briefTitle":357,"status":263,"phases":815,"start":342,"enrollment":359,"conditions":816,"interventions":817},[69],[292],[274,274,362],{"trials":819,"activeCount":76},[],{"intervention":624,"totalTrials":26,"cells":821},{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":844},{"trials":823,"activeCount":76},[],{"trials":825,"activeCount":76},[],{"trials":827,"activeCount":76},[],{"trials":829,"activeCount":76},[],{"trials":831,"activeCount":76},[832,836],{"nctId":616,"briefTitle":617,"status":86,"phases":833,"primaryCompletion":619,"start":620,"enrollment":621,"conditions":834,"interventions":835},[69],[601,602],[624,583,625],{"nctId":837,"briefTitle":838,"status":86,"phases":839,"primaryCompletion":569,"start":403,"enrollment":840,"conditions":841,"interventions":842},"NCT00233532","Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)",[69],2000,[601],[843],"Trandolapril",{"trials":845,"activeCount":76},[],{"intervention":847,"totalTrials":26,"cells":848},"fenofibrate",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":867,"NA":882},{"trials":850,"activeCount":76},[],{"trials":852,"activeCount":76},[],{"trials":854,"activeCount":76},[],{"trials":856,"activeCount":76},[857],{"nctId":858,"briefTitle":859,"status":86,"phases":860,"start":479,"enrollment":861,"conditions":862,"interventions":864},"NCT00195793","A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin",[68],174,[863],"Hyperlipidemia",[847,865,866],"ezetimibe","atorvastatin",{"trials":868,"activeCount":76},[869],{"nctId":870,"briefTitle":871,"status":86,"phases":872,"primaryCompletion":873,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":881},"NCT01462877","A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic",[69],"2014-02","2014-03","2011-10",506,[878,879,880],"Dyslipidemias","Cardiovascular Diseases","Hypertriglyceridemia",[847],{"trials":883,"activeCount":76},[],{"intervention":885,"totalTrials":106,"cells":886},"Venocur Triplex®",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":895,"NA":906},{"trials":888,"activeCount":76},[],{"trials":890,"activeCount":76},[],{"trials":892,"activeCount":76},[],{"trials":894,"activeCount":76},[],{"trials":896,"activeCount":76},[897],{"nctId":898,"briefTitle":899,"status":86,"phases":900,"primaryCompletion":901,"start":902,"enrollment":209,"conditions":903,"interventions":905},"NCT00835822","Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency",[69],"2006-10","2005-05",[904],"Venous Insufficiency",[885],{"trials":907,"activeCount":76},[],{"intervention":605,"totalTrials":106,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":924},{"trials":911,"activeCount":76},[],{"trials":913,"activeCount":76},[],{"trials":915,"activeCount":76},[],{"trials":917,"activeCount":76},[],{"trials":919,"activeCount":76},[920],{"nctId":597,"briefTitle":598,"status":86,"phases":921,"primaryCompletion":444,"start":393,"enrollment":395,"conditions":922,"interventions":923},[69],[601,602,603],[583,605],{"trials":925,"activeCount":76},[],{"intervention":249,"totalTrials":106,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":936,"NA":942},{"trials":929,"activeCount":76},[],{"trials":931,"activeCount":76},[],{"trials":933,"activeCount":76},[],{"trials":935,"activeCount":76},[],{"trials":937,"activeCount":76},[938],{"nctId":242,"briefTitle":243,"status":86,"phases":939,"primaryCompletion":245,"completion":245,"start":208,"enrollment":246,"conditions":940,"interventions":941},[69],[160,149,150],[173,249],{"trials":943,"activeCount":76},[],{"intervention":625,"totalTrials":106,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":954,"NA":960},{"trials":947,"activeCount":76},[],{"trials":949,"activeCount":76},[],{"trials":951,"activeCount":76},[],{"trials":953,"activeCount":76},[],{"trials":955,"activeCount":76},[956],{"nctId":616,"briefTitle":617,"status":86,"phases":957,"primaryCompletion":619,"start":620,"enrollment":621,"conditions":958,"interventions":959},[69],[601,602],[624,583,625],{"trials":961,"activeCount":76},[],{"intervention":408,"totalTrials":106,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":970,"PHASE4":972,"NA":978},{"trials":965,"activeCount":76},[],{"trials":967,"activeCount":76},[],{"trials":969,"activeCount":76},[],{"trials":971,"activeCount":76},[],{"trials":973,"activeCount":76},[974],{"nctId":400,"briefTitle":401,"status":86,"phases":975,"primaryCompletion":403,"start":394,"enrollment":404,"conditions":976,"interventions":977},[69],[406],[366,408],{"trials":979,"activeCount":76},[],{"intervention":981,"totalTrials":106,"cells":982},"betahistine dihydrochloride",{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":991,"NA":1003},{"trials":984,"activeCount":76},[],{"trials":986,"activeCount":76},[],{"trials":988,"activeCount":76},[],{"trials":990,"activeCount":76},[],{"trials":992,"activeCount":76},[993],{"nctId":994,"briefTitle":995,"status":86,"phases":996,"primaryCompletion":997,"completion":997,"start":998,"enrollment":999,"conditions":1000,"interventions":1002},"NCT01468285","The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow",[69],"2013-04","2012-02",27,[1001],"Gait or Balance Disorder Problems",[981],{"trials":1004,"activeCount":76},[],{"intervention":635,"totalTrials":106,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1021},{"trials":1008,"activeCount":76},[],{"trials":1010,"activeCount":76},[],{"trials":1012,"activeCount":76},[],{"trials":1014,"activeCount":76},[],{"trials":1016,"activeCount":76},[1017],{"nctId":627,"briefTitle":628,"status":86,"phases":1018,"primaryCompletion":630,"start":403,"enrollment":631,"conditions":1019,"interventions":1020},[69],[601,633],[583,635],{"trials":1022,"activeCount":76},[],{"intervention":1024,"totalTrials":106,"cells":1025},"clopidogrel + aspirin OR prasugrel + aspirin",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1050},{"trials":1027,"activeCount":76},[],{"trials":1029,"activeCount":76},[],{"trials":1031,"activeCount":76},[],{"trials":1033,"activeCount":76},[],{"trials":1035,"activeCount":76},[1036],{"nctId":1037,"briefTitle":1038,"status":86,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1049},"NCT01106534","XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort",[69],"2015-02","2015-07","2009-08",870,[1045,1046,1047,51,42,33,1048],"Chronic Total Occlusion of Coronary Artery","Vascular Disease","Myocardial Ischemia","Coronary Restenosis",[1024],{"trials":1051,"activeCount":76},[],{"intervention":1053,"totalTrials":106,"cells":1054},"Zemplar®",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1076},{"trials":1056,"activeCount":76},[],{"trials":1058,"activeCount":76},[],{"trials":1060,"activeCount":76},[],{"trials":1062,"activeCount":76},[],{"trials":1064,"activeCount":76},[1065],{"nctId":1066,"briefTitle":1067,"status":86,"phases":1068,"primaryCompletion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1074},"NCT00257920","A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease",[69],"2008-01","2006-06",41,[1073,149],"Chronic Kidney Disease, Stage 5",[1053,1075],"Hectorol®",{"trials":1077,"activeCount":76},[],{"intervention":1075,"totalTrials":106,"cells":1079},{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1094},{"trials":1081,"activeCount":76},[],{"trials":1083,"activeCount":76},[],{"trials":1085,"activeCount":76},[],{"trials":1087,"activeCount":76},[],{"trials":1089,"activeCount":76},[1090],{"nctId":1066,"briefTitle":1067,"status":86,"phases":1091,"primaryCompletion":1069,"start":1070,"enrollment":1071,"conditions":1092,"interventions":1093},[69],[1073,149],[1053,1075],{"trials":1095,"activeCount":76},[],{"intervention":1097,"totalTrials":106,"cells":1098},"sibutramine hydochloride monohydrate",{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1107,"NA":1117},{"trials":1100,"activeCount":76},[],{"trials":1102,"activeCount":76},[],{"trials":1104,"activeCount":76},[],{"trials":1106,"activeCount":76},[],{"trials":1108,"activeCount":76},[1109],{"nctId":1110,"briefTitle":1111,"status":86,"phases":1112,"primaryCompletion":619,"start":611,"enrollment":1113,"conditions":1114,"interventions":1116},"NCT00234988","A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.",[69],93,[1115],"Obesity",[1097],{"trials":1118,"activeCount":76},[],{"intervention":270,"totalTrials":106,"cells":1120},{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1129,"NA":1135},{"trials":1122,"activeCount":76},[],{"trials":1124,"activeCount":76},[],{"trials":1126,"activeCount":76},[],{"trials":1128,"activeCount":76},[],{"trials":1130,"activeCount":76},[1131],{"nctId":261,"briefTitle":262,"status":263,"phases":1132,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":1133,"interventions":1134},[69],[149,258],[270,173],{"trials":1136,"activeCount":76},[],{"intervention":1138,"totalTrials":106,"cells":1139},"Sevoflurane Inhalational Induction and Maintenance",{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1146,"PHASE4":1148,"NA":1160},{"trials":1141,"activeCount":76},[],{"trials":1143,"activeCount":76},[],{"trials":1145,"activeCount":76},[],{"trials":1147,"activeCount":76},[],{"trials":1149,"activeCount":76},[1150],{"nctId":1151,"briefTitle":1152,"status":86,"phases":1153,"primaryCompletion":245,"completion":245,"start":207,"enrollment":1154,"conditions":1155,"interventions":1157},"NCT01191476","Compare Pharmaceutical Economics and Efficacy of Sevoflurane With Low Fresh Gas Flow Balanced Anesthesia, Propofol Target Controlled Infusion Anesthesia and Propofol Induction Sevoflurane Maintenance Anesthesia",[69],336,[1156],"Elective Laparoscopic Surgery",[1138,1158,1159],"Propofol Target Controlled Infusion for Induction and Maintenance","Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance",{"trials":1161,"activeCount":76},[],{"intervention":1158,"totalTrials":106,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1178},{"trials":1165,"activeCount":76},[],{"trials":1167,"activeCount":76},[],{"trials":1169,"activeCount":76},[],{"trials":1171,"activeCount":76},[],{"trials":1173,"activeCount":76},[1174],{"nctId":1151,"briefTitle":1152,"status":86,"phases":1175,"primaryCompletion":245,"completion":245,"start":207,"enrollment":1154,"conditions":1176,"interventions":1177},[69],[1156],[1138,1158,1159],{"trials":1179,"activeCount":76},[],{"intervention":1159,"totalTrials":106,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1196},{"trials":1183,"activeCount":76},[],{"trials":1185,"activeCount":76},[],{"trials":1187,"activeCount":76},[],{"trials":1189,"activeCount":76},[],{"trials":1191,"activeCount":76},[1192],{"nctId":1151,"briefTitle":1152,"status":86,"phases":1193,"primaryCompletion":245,"completion":245,"start":207,"enrollment":1154,"conditions":1194,"interventions":1195},[69],[1156],[1138,1158,1159],{"trials":1197,"activeCount":76},[],{"intervention":1199,"totalTrials":106,"cells":1200},"Buffered pantoprazole",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1220},{"trials":1202,"activeCount":76},[],{"trials":1204,"activeCount":76},[],{"trials":1206,"activeCount":76},[],{"trials":1208,"activeCount":76},[],{"trials":1210,"activeCount":76},[1211],{"nctId":1212,"briefTitle":1213,"status":86,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":147,"conditions":1217,"interventions":1219},"NCT01214408","Effect of Digene Total (Buffered Pantoprazole) on 24 Hour Gastric Potential Hydrogen (pH) in Patients From Acid Peptic Disorder After Single and Repeated Dosing.",[69],"2011-07","2011-03",[1218],"Acid Peptic Disorder",[1199,1199],{"trials":1221,"activeCount":76},[],{"intervention":1223,"totalTrials":106,"cells":1224},"Warfarin",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1245},{"trials":1226,"activeCount":76},[],{"trials":1228,"activeCount":76},[],{"trials":1230,"activeCount":76},[],{"trials":1232,"activeCount":76},[],{"trials":1234,"activeCount":76},[1235],{"nctId":1236,"briefTitle":1237,"status":86,"phases":1238,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":34,"conditions":1242,"interventions":1243},"NCT02836652","Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy",[69],"2019-02-21","2019-07-18","2016-11",[30],[1223,1244],"acetylsalicylic acid (ASA) therapy",{"trials":1246,"activeCount":76},[],{"intervention":1244,"totalTrials":106,"cells":1248},{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1255,"PHASE4":1257,"NA":1263},{"trials":1250,"activeCount":76},[],{"trials":1252,"activeCount":76},[],{"trials":1254,"activeCount":76},[],{"trials":1256,"activeCount":76},[],{"trials":1258,"activeCount":76},[1259],{"nctId":1236,"briefTitle":1237,"status":86,"phases":1260,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":34,"conditions":1261,"interventions":1262},[69],[30],[1223,1244],{"trials":1264,"activeCount":76},[],{"intervention":449,"totalTrials":106,"cells":1266},{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1281},{"trials":1268,"activeCount":76},[],{"trials":1270,"activeCount":76},[],{"trials":1272,"activeCount":76},[],{"trials":1274,"activeCount":76},[],{"trials":1276,"activeCount":76},[1277],{"nctId":441,"briefTitle":442,"status":86,"phases":1278,"start":444,"enrollment":445,"conditions":1279,"interventions":1280},[69],[447],[366,449],{"trials":1282,"activeCount":76},[],{"intervention":1284,"totalTrials":1285,"cells":1286},"Asoprisnil",12,{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1342,"PHASE4":1393,"NA":1395},{"trials":1288,"activeCount":76},[],{"trials":1290,"activeCount":76},[],{"trials":1292,"activeCount":76},[1293,1301,1309,1317,1326,1335],{"nctId":1294,"briefTitle":1295,"status":86,"phases":1296,"primaryCompletion":902,"completion":902,"start":342,"enrollment":40,"conditions":1297,"interventions":1300},"NCT00150644","A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy",[67],[1298,1299],"Uterine Fibroids","Leiomyoma",[1284,1284],{"nctId":1302,"briefTitle":1303,"status":86,"phases":1304,"primaryCompletion":317,"completion":317,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1308},"NCT00160420","A Long-Term Study to Evaluate the Safety of Asoprisnil in the Treatment of Women With Endometriosis From Study M01-398",[67],"2002-12",73,[104],[1284],{"nctId":1310,"briefTitle":1311,"status":86,"phases":1312,"primaryCompletion":499,"completion":499,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1316},"NCT00160433","A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.",[67],"2002-08",131,[104],[1284,1284,1284],{"nctId":1318,"briefTitle":1319,"status":86,"phases":1320,"primaryCompletion":1321,"completion":1321,"start":1322,"enrollment":1323,"conditions":1324,"interventions":1325},"NCT00156182","A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.",[67],"2001-12","2001-04",38,[1299],[1284],{"nctId":1327,"briefTitle":1328,"status":86,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":1332,"conditions":1333,"interventions":1334},"NCT00160446","A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis",[67],"2001-07","2000-05",130,[104],[1284,1284,1284],{"nctId":1336,"briefTitle":1337,"status":86,"phases":1338,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":1339,"conditions":1340,"interventions":1341},"NCT00160459","A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids",[67],129,[1299],[1284,1284,1284],{"trials":1343,"activeCount":76},[1344,1354,1362,1370,1378,1385],{"nctId":1345,"briefTitle":1346,"status":86,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":89,"enrollment":1349,"conditions":1350,"interventions":1353},"NCT00156195","Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids",[68],"2007-01",523,[1299,1351,1352],"Menorrhagia","Metrorrhagia",[1284,1284],{"nctId":1355,"briefTitle":1356,"status":86,"phases":1357,"primaryCompletion":308,"completion":308,"start":89,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT00152256","A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids",[68],239,[1360,1299,1351,1352,1298],"Fibroid Uterus",[1284,1284],{"nctId":1363,"briefTitle":1337,"status":86,"phases":1364,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1369},"NCT00160381",[68],"2005-01","2002-09",432,[1299,1351,1352],[1284,1284],{"nctId":1371,"briefTitle":1372,"status":86,"phases":1373,"primaryCompletion":157,"completion":157,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1377},"NCT00156156","Study of Asoprisnil in the Treatment of Uterine Fibroids.",[68],"2004-11",149,[1360,1299,1351,1352,1298],[1284,1284],{"nctId":1379,"briefTitle":1380,"status":86,"phases":1381,"primaryCompletion":1365,"completion":1365,"start":382,"enrollment":1382,"conditions":1383,"interventions":1384},"NCT00152269","Treatment of Uterine Fibroids With Asoprisnil(J867)",[68],475,[1299,1351,1352],[1284,1284],{"nctId":1386,"briefTitle":1387,"status":86,"phases":1388,"primaryCompletion":466,"completion":466,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1392},"NCT00156208","Safety of Treatment of Uterine Fibroids With Asoprisnil",[68],"2004-04",166,[1360,1299,1351,1352,1298],[1284,1284],{"trials":1394,"activeCount":76},[],{"trials":1396,"activeCount":76},[],{"intervention":1398,"totalTrials":1399,"cells":1400},"ABT-335",7,{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1424,"PHASE3":1426,"PHASE4":1478,"NA":1480},{"trials":1402,"activeCount":76},[],{"trials":1404,"activeCount":76},[1405,1413],{"nctId":1406,"briefTitle":1407,"status":86,"phases":1408,"primaryCompletion":166,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1412},"NCT00839293","Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules",[66],"2009-02",32,[415],[1398],{"nctId":1414,"briefTitle":1415,"status":86,"phases":1416,"primaryCompletion":1417,"start":167,"enrollment":1418,"conditions":1419,"interventions":1421},"NCT00681525","A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe",[66],"2008-06",18,[1420],"Pharmacokinetics",[1398,1422,1423],"Atorvastatin","Ezetimibe",{"trials":1425,"activeCount":76},[],{"trials":1427,"activeCount":76},[1428,1441,1448,1458,1470],{"nctId":1429,"briefTitle":1430,"status":86,"phases":1431,"primaryCompletion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1439},"NCT00300456","Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood",[68],"2007-03","2006-03",657,[1436,1437,1438],"Dyslipidemia","Coronary Heart Disease","Mixed Dyslipidemia",[1398,1440],"Simvastatin",{"nctId":1442,"briefTitle":1443,"status":86,"phases":1444,"primaryCompletion":157,"start":1433,"enrollment":1445,"conditions":1446,"interventions":1447},"NCT00300469","Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood",[68],613,[1438,1437,1436],[1398,1422],{"nctId":1449,"briefTitle":1450,"status":86,"phases":1451,"primaryCompletion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1457},"NCT00639158","Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood",[68],"2008-10","2008-02",543,[878,1437,1456,1438],"Combined (Atherogenic) Dyslipidemia",[1398,866,865],{"nctId":1459,"briefTitle":1460,"status":86,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT00491530","A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",[68],"2008-11","2007-06",310,[1438],[1398,1467,1468,1469],"rosuvastatin calcium","simvastatin","atorvastatin calcium",{"nctId":1471,"briefTitle":1472,"status":86,"phases":1473,"primaryCompletion":466,"start":1433,"enrollment":1474,"conditions":1475,"interventions":1476},"NCT00300482","Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood",[68],1445,[1436,1437,1438],[1398,1477],"Rosuvastatin Calcium",{"trials":1479,"activeCount":76},[],{"trials":1481,"activeCount":76},[],{"intervention":866,"totalTrials":527,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1492,"PHASE3":1494,"PHASE4":1517,"NA":1519},{"trials":1485,"activeCount":76},[],{"trials":1487,"activeCount":76},[1488],{"nctId":1414,"briefTitle":1415,"status":86,"phases":1489,"primaryCompletion":1417,"start":167,"enrollment":1418,"conditions":1490,"interventions":1491},[66],[1420],[1398,1422,1423],{"trials":1493,"activeCount":76},[],{"trials":1495,"activeCount":76},[1496,1500,1509,1513],{"nctId":1442,"briefTitle":1443,"status":86,"phases":1497,"primaryCompletion":157,"start":1433,"enrollment":1445,"conditions":1498,"interventions":1499},[68],[1438,1437,1436],[1398,1422],{"nctId":1501,"briefTitle":1502,"status":86,"phases":1503,"primaryCompletion":1453,"start":1504,"enrollment":1505,"conditions":1506,"interventions":1507},"NCT00465088","An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)",[68],"2007-04",199,[863,1438],[1508,866],"Niacin ER\u002FSimvastatin",{"nctId":1449,"briefTitle":1450,"status":86,"phases":1510,"primaryCompletion":1452,"start":1453,"enrollment":1454,"conditions":1511,"interventions":1512},[68],[878,1437,1456,1438],[1398,866,865],{"nctId":858,"briefTitle":859,"status":86,"phases":1514,"start":479,"enrollment":861,"conditions":1515,"interventions":1516},[68],[863],[847,865,866],{"trials":1518,"activeCount":76},[],{"trials":1520,"activeCount":76},[],{"intervention":1522,"totalTrials":584,"cells":1523},"Atrasentan",{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1538,"PHASE4":1564,"NA":1566},{"trials":1525,"activeCount":76},[],{"trials":1527,"activeCount":76},[],{"trials":1529,"activeCount":76},[1530],{"nctId":1531,"briefTitle":1532,"status":86,"phases":1533,"start":1534,"enrollment":542,"conditions":1535,"interventions":1537},"NCT00038662","Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure",[67],"2002-05",[1536],"Prostatic Neoplasms",[1522],{"trials":1539,"activeCount":76},[1540,1548,1557],{"nctId":1541,"briefTitle":1542,"status":86,"phases":1543,"start":1544,"enrollment":1545,"conditions":1546,"interventions":1547},"NCT00036556","Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer",[68],"2001-06",941,[1536],[1522],{"nctId":1549,"briefTitle":1550,"status":86,"phases":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1556},"NCT00036543","A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer",[68],"2001-05",1000,[1555],"Prostate Cancer",[1522],{"nctId":1558,"briefTitle":1559,"status":86,"phases":1560,"completion":1463,"start":1330,"enrollment":1390,"conditions":1561,"interventions":1563},"NCT00127478","A Long Term Safety Study With Atrasentan",[67,68],[1555,1562],"Adenocarcinoma",[1522],{"trials":1565,"activeCount":76},[],{"trials":1567,"activeCount":76},[],{"intervention":1569,"totalTrials":584,"cells":1570},"sibutramine",{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1614,"NA":1616},{"trials":1572,"activeCount":76},[],{"trials":1574,"activeCount":76},[],{"trials":1576,"activeCount":76},[],{"trials":1578,"activeCount":76},[1579,1587,1597,1605],{"nctId":1580,"briefTitle":1581,"status":86,"phases":1582,"completion":198,"start":1583,"enrollment":1584,"conditions":1585,"interventions":1586},"NCT00261911","A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.",[68],"2000-07",498,[1115],[1569],{"nctId":1588,"briefTitle":1589,"status":86,"phases":1590,"primaryCompletion":541,"start":198,"enrollment":1591,"conditions":1592,"interventions":1593},"NCT00679653","Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives",[68],171,[1115,601],[1569,1569,1594,1595,1596],"verapamil\u002Ftrandolapril","metoprolol\u002FHCT","felodipine\u002Framipril",{"nctId":1598,"briefTitle":1599,"status":86,"phases":1600,"primaryCompletion":1374,"start":1305,"enrollment":1601,"conditions":1602,"interventions":1603},"NCT00677391","Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population",[68],103,[1115],[1604],"Sibutramine",{"nctId":1606,"briefTitle":1607,"status":86,"phases":1608,"start":1609,"enrollment":1610,"conditions":1611,"interventions":1613},"NCT00402584","A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder",[68],"2000-08",304,[1612,1115],"Binge Eating Disorder",[1569],{"trials":1615,"activeCount":76},[],{"trials":1617,"activeCount":76},[],{"intervention":1619,"totalTrials":584,"cells":1620},"Trivalent influenza subunit vaccine Influvac",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1625,"PHASE3":1627,"PHASE4":1659,"NA":1661},{"trials":1622,"activeCount":76},[],{"trials":1624,"activeCount":76},[],{"trials":1626,"activeCount":76},[],{"trials":1628,"activeCount":76},[1629,1636,1644,1652],{"nctId":1630,"briefTitle":1631,"status":86,"phases":1632,"primaryCompletion":88,"completion":88,"start":265,"enrollment":612,"conditions":1633,"interventions":1635},"NCT00881842","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09\u002F10 Season",[68],[1634],"Influenza",[1619],{"nctId":1637,"briefTitle":1638,"status":86,"phases":1639,"primaryCompletion":254,"completion":254,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1643},"NCT01146015","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010\u002F2011 Season",[68],"2010-06",121,[1634],[1619],{"nctId":1645,"briefTitle":1646,"status":86,"phases":1647,"primaryCompletion":1648,"completion":1648,"start":1648,"enrollment":612,"conditions":1649,"interventions":1651},"NCT01633749","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012\u002F2013 Season",[68],"2012-07",[1650],"Prophylaxis of Influenza",[1619],{"nctId":1653,"briefTitle":1654,"status":86,"phases":1655,"primaryCompletion":1656,"completion":1656,"start":1656,"enrollment":612,"conditions":1657,"interventions":1658},"NCT02381418","Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season",[68],"2015-03",[1634],[1619],{"trials":1660,"activeCount":76},[],{"trials":1662,"activeCount":76},[],{"intervention":1664,"totalTrials":676,"cells":1665},"ABT-869",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1687,"PHASE3":1689,"PHASE4":1712,"NA":1714},{"trials":1667,"activeCount":76},[],{"trials":1669,"activeCount":76},[1670,1679],{"nctId":1671,"briefTitle":1672,"status":86,"phases":1673,"primaryCompletion":1674,"completion":1674,"start":145,"enrollment":1285,"conditions":1675,"interventions":1677},"NCT01114191","A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)",[66],"2011-02",[1676],"Solid Tumors",[1664,1678],"ketoconazole",{"nctId":1680,"briefTitle":1681,"status":687,"phases":1682,"primaryCompletion":1683,"start":699,"enrollment":76,"conditions":1684,"interventions":1685},"NCT00754104","Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors",[66],"2008-12",[1676],[1664,1686],"Tarceva",{"trials":1688,"activeCount":76},[],{"trials":1690,"activeCount":76},[1691],{"nctId":1692,"briefTitle":1693,"status":263,"phases":1694,"primaryCompletion":1648,"completion":1648,"start":1695,"enrollment":1696,"conditions":1697,"interventions":1710},"NCT01009593","Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)",[68],"2010-01",1035,[1698,1699,1700,1701,1702,1703,1704,1705,1706,1707,1708,1562,1709],"Hepatocellular Carcinoma Non-resectable","Hepatocellular Carcinoma Recurrent","Carcinoma, Hepatocellular","Liver Diseases","Neoplasms by Histologic Type","Digestive System Neoplasms","Carcinoma","Liver Neoplasms","Neoplasms","Neoplasms by Site","Digestive System Diseases","Neoplasms, Glandular and Epithelial",[1664,1711],"Sorafenib",{"trials":1713,"activeCount":76},[],{"trials":1715,"activeCount":76},[],{"intervention":1717,"totalTrials":676,"cells":1718},"Lamivudine",{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1746,"PHASE4":1757,"NA":1759},{"trials":1720,"activeCount":76},[],{"trials":1722,"activeCount":76},[],{"trials":1724,"activeCount":76},[1725,1736],{"nctId":1726,"briefTitle":1727,"status":86,"phases":1728,"start":1583,"enrollment":1729,"conditions":1730,"interventions":1732},"NCT00038220","Effectiveness of ABT-378\u002FRitonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients",[67],40,[1731],"HIV Infections",[1733,1734,1717,1735],"Lopinavir\u002Fritonavir","Efavirenz","Tenofovir DF",{"nctId":1737,"briefTitle":1738,"status":86,"phases":1739,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":510,"conditions":1742,"interventions":1743},"NCT00004578","ABT-378\u002FRitonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects",[66,67],"2005-04","1997-11",[1731],[1744,1717,1745],"Lopinavir\u002FRitonavir","Stavudine",{"trials":1747,"activeCount":76},[1748],{"nctId":1749,"briefTitle":1750,"status":86,"phases":1751,"start":1752,"enrollment":1753,"conditions":1754,"interventions":1755},"NCT00004583","A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy",[68],"1999-03",660,[1731],[1744,1756,1717,1745],"Nelfinavir mesylate",{"trials":1758,"activeCount":76},[],{"trials":1760,"activeCount":76},[],{"intervention":1762,"totalTrials":676,"cells":1763},"Hydrocodone\u002FAcetaminophen Extended Release",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1779,"PHASE4":1800,"NA":1802},{"trials":1765,"activeCount":76},[],{"trials":1767,"activeCount":76},[],{"trials":1769,"activeCount":76},[1770],{"nctId":1771,"briefTitle":1772,"status":86,"phases":1773,"primaryCompletion":403,"completion":403,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1778},"NCT00404391","A Study Comparing the Analgesic Activity of Extended Release Hydrocodone\u002FAcetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery",[67],"2003-10",210,[1777],"Pain",[1762,1762],{"trials":1780,"activeCount":76},[1781,1788],{"nctId":1782,"briefTitle":1783,"status":86,"phases":1784,"primaryCompletion":1504,"completion":1504,"start":466,"enrollment":326,"conditions":1785,"interventions":1786},"NCT00402792","A Study of Extended-Release Hydrocodone\u002FAcetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy",[68],[1777],[1787,1762],"Hydrocodone\u002FAcetaminophen Extended-Release",{"nctId":1789,"briefTitle":1790,"status":86,"phases":1791,"primaryCompletion":1792,"completion":1463,"start":1793,"enrollment":1794,"conditions":1795,"interventions":1797},"NCT00325949","A Study of Pain Relief in Low Back Pain",[68],"2007-05","2006-05",770,[1796],"Chronic Low Back Pain",[1798,1799],"Extended release hydrocodone and acetaminophen","hydrocodone\u002Facetaminophen extended release",{"trials":1801,"activeCount":76},[],{"trials":1803,"activeCount":76},[],{"intervention":1735,"totalTrials":676,"cells":1805},{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1816,"PHASE4":1834,"NA":1836},{"trials":1807,"activeCount":76},[],{"trials":1809,"activeCount":76},[],{"trials":1811,"activeCount":76},[1812],{"nctId":1726,"briefTitle":1727,"status":86,"phases":1813,"start":1583,"enrollment":1729,"conditions":1814,"interventions":1815},[67],[1731],[1733,1734,1717,1735],{"trials":1817,"activeCount":76},[1818,1825],{"nctId":1819,"briefTitle":1820,"status":86,"phases":1821,"start":382,"enrollment":542,"conditions":1822,"interventions":1823},"NCT00043966","Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects",[68],[1731],[1733,1735,1824],"Emtricitabine",{"nctId":1826,"briefTitle":1827,"status":86,"phases":1828,"primaryCompletion":1463,"completion":1417,"start":1365,"enrollment":1829,"conditions":1830,"interventions":1832},"NCT00234910","Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients",[68],152,[1831],"HIV Infection",[1735,1833],"lopinavir\u002Fritonavir with 2 Nucleoside RTIs",{"trials":1835,"activeCount":76},[],{"trials":1837,"activeCount":76},[],{"intervention":865,"totalTrials":676,"cells":1839},{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1848,"PHASE3":1850,"PHASE4":1860,"NA":1862},{"trials":1841,"activeCount":76},[],{"trials":1843,"activeCount":76},[1844],{"nctId":1414,"briefTitle":1415,"status":86,"phases":1845,"primaryCompletion":1417,"start":167,"enrollment":1418,"conditions":1846,"interventions":1847},[66],[1420],[1398,1422,1423],{"trials":1849,"activeCount":76},[],{"trials":1851,"activeCount":76},[1852,1856],{"nctId":1449,"briefTitle":1450,"status":86,"phases":1853,"primaryCompletion":1452,"start":1453,"enrollment":1454,"conditions":1854,"interventions":1855},[68],[878,1437,1456,1438],[1398,866,865],{"nctId":858,"briefTitle":859,"status":86,"phases":1857,"start":479,"enrollment":861,"conditions":1858,"interventions":1859},[68],[863],[847,865,866],{"trials":1861,"activeCount":76},[],{"trials":1863,"activeCount":76},[],{"intervention":1865,"totalTrials":26,"cells":1866},"Dydrogesterone 30 mg",{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1895,"NA":1897},{"trials":1868,"activeCount":76},[],{"trials":1870,"activeCount":76},[],{"trials":1872,"activeCount":76},[],{"trials":1874,"activeCount":76},[1875,1885],{"nctId":1876,"briefTitle":1877,"status":86,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1041,"enrollment":1880,"conditions":1881,"interventions":1883},"NCT02491437","A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)",[68],"2017-05",1034,[1882],"Female Infertility",[1865,1884],"intravaginal progesterone gel 90 mg",{"nctId":1886,"briefTitle":1887,"status":86,"phases":1888,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1893},"NCT01850030","A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization",[68],"2016-03","2013-08",1070,[1882],[1865,1894],"Micronized Progesterone 600 mg",{"trials":1896,"activeCount":76},[],{"trials":1898,"activeCount":76},[],{"intervention":1900,"totalTrials":26,"cells":1901},"Creon®",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1917,"PHASE4":1928,"NA":1930},{"trials":1903,"activeCount":76},[],{"trials":1905,"activeCount":76},[],{"trials":1907,"activeCount":76},[1908],{"nctId":1909,"briefTitle":1910,"status":86,"phases":1911,"primaryCompletion":1041,"completion":1041,"start":1656,"enrollment":1912,"conditions":1913,"interventions":1915},"NCT02415959","Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",[67],70,[1914],"Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis",[1916,1900],"Creon IR",{"trials":1918,"activeCount":76},[1919],{"nctId":1920,"briefTitle":1921,"status":86,"phases":1922,"primaryCompletion":732,"completion":732,"start":1923,"enrollment":1071,"conditions":1924,"interventions":1926},"NCT02137382","A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",[68],"2014-01",[1925],"Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",[1900,1927],"Creon N",{"trials":1929,"activeCount":76},[],{"trials":1931,"activeCount":76},[],{"intervention":1933,"totalTrials":26,"cells":1934},"niacin extended-release",{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1941,"PHASE4":1963,"NA":1965},{"trials":1936,"activeCount":76},[],{"trials":1938,"activeCount":76},[],{"trials":1940,"activeCount":76},[],{"trials":1942,"activeCount":76},[1943,1952],{"nctId":1944,"briefTitle":1945,"status":86,"phases":1946,"primaryCompletion":167,"completion":167,"start":1453,"enrollment":1947,"conditions":1948,"interventions":1949},"NCT00626392","Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia",[68],277,[1436],[1933,1950,1951],"aspirin","aspirin placebo",{"nctId":1953,"briefTitle":1954,"status":86,"phases":1955,"primaryCompletion":1417,"completion":1417,"start":1453,"enrollment":1956,"conditions":1957,"interventions":1958},"NCT00630877","Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin",[68],276,[1436],[1959,1960,1961,1962],"Niacin extended-release","Niacin extended-release (NER) placebo","Aspirin","Aspirin (ASA) placebo",{"trials":1964,"activeCount":76},[],{"trials":1966,"activeCount":76},[],{"intervention":1950,"totalTrials":26,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1985,"NA":1987},{"trials":1970,"activeCount":76},[],{"trials":1972,"activeCount":76},[],{"trials":1974,"activeCount":76},[],{"trials":1976,"activeCount":76},[1977,1981],{"nctId":1944,"briefTitle":1945,"status":86,"phases":1978,"primaryCompletion":167,"completion":167,"start":1453,"enrollment":1947,"conditions":1979,"interventions":1980},[68],[1436],[1933,1950,1951],{"nctId":1953,"briefTitle":1954,"status":86,"phases":1982,"primaryCompletion":1417,"completion":1417,"start":1453,"enrollment":1956,"conditions":1983,"interventions":1984},[68],[1436],[1959,1960,1961,1962],{"trials":1986,"activeCount":76},[],{"trials":1988,"activeCount":76},[],{"intervention":808,"totalTrials":26,"cells":1990},{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":2001,"PHASE4":2009,"NA":2011},{"trials":1992,"activeCount":76},[],{"trials":1994,"activeCount":76},[],{"trials":1996,"activeCount":76},[1997],{"nctId":801,"briefTitle":802,"status":86,"phases":1998,"start":342,"enrollment":804,"conditions":1999,"interventions":2000},[67],[806],[808,362,809],{"trials":2002,"activeCount":76},[2003],{"nctId":2004,"briefTitle":2005,"status":86,"phases":2006,"start":559,"enrollment":326,"conditions":2007,"interventions":2008},"NCT00067262","An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania\u002FBipolar Disorder in Children and Adolescents",[68],[292],[808],{"trials":2010,"activeCount":76},[],{"trials":2012,"activeCount":76},[],{"intervention":2014,"totalTrials":26,"cells":2015},"Amprenavir\u002Fritonavir",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2029,"PHASE4":2038,"NA":2040},{"trials":2017,"activeCount":76},[],{"trials":2019,"activeCount":76},[],{"trials":2021,"activeCount":76},[2022],{"nctId":2023,"briefTitle":2024,"status":86,"phases":2025,"start":1322,"enrollment":49,"conditions":2026,"interventions":2027},"NCT00038532","Amprenavir\u002FRitonavir, Saquinavir\u002FRitonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378\u002FRitonavir) as Their First Protease Inhibitor Based HAART",[67],[1731],[2014,2028,1734],"Saquinavir\u002Fritonavir",{"trials":2030,"activeCount":76},[2031],{"nctId":2032,"briefTitle":2033,"status":86,"phases":2034,"start":1322,"enrollment":2035,"conditions":2036,"interventions":2037},"NCT00038519","Amprenavir\u002FRitonavir or Saquinavir\u002FRitonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor",[67,68],16,[1731],[2014,2028],{"trials":2039,"activeCount":76},[],{"trials":2041,"activeCount":76},[],{"intervention":2028,"totalTrials":26,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2054,"PHASE4":2060,"NA":2062},{"trials":2045,"activeCount":76},[],{"trials":2047,"activeCount":76},[],{"trials":2049,"activeCount":76},[2050],{"nctId":2023,"briefTitle":2024,"status":86,"phases":2051,"start":1322,"enrollment":49,"conditions":2052,"interventions":2053},[67],[1731],[2014,2028,1734],{"trials":2055,"activeCount":76},[2056],{"nctId":2032,"briefTitle":2033,"status":86,"phases":2057,"start":1322,"enrollment":2035,"conditions":2058,"interventions":2059},[67,68],[1731],[2014,2028],{"trials":2061,"activeCount":76},[],{"trials":2063,"activeCount":76},[],{"intervention":2065,"totalTrials":26,"cells":2066},"SA-001",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2091,"NA":2093},{"trials":2068,"activeCount":76},[],{"trials":2070,"activeCount":76},[],{"trials":2072,"activeCount":76},[],{"trials":2074,"activeCount":76},[2075,2083],{"nctId":2076,"briefTitle":2077,"status":86,"phases":2078,"primaryCompletion":1042,"completion":1042,"start":1792,"enrollment":2079,"conditions":2080,"interventions":2082},"NCT00400842","A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency",[68],274,[2081],"Exocrine Pancreatic Insufficiency, Chronic Pancreatitis",[2065,2065],{"nctId":2084,"briefTitle":2085,"status":86,"phases":2086,"primaryCompletion":508,"completion":508,"start":188,"enrollment":2087,"conditions":2088,"interventions":2090},"NCT00401076","A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency",[68],80,[2089],"Pancreatic Exocrine Insufficiency, Chronic Pancreatitis, Pancreatectomy",[2065],{"trials":2092,"activeCount":76},[],{"trials":2094,"activeCount":76},[],{"intervention":1440,"totalTrials":26,"cells":2096},{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2113,"NA":2115},{"trials":2098,"activeCount":76},[],{"trials":2100,"activeCount":76},[],{"trials":2102,"activeCount":76},[],{"trials":2104,"activeCount":76},[2105,2109],{"nctId":1429,"briefTitle":1430,"status":86,"phases":2106,"primaryCompletion":1432,"start":1433,"enrollment":1434,"conditions":2107,"interventions":2108},[68],[1436,1437,1438],[1398,1440],{"nctId":1459,"briefTitle":1460,"status":86,"phases":2110,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":2111,"interventions":2112},[68],[1438],[1398,1467,1468,1469],{"trials":2114,"activeCount":76},[],{"trials":2116,"activeCount":76},[],{"intervention":1745,"totalTrials":26,"cells":2118},{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2129,"PHASE4":2135,"NA":2137},{"trials":2120,"activeCount":76},[],{"trials":2122,"activeCount":76},[],{"trials":2124,"activeCount":76},[2125],{"nctId":1737,"briefTitle":1738,"status":86,"phases":2126,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":510,"conditions":2127,"interventions":2128},[66,67],[1731],[1744,1717,1745],{"trials":2130,"activeCount":76},[2131],{"nctId":1749,"briefTitle":1750,"status":86,"phases":2132,"start":1752,"enrollment":1753,"conditions":2133,"interventions":2134},[68],[1731],[1744,1756,1717,1745],{"trials":2136,"activeCount":76},[],{"trials":2138,"activeCount":76},[],{"intervention":2140,"totalTrials":26,"cells":2141},"Influenza Vaccine",{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2157,"PHASE4":2167,"NA":2169},{"trials":2143,"activeCount":76},[],{"trials":2145,"activeCount":76},[],{"trials":2147,"activeCount":76},[2148],{"nctId":2149,"briefTitle":2150,"status":86,"phases":2151,"primaryCompletion":2152,"completion":2152,"start":208,"enrollment":2153,"conditions":2154,"interventions":2156},"NCT01013675","Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly",[67],"2011-04",622,[2155],"Influenza Vaccines",[2140,2140],{"trials":2158,"activeCount":76},[2159],{"nctId":2160,"briefTitle":2161,"status":86,"phases":2162,"primaryCompletion":2163,"completion":2163,"start":1695,"enrollment":2164,"conditions":2165,"interventions":2166},"NCT00999206","Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine",[68],"2010-08",3138,[1634],[2140,2140,2140,2140],{"trials":2168,"activeCount":76},[],{"trials":2170,"activeCount":76},[],{"intervention":2172,"totalTrials":26,"cells":2173},"lamivudine\u002Fzidovudine",{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2188,"PHASE4":2199,"NA":2201},{"trials":2175,"activeCount":76},[],{"trials":2177,"activeCount":76},[],{"trials":2179,"activeCount":76},[2180],{"nctId":2181,"briefTitle":2182,"status":86,"phases":2183,"start":1313,"enrollment":520,"conditions":2184,"interventions":2185},"NCT00043953","Lopinavir\u002FRitonavir in Combination With Saquinavir Mesylate or Lamivudine\u002FZidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects",[67],[1731],[1733,2186,2187],"Saquinavir mesylate","Lamivudine\u002Fzidovudine",{"trials":2189,"activeCount":76},[2190],{"nctId":2191,"briefTitle":2192,"status":86,"phases":2193,"primaryCompletion":157,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2197},"NCT00234923","Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients",[68],"2003-08",138,[1831],[2198,2172],"lopinavir\u002Fritonavir",{"trials":2200,"activeCount":76},[],{"trials":2202,"activeCount":76},[],{"intervention":1787,"totalTrials":26,"cells":2204},{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2209,"PHASE3":2220,"PHASE4":2226,"NA":2228},{"trials":2206,"activeCount":76},[],{"trials":2208,"activeCount":76},[],{"trials":2210,"activeCount":76},[2211],{"nctId":2212,"briefTitle":2213,"status":86,"phases":2214,"primaryCompletion":2215,"completion":2215,"start":158,"enrollment":2216,"conditions":2217,"interventions":2218},"NCT00404222","A Study Comparing Vicodin® CR and NORCO® to Placebo in Subjects With Acute Pain Following Bunionectomy",[67],"2006-02",90,[1777],[1787,2219],"Hydrocodone\u002FAcetaminophen Immediate Release",{"trials":2221,"activeCount":76},[2222],{"nctId":1782,"briefTitle":1783,"status":86,"phases":2223,"primaryCompletion":1504,"completion":1504,"start":466,"enrollment":326,"conditions":2224,"interventions":2225},[68],[1777],[1787,1762],{"trials":2227,"activeCount":76},[],{"trials":2229,"activeCount":76},[],{"intervention":2231,"totalTrials":26,"cells":2232},"Nevirapine",{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2243,"PHASE3":2245,"PHASE4":2253,"NA":2255},{"trials":2234,"activeCount":76},[],{"trials":2236,"activeCount":76},[2237],{"nctId":2238,"briefTitle":2239,"status":86,"phases":2240,"conditions":2241,"interventions":2242},"NCT00004580","A Study of ABT-378\u002FRitonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors",[66],[1731],[1744,2231],{"trials":2244,"activeCount":76},[],{"trials":2246,"activeCount":76},[2247],{"nctId":2248,"briefTitle":2249,"status":86,"phases":2250,"enrollment":299,"conditions":2251,"interventions":2252},"NCT00004581","A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment",[68],[1731],[1744,2231],{"trials":2254,"activeCount":76},[],{"trials":2256,"activeCount":76},[],{"intervention":2258,"totalTrials":26,"cells":2259},"Levosimendan",{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2264,"PHASE3":2266,"PHASE4":2287,"NA":2289},{"trials":2261,"activeCount":76},[],{"trials":2263,"activeCount":76},[],{"trials":2265,"activeCount":76},[],{"trials":2267,"activeCount":76},[2268,2277],{"nctId":2269,"briefTitle":2270,"status":86,"phases":2271,"completion":2272,"start":1366,"enrollment":2273,"conditions":2274,"interventions":2276},"NCT00048425","Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.",[68],"2004-12",600,[2275],"Heart Failure, Congestive",[2258],{"nctId":2278,"briefTitle":2279,"status":86,"phases":2280,"completion":569,"start":559,"enrollment":2281,"conditions":2282,"interventions":2284},"NCT00348504","Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.",[68],1300,[2283],"Acute Heart Failure",[2285,2286],"levosimendan","dobutamine",{"trials":2288,"activeCount":76},[],{"trials":2290,"activeCount":76},[],{"intervention":1467,"totalTrials":26,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2309,"NA":2311},{"trials":2294,"activeCount":76},[],{"trials":2296,"activeCount":76},[],{"trials":2298,"activeCount":76},[],{"trials":2300,"activeCount":76},[2301,2305],{"nctId":1459,"briefTitle":1460,"status":86,"phases":2302,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":2303,"interventions":2304},[68],[1438],[1398,1467,1468,1469],{"nctId":1471,"briefTitle":1472,"status":86,"phases":2306,"primaryCompletion":466,"start":1433,"enrollment":1474,"conditions":2307,"interventions":2308},[68],[1436,1437,1438],[1398,1477],{"trials":2310,"activeCount":76},[],{"trials":2312,"activeCount":76},[],{"intervention":2314,"totalTrials":26,"cells":2315},"Racecadotril plus ORS",{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2322,"PHASE4":2345,"NA":2347},{"trials":2317,"activeCount":76},[],{"trials":2319,"activeCount":76},[],{"trials":2321,"activeCount":76},[],{"trials":2323,"activeCount":76},[2324,2335],{"nctId":2325,"briefTitle":2326,"status":86,"phases":2327,"primaryCompletion":2328,"completion":2328,"start":2329,"enrollment":2330,"conditions":2331,"interventions":2333},"NCT03463512","Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea",[68],"2018-09-10","2018-03-29",124,[2332],"Diarrhea",[2314,2334],"ORS",{"nctId":2336,"briefTitle":2337,"status":86,"phases":2338,"primaryCompletion":2339,"completion":2339,"start":2340,"enrollment":2341,"conditions":2342,"interventions":2344},"NCT03473561","Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea",[68],"2020-01-08","2018-08-25",31,[2343],"Diarrhea, Infantile",[2314],{"trials":2346,"activeCount":76},[],{"trials":2348,"activeCount":76},[],{"intervention":2350,"totalTrials":26,"cells":2351},"Pancreatin",{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2358,"PHASE4":2376,"NA":2378},{"trials":2353,"activeCount":76},[],{"trials":2355,"activeCount":76},[],{"trials":2357,"activeCount":76},[],{"trials":2359,"activeCount":76},[2360,2367],{"nctId":2361,"briefTitle":2362,"status":86,"phases":2363,"primaryCompletion":145,"completion":145,"start":1417,"enrollment":2364,"conditions":2365,"interventions":2366},"NCT00705978","Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis",[68],62,[744],[2350],{"nctId":2368,"briefTitle":2369,"status":86,"phases":2370,"primaryCompletion":2371,"completion":2371,"start":2372,"enrollment":1729,"conditions":2373,"interventions":2375},"NCT01747330","Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency",[68],"2012-12","2012-06",[2374],"Pancreatic Exocrine Insufficiency",[2350],{"trials":2377,"activeCount":76},[],{"trials":2379,"activeCount":76},[],{"intervention":1884,"totalTrials":106,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2394,"NA":2396},{"trials":2383,"activeCount":76},[],{"trials":2385,"activeCount":76},[],{"trials":2387,"activeCount":76},[],{"trials":2389,"activeCount":76},[2390],{"nctId":1876,"briefTitle":1877,"status":86,"phases":2391,"primaryCompletion":1879,"completion":1879,"start":1041,"enrollment":1880,"conditions":2392,"interventions":2393},[68],[1882],[1865,1884],{"trials":2395,"activeCount":76},[],{"trials":2397,"activeCount":76},[],{"intervention":1951,"totalTrials":106,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2412,"NA":2414},{"trials":2401,"activeCount":76},[],{"trials":2403,"activeCount":76},[],{"trials":2405,"activeCount":76},[],{"trials":2407,"activeCount":76},[2408],{"nctId":1944,"briefTitle":1945,"status":86,"phases":2409,"primaryCompletion":167,"completion":167,"start":1453,"enrollment":1947,"conditions":2410,"interventions":2411},[68],[1436],[1933,1950,1951],{"trials":2413,"activeCount":76},[],{"trials":2415,"activeCount":76},[],{"intervention":2417,"totalTrials":106,"cells":2418},"Omega-3-acid ethyl ester or Placebo",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2436,"NA":2438},{"trials":2420,"activeCount":76},[],{"trials":2422,"activeCount":76},[],{"trials":2424,"activeCount":76},[],{"trials":2426,"activeCount":76},[2427],{"nctId":2428,"briefTitle":2429,"status":86,"phases":2430,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":2433,"conditions":2434,"interventions":2435},"NCT04756180","An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.",[68],"2019-04","2016-10",248,[880],[2417],{"trials":2437,"activeCount":76},[],{"trials":2439,"activeCount":76},[],{"intervention":2441,"totalTrials":106,"cells":2442},"Adalimumab 40 mg eow or ew",{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2447,"PHASE3":2449,"PHASE4":2459,"NA":2461},{"trials":2444,"activeCount":76},[],{"trials":2446,"activeCount":76},[],{"trials":2448,"activeCount":76},[],{"trials":2450,"activeCount":76},[2451],{"nctId":2452,"briefTitle":2453,"status":86,"phases":2454,"primaryCompletion":1683,"completion":1683,"start":1313,"enrollment":2455,"conditions":2456,"interventions":2458},"NCT01070303","Remission in Subjects With Crohn's Disease, Open Label Extension",[68],177,[2457],"Crohn's Disease",[2441],{"trials":2460,"activeCount":76},[],{"trials":2462,"activeCount":76},[],{"intervention":1711,"totalTrials":106,"cells":2464},{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2477,"NA":2479},{"trials":2466,"activeCount":76},[],{"trials":2468,"activeCount":76},[],{"trials":2470,"activeCount":76},[],{"trials":2472,"activeCount":76},[2473],{"nctId":1692,"briefTitle":1693,"status":263,"phases":2474,"primaryCompletion":1648,"completion":1648,"start":1695,"enrollment":1696,"conditions":2475,"interventions":2476},[68],[1698,1699,1700,1701,1702,1703,1704,1705,1706,1707,1708,1562,1709],[1664,1711],{"trials":2478,"activeCount":76},[],{"trials":2480,"activeCount":76},[],{"intervention":2482,"totalTrials":106,"cells":2483},"Leuprolide acetate - Formulation A",{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2490,"PHASE4":2500,"NA":2502},{"trials":2485,"activeCount":76},[],{"trials":2487,"activeCount":76},[],{"trials":2489,"activeCount":76},[],{"trials":2491,"activeCount":76},[2492],{"nctId":2493,"briefTitle":2494,"status":86,"phases":2495,"primaryCompletion":1042,"completion":2496,"start":1453,"enrollment":1464,"conditions":2497,"interventions":2498},"NCT00626431","A Study of Leuprolide to Treat Prostate Cancer",[68],"2009-09",[1555],[2482,2499],"Leuprolide acetate - Formulation B",{"trials":2501,"activeCount":76},[],{"trials":2503,"activeCount":76},[],{"intervention":2499,"totalTrials":106,"cells":2505},{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2510,"PHASE3":2512,"PHASE4":2518,"NA":2520},{"trials":2507,"activeCount":76},[],{"trials":2509,"activeCount":76},[],{"trials":2511,"activeCount":76},[],{"trials":2513,"activeCount":76},[2514],{"nctId":2493,"briefTitle":2494,"status":86,"phases":2515,"primaryCompletion":1042,"completion":2496,"start":1453,"enrollment":1464,"conditions":2516,"interventions":2517},[68],[1555],[2482,2499],{"trials":2519,"activeCount":76},[],{"trials":2521,"activeCount":76},[],{"intervention":2523,"totalTrials":106,"cells":2524},"Medical management\u002Fcurrent medications per standard of care by personal physician.",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2543,"NA":2545},{"trials":2526,"activeCount":76},[],{"trials":2528,"activeCount":76},[],{"trials":2530,"activeCount":76},[],{"trials":2532,"activeCount":76},[2533],{"nctId":2534,"briefTitle":2535,"status":263,"phases":2536,"primaryCompletion":2537,"completion":2537,"start":158,"enrollment":2538,"conditions":2539,"interventions":2542},"NCT00267371","ESCAPE Migraine Trial",[68],"2012-03",168,[2540,2541],"Migraine Disorders","Heart Septal Defects, Atrial",[2523],{"trials":2544,"activeCount":76},[],{"trials":2546,"activeCount":76},[],{"intervention":2548,"totalTrials":106,"cells":2549},"Fixed Combination of Fenofibrate\u002Fsimvastatin 145\u002F20 mg",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2556,"PHASE4":2570,"NA":2572},{"trials":2551,"activeCount":76},[],{"trials":2553,"activeCount":76},[],{"trials":2555,"activeCount":76},[],{"trials":2557,"activeCount":76},[2558],{"nctId":2559,"briefTitle":2560,"status":86,"phases":2561,"primaryCompletion":2562,"completion":2562,"start":2372,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT01674712","A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate\u002FSimvastatin 145\u002F20mg and Fenofibrate\u002FSimvastatin 145\u002F40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease",[68],"2013-10",575,[1436],[2548,2566,2567,2568,2569],"Simvastatin 20 mg","Fenofibrate 145 mg","Fixed Combination of Fenofibrate\u002Fsimvastatin 145\u002F40 mg","Simvastatin 40 mg",{"trials":2571,"activeCount":76},[],{"trials":2573,"activeCount":76},[],{"intervention":2566,"totalTrials":106,"cells":2575},{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2588,"NA":2590},{"trials":2577,"activeCount":76},[],{"trials":2579,"activeCount":76},[],{"trials":2581,"activeCount":76},[],{"trials":2583,"activeCount":76},[2584],{"nctId":2559,"briefTitle":2560,"status":86,"phases":2585,"primaryCompletion":2562,"completion":2562,"start":2372,"enrollment":2563,"conditions":2586,"interventions":2587},[68],[1436],[2548,2566,2567,2568,2569],{"trials":2589,"activeCount":76},[],{"trials":2591,"activeCount":76},[],{"intervention":2567,"totalTrials":106,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2606,"NA":2608},{"trials":2595,"activeCount":76},[],{"trials":2597,"activeCount":76},[],{"trials":2599,"activeCount":76},[],{"trials":2601,"activeCount":76},[2602],{"nctId":2559,"briefTitle":2560,"status":86,"phases":2603,"primaryCompletion":2562,"completion":2562,"start":2372,"enrollment":2563,"conditions":2604,"interventions":2605},[68],[1436],[2548,2566,2567,2568,2569],{"trials":2607,"activeCount":76},[],{"trials":2609,"activeCount":76},[],{"intervention":2568,"totalTrials":106,"cells":2611},{"EARLY_PHASE1":2612,"PHASE1":2614,"PHASE2":2616,"PHASE3":2618,"PHASE4":2624,"NA":2626},{"trials":2613,"activeCount":76},[],{"trials":2615,"activeCount":76},[],{"trials":2617,"activeCount":76},[],{"trials":2619,"activeCount":76},[2620],{"nctId":2559,"briefTitle":2560,"status":86,"phases":2621,"primaryCompletion":2562,"completion":2562,"start":2372,"enrollment":2563,"conditions":2622,"interventions":2623},[68],[1436],[2548,2566,2567,2568,2569],{"trials":2625,"activeCount":76},[],{"trials":2627,"activeCount":76},[],{"intervention":2569,"totalTrials":106,"cells":2629},{"EARLY_PHASE1":2630,"PHASE1":2632,"PHASE2":2634,"PHASE3":2636,"PHASE4":2642,"NA":2644},{"trials":2631,"activeCount":76},[],{"trials":2633,"activeCount":76},[],{"trials":2635,"activeCount":76},[],{"trials":2637,"activeCount":76},[2638],{"nctId":2559,"briefTitle":2560,"status":86,"phases":2639,"primaryCompletion":2562,"completion":2562,"start":2372,"enrollment":2563,"conditions":2640,"interventions":2641},[68],[1436],[2548,2566,2567,2568,2569],{"trials":2643,"activeCount":76},[],{"trials":2645,"activeCount":76},[],{"intervention":2647,"totalTrials":106,"cells":2648},"Calcipotriol\u002FBetamethasone Ointment",{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2655,"PHASE4":2666,"NA":2668},{"trials":2650,"activeCount":76},[],{"trials":2652,"activeCount":76},[],{"trials":2654,"activeCount":76},[],{"trials":2656,"activeCount":76},[2657],{"nctId":2658,"briefTitle":2659,"status":86,"phases":2660,"primaryCompletion":1452,"start":2661,"enrollment":2662,"conditions":2663,"interventions":2665},"NCT00574249","Adalimumab in Combination With Topical Treatment (Calcipotriol\u002FBetamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment",[68],"2007-11",730,[2664],"Chronic Plaque Psoriasis",[554,2647],{"trials":2667,"activeCount":76},[],{"trials":2669,"activeCount":76},[],{"intervention":2671,"totalTrials":106,"cells":2672},"Double-blind (DB) adalimumab placebo",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2690,"NA":2692},{"trials":2674,"activeCount":76},[],{"trials":2676,"activeCount":76},[],{"trials":2678,"activeCount":76},[],{"trials":2680,"activeCount":76},[2681],{"nctId":2682,"briefTitle":2683,"status":86,"phases":2684,"primaryCompletion":1365,"completion":1683,"start":1313,"enrollment":1956,"conditions":2685,"interventions":2686},"NCT00055497","Remission in Subjects With Crohn's Disease, 1 Year Phase",[68],[2457],[2671,2687,2688,2689],"DB adalimumab 40 mg eow","DB adalimumab 40 mg ew","OL adalimumab 40 mg",{"trials":2691,"activeCount":76},[],{"trials":2693,"activeCount":76},[],{"intervention":2687,"totalTrials":106,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2702,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":76},[],{"trials":2699,"activeCount":76},[],{"trials":2701,"activeCount":76},[],{"trials":2703,"activeCount":76},[2704],{"nctId":2682,"briefTitle":2683,"status":86,"phases":2705,"primaryCompletion":1365,"completion":1683,"start":1313,"enrollment":1956,"conditions":2706,"interventions":2707},[68],[2457],[2671,2687,2688,2689],{"trials":2709,"activeCount":76},[],{"trials":2711,"activeCount":76},[],{"intervention":2688,"totalTrials":106,"cells":2713},{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2718,"PHASE3":2720,"PHASE4":2726,"NA":2728},{"trials":2715,"activeCount":76},[],{"trials":2717,"activeCount":76},[],{"trials":2719,"activeCount":76},[],{"trials":2721,"activeCount":76},[2722],{"nctId":2682,"briefTitle":2683,"status":86,"phases":2723,"primaryCompletion":1365,"completion":1683,"start":1313,"enrollment":1956,"conditions":2724,"interventions":2725},[68],[2457],[2671,2687,2688,2689],{"trials":2727,"activeCount":76},[],{"trials":2729,"activeCount":76},[],{"intervention":2689,"totalTrials":106,"cells":2731},{"EARLY_PHASE1":2732,"PHASE1":2734,"PHASE2":2736,"PHASE3":2738,"PHASE4":2744,"NA":2746},{"trials":2733,"activeCount":76},[],{"trials":2735,"activeCount":76},[],{"trials":2737,"activeCount":76},[],{"trials":2739,"activeCount":76},[2740],{"nctId":2682,"briefTitle":2683,"status":86,"phases":2741,"primaryCompletion":1365,"completion":1683,"start":1313,"enrollment":1956,"conditions":2742,"interventions":2743},[68],[2457],[2671,2687,2688,2689],{"trials":2745,"activeCount":76},[],{"trials":2747,"activeCount":76},[],{"intervention":1824,"totalTrials":106,"cells":2749},{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2756,"PHASE4":2762,"NA":2764},{"trials":2751,"activeCount":76},[],{"trials":2753,"activeCount":76},[],{"trials":2755,"activeCount":76},[],{"trials":2757,"activeCount":76},[2758],{"nctId":1819,"briefTitle":1820,"status":86,"phases":2759,"start":382,"enrollment":542,"conditions":2760,"interventions":2761},[68],[1731],[1733,1735,1824],{"trials":2763,"activeCount":76},[],{"trials":2765,"activeCount":76},[],{"intervention":1927,"totalTrials":106,"cells":2767},{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2774,"PHASE4":2780,"NA":2782},{"trials":2769,"activeCount":76},[],{"trials":2771,"activeCount":76},[],{"trials":2773,"activeCount":76},[],{"trials":2775,"activeCount":76},[2776],{"nctId":1920,"briefTitle":1921,"status":86,"phases":2777,"primaryCompletion":732,"completion":732,"start":1923,"enrollment":1071,"conditions":2778,"interventions":2779},[68],[1925],[1900,1927],{"trials":2781,"activeCount":76},[],{"trials":2783,"activeCount":76},[],{"intervention":1508,"totalTrials":106,"cells":2785},{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2792,"PHASE4":2798,"NA":2800},{"trials":2787,"activeCount":76},[],{"trials":2789,"activeCount":76},[],{"trials":2791,"activeCount":76},[],{"trials":2793,"activeCount":76},[2794],{"nctId":1501,"briefTitle":1502,"status":86,"phases":2795,"primaryCompletion":1453,"start":1504,"enrollment":1505,"conditions":2796,"interventions":2797},[68],[863,1438],[1508,866],{"trials":2799,"activeCount":76},[],{"trials":2801,"activeCount":76},[],{"intervention":1798,"totalTrials":106,"cells":2803},{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2810,"PHASE4":2816,"NA":2818},{"trials":2805,"activeCount":76},[],{"trials":2807,"activeCount":76},[],{"trials":2809,"activeCount":76},[],{"trials":2811,"activeCount":76},[2812],{"nctId":1789,"briefTitle":1790,"status":86,"phases":2813,"primaryCompletion":1792,"completion":1463,"start":1793,"enrollment":1794,"conditions":2814,"interventions":2815},[68],[1796],[1798,1799],{"trials":2817,"activeCount":76},[],{"trials":2819,"activeCount":76},[],{"intervention":2821,"totalTrials":106,"cells":2822},"paricalcitol injection 4 mcg\u002FmL",{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2827,"PHASE3":2829,"PHASE4":2839,"NA":2841},{"trials":2824,"activeCount":76},[],{"trials":2826,"activeCount":76},[],{"trials":2828,"activeCount":76},[],{"trials":2830,"activeCount":76},[2831],{"nctId":2832,"briefTitle":2833,"status":263,"phases":2834,"primaryCompletion":509,"completion":509,"start":266,"enrollment":1285,"conditions":2835,"interventions":2838},"NCT00616902","The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5",[68],[2836,2837],"Chronic Kidney Disease (CKD) Stage 5","Hypertrophy, Left Ventricular",[2821],{"trials":2840,"activeCount":76},[],{"trials":2842,"activeCount":76},[],{"intervention":2844,"totalTrials":106,"cells":2845},"sibutramine or placebo",{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2852,"PHASE4":2863,"NA":2865},{"trials":2847,"activeCount":76},[],{"trials":2849,"activeCount":76},[],{"trials":2851,"activeCount":76},[],{"trials":2853,"activeCount":76},[2854],{"nctId":2855,"briefTitle":2856,"status":263,"phases":2857,"primaryCompletion":289,"start":2858,"enrollment":2859,"conditions":2860,"interventions":2862},"NCT00645255","Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects",[68],"1998-09",466,[1115,2861],"Weight Loss",[2844],{"trials":2864,"activeCount":76},[],{"trials":2866,"activeCount":76},[],{"intervention":2868,"totalTrials":106,"cells":2869},"Leuprolide acetate 11.25 mg",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2876,"PHASE4":2886,"NA":2888},{"trials":2871,"activeCount":76},[],{"trials":2873,"activeCount":76},[],{"trials":2875,"activeCount":76},[],{"trials":2877,"activeCount":76},[2878],{"nctId":2879,"briefTitle":2880,"status":86,"phases":2881,"primaryCompletion":1695,"completion":1640,"start":1417,"enrollment":23,"conditions":2882,"interventions":2884},"NCT00635817","A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty",[68],[2883],"Puberty, Precocious",[2868,2885],"Leuprolide acetate 30 mg",{"trials":2887,"activeCount":76},[],{"trials":2889,"activeCount":76},[],{"intervention":2885,"totalTrials":106,"cells":2891},{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2898,"PHASE4":2904,"NA":2906},{"trials":2893,"activeCount":76},[],{"trials":2895,"activeCount":76},[],{"trials":2897,"activeCount":76},[],{"trials":2899,"activeCount":76},[2900],{"nctId":2879,"briefTitle":2880,"status":86,"phases":2901,"primaryCompletion":1695,"completion":1640,"start":1417,"enrollment":23,"conditions":2902,"interventions":2903},[68],[2883],[2868,2885],{"trials":2905,"activeCount":76},[],{"trials":2907,"activeCount":76},[],{"intervention":2909,"totalTrials":106,"cells":2910},"Sibutramine hydrochloride",{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2917,"PHASE4":2926,"NA":2928},{"trials":2912,"activeCount":76},[],{"trials":2914,"activeCount":76},[],{"trials":2916,"activeCount":76},[],{"trials":2918,"activeCount":76},[2919],{"nctId":2920,"briefTitle":2921,"status":86,"phases":2922,"primaryCompletion":166,"completion":208,"start":289,"enrollment":2923,"conditions":2924,"interventions":2925},"NCT00234832","A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients",[68],10777,[1115],[2909,2909],{"trials":2927,"activeCount":76},[],{"trials":2929,"activeCount":76},[],{"intervention":1594,"totalTrials":106,"cells":2931},{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2944,"NA":2946},{"trials":2933,"activeCount":76},[],{"trials":2935,"activeCount":76},[],{"trials":2937,"activeCount":76},[],{"trials":2939,"activeCount":76},[2940],{"nctId":1588,"briefTitle":1589,"status":86,"phases":2941,"primaryCompletion":541,"start":198,"enrollment":1591,"conditions":2942,"interventions":2943},[68],[1115,601],[1569,1569,1594,1595,1596],{"trials":2945,"activeCount":76},[],{"trials":2947,"activeCount":76},[],{"intervention":1595,"totalTrials":106,"cells":2949},{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2962,"NA":2964},{"trials":2951,"activeCount":76},[],{"trials":2953,"activeCount":76},[],{"trials":2955,"activeCount":76},[],{"trials":2957,"activeCount":76},[2958],{"nctId":1588,"briefTitle":1589,"status":86,"phases":2959,"primaryCompletion":541,"start":198,"enrollment":1591,"conditions":2960,"interventions":2961},[68],[1115,601],[1569,1569,1594,1595,1596],{"trials":2963,"activeCount":76},[],{"trials":2965,"activeCount":76},[],{"intervention":1596,"totalTrials":106,"cells":2967},{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":2974,"PHASE4":2980,"NA":2982},{"trials":2969,"activeCount":76},[],{"trials":2971,"activeCount":76},[],{"trials":2973,"activeCount":76},[],{"trials":2975,"activeCount":76},[2976],{"nctId":1588,"briefTitle":1589,"status":86,"phases":2977,"primaryCompletion":541,"start":198,"enrollment":1591,"conditions":2978,"interventions":2979},[68],[1115,601],[1569,1569,1594,1595,1596],{"trials":2981,"activeCount":76},[],{"trials":2983,"activeCount":76},[],{"intervention":2985,"totalTrials":106,"cells":2986},"Double-Blind Adalimumab\u002FPlacebo + MTX",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":2993,"PHASE4":3005,"NA":3007},{"trials":2988,"activeCount":76},[],{"trials":2990,"activeCount":76},[],{"trials":2992,"activeCount":76},[],{"trials":2994,"activeCount":76},[2995],{"nctId":2996,"briefTitle":2997,"status":86,"phases":2998,"primaryCompletion":1365,"completion":1640,"start":1366,"enrollment":1591,"conditions":2999,"interventions":3001},"NCT00048542","Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)",[68],[3000],"Arthritis, Juvenile Idiopathic",[2985,3002,3003,3004],"Double-Blind Adalimumab\u002FPlacebo","OLE BSA Adalimumab +\u002F- MTX","OLE FD Adalimumab +\u002F- MTX",{"trials":3006,"activeCount":76},[],{"trials":3008,"activeCount":76},[],{"intervention":3002,"totalTrials":106,"cells":3010},{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3017,"PHASE4":3023,"NA":3025},{"trials":3012,"activeCount":76},[],{"trials":3014,"activeCount":76},[],{"trials":3016,"activeCount":76},[],{"trials":3018,"activeCount":76},[3019],{"nctId":2996,"briefTitle":2997,"status":86,"phases":3020,"primaryCompletion":1365,"completion":1640,"start":1366,"enrollment":1591,"conditions":3021,"interventions":3022},[68],[3000],[2985,3002,3003,3004],{"trials":3024,"activeCount":76},[],{"trials":3026,"activeCount":76},[],{"intervention":3003,"totalTrials":106,"cells":3028},{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3033,"PHASE3":3035,"PHASE4":3041,"NA":3043},{"trials":3030,"activeCount":76},[],{"trials":3032,"activeCount":76},[],{"trials":3034,"activeCount":76},[],{"trials":3036,"activeCount":76},[3037],{"nctId":2996,"briefTitle":2997,"status":86,"phases":3038,"primaryCompletion":1365,"completion":1640,"start":1366,"enrollment":1591,"conditions":3039,"interventions":3040},[68],[3000],[2985,3002,3003,3004],{"trials":3042,"activeCount":76},[],{"trials":3044,"activeCount":76},[],{"intervention":3004,"totalTrials":106,"cells":3046},{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3051,"PHASE3":3053,"PHASE4":3059,"NA":3061},{"trials":3048,"activeCount":76},[],{"trials":3050,"activeCount":76},[],{"trials":3052,"activeCount":76},[],{"trials":3054,"activeCount":76},[3055],{"nctId":2996,"briefTitle":2997,"status":86,"phases":3056,"primaryCompletion":1365,"completion":1640,"start":1366,"enrollment":1591,"conditions":3057,"interventions":3058},[68],[3000],[2985,3002,3003,3004],{"trials":3060,"activeCount":76},[],{"trials":3062,"activeCount":76},[],{"intervention":3064,"totalTrials":106,"cells":3065},"Ademetionine IV+tablet",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3072,"PHASE4":3083,"NA":3085},{"trials":3067,"activeCount":76},[],{"trials":3069,"activeCount":76},[],{"trials":3071,"activeCount":76},[],{"trials":3073,"activeCount":76},[3074],{"nctId":3075,"briefTitle":3076,"status":86,"phases":3077,"primaryCompletion":1040,"completion":1040,"start":3078,"enrollment":223,"conditions":3079,"interventions":3081},"NCT02200029","Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption",[68],"2014-06",[3080],"Intrahepatic Cholestasis Associated With Alcoholic Liver Disease",[3064,3082],"Ademetionine",{"trials":3084,"activeCount":76},[],{"trials":3086,"activeCount":76},[],{"intervention":3082,"totalTrials":106,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3095,"PHASE4":3101,"NA":3103},{"trials":3090,"activeCount":76},[],{"trials":3092,"activeCount":76},[],{"trials":3094,"activeCount":76},[],{"trials":3096,"activeCount":76},[3097],{"nctId":3075,"briefTitle":3076,"status":86,"phases":3098,"primaryCompletion":1040,"completion":1040,"start":3078,"enrollment":223,"conditions":3099,"interventions":3100},[68],[3080],[3064,3082],{"trials":3102,"activeCount":76},[],{"trials":3104,"activeCount":76},[],{"intervention":1960,"totalTrials":106,"cells":3106},{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3119,"NA":3121},{"trials":3108,"activeCount":76},[],{"trials":3110,"activeCount":76},[],{"trials":3112,"activeCount":76},[],{"trials":3114,"activeCount":76},[3115],{"nctId":1953,"briefTitle":1954,"status":86,"phases":3116,"primaryCompletion":1417,"completion":1417,"start":1453,"enrollment":1956,"conditions":3117,"interventions":3118},[68],[1436],[1959,1960,1961,1962],{"trials":3120,"activeCount":76},[],{"trials":3122,"activeCount":76},[],{"intervention":1962,"totalTrials":106,"cells":3124},{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3131,"PHASE4":3137,"NA":3139},{"trials":3126,"activeCount":76},[],{"trials":3128,"activeCount":76},[],{"trials":3130,"activeCount":76},[],{"trials":3132,"activeCount":76},[3133],{"nctId":1953,"briefTitle":1954,"status":86,"phases":3134,"primaryCompletion":1417,"completion":1417,"start":1453,"enrollment":1956,"conditions":3135,"interventions":3136},[68],[1436],[1959,1960,1961,1962],{"trials":3138,"activeCount":76},[],{"trials":3140,"activeCount":76},[],{"intervention":3142,"totalTrials":106,"cells":3143},"MTX",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3150,"PHASE4":3159,"NA":3161},{"trials":3145,"activeCount":76},[],{"trials":3147,"activeCount":76},[],{"trials":3149,"activeCount":76},[],{"trials":3151,"activeCount":76},[3152],{"nctId":3153,"briefTitle":3154,"status":86,"phases":3155,"primaryCompletion":1793,"start":3156,"enrollment":404,"conditions":3157,"interventions":3158},"NCT00235820","Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[68],"2005-07",[702],[554,3142],{"trials":3160,"activeCount":76},[],{"trials":3162,"activeCount":76},[],{"intervention":3164,"totalTrials":106,"cells":3165},"atrasentan hydrochloride",{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3172,"PHASE4":3180,"NA":3182},{"trials":3167,"activeCount":76},[],{"trials":3169,"activeCount":76},[],{"trials":3171,"activeCount":76},[],{"trials":3173,"activeCount":76},[3174],{"nctId":3175,"briefTitle":3176,"status":86,"phases":3177,"primaryCompletion":1463,"start":1366,"conditions":3178,"interventions":3179},"NCT00046943","Atrasentan in Treating Patients With Prostate Cancer",[68],[1555],[3164],{"trials":3181,"activeCount":76},[],{"trials":3183,"activeCount":76},[],{"intervention":3185,"totalTrials":106,"cells":3186},"Phleum pratense grass pollen allergen extract",{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3203,"NA":3205},{"trials":3188,"activeCount":76},[],{"trials":3190,"activeCount":76},[],{"trials":3192,"activeCount":76},[],{"trials":3194,"activeCount":76},[3195],{"nctId":3196,"briefTitle":3197,"status":86,"phases":3198,"primaryCompletion":1656,"completion":1656,"start":3199,"enrollment":189,"conditions":3200,"interventions":3202},"NCT02245360","Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis",[68],"2014-10",[3201],"Seasonal Allergic Rhinitis",[3185],{"trials":3204,"activeCount":76},[],{"trials":3206,"activeCount":76},[],{"intervention":3208,"totalTrials":106,"cells":3209},"Human anti-TNF monoclonal antibody\u002Fadalimumab",{"EARLY_PHASE1":3210,"PHASE1":3212,"PHASE2":3214,"PHASE3":3216,"PHASE4":3225,"NA":3227},{"trials":3211,"activeCount":76},[],{"trials":3213,"activeCount":76},[],{"trials":3215,"activeCount":76},[],{"trials":3217,"activeCount":76},[3218],{"nctId":3219,"briefTitle":3220,"status":86,"phases":3221,"start":2194,"enrollment":804,"conditions":3222,"interventions":3224},"NCT00195689","Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis",[68],[3223],"Psoriatic Arthritis",[3208],{"trials":3226,"activeCount":76},[],{"trials":3228,"activeCount":76},[],{"intervention":3230,"totalTrials":106,"cells":3231},"SAMe 1000 mg",{"EARLY_PHASE1":3232,"PHASE1":3234,"PHASE2":3236,"PHASE3":3238,"PHASE4":3251,"NA":3253},{"trials":3233,"activeCount":76},[],{"trials":3235,"activeCount":76},[],{"trials":3237,"activeCount":76},[],{"trials":3239,"activeCount":76},[3240],{"nctId":3241,"briefTitle":3242,"status":86,"phases":3243,"primaryCompletion":3244,"completion":3244,"start":2371,"enrollment":3245,"conditions":3246,"interventions":3248},"NCT01754714","Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group",[68],"2014-09",108,[3247],"Non Alcoholic Fatty Liver Disease",[3230,3249,3250],"SAMe 1500 mg","SAMe 2000 mg",{"trials":3252,"activeCount":76},[],{"trials":3254,"activeCount":76},[],{"intervention":3249,"totalTrials":106,"cells":3256},{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3269,"NA":3271},{"trials":3258,"activeCount":76},[],{"trials":3260,"activeCount":76},[],{"trials":3262,"activeCount":76},[],{"trials":3264,"activeCount":76},[3265],{"nctId":3241,"briefTitle":3242,"status":86,"phases":3266,"primaryCompletion":3244,"completion":3244,"start":2371,"enrollment":3245,"conditions":3267,"interventions":3268},[68],[3247],[3230,3249,3250],{"trials":3270,"activeCount":76},[],{"trials":3272,"activeCount":76},[],{"intervention":3250,"totalTrials":106,"cells":3274},{"EARLY_PHASE1":3275,"PHASE1":3277,"PHASE2":3279,"PHASE3":3281,"PHASE4":3287,"NA":3289},{"trials":3276,"activeCount":76},[],{"trials":3278,"activeCount":76},[],{"trials":3280,"activeCount":76},[],{"trials":3282,"activeCount":76},[3283],{"nctId":3241,"briefTitle":3242,"status":86,"phases":3284,"primaryCompletion":3244,"completion":3244,"start":2371,"enrollment":3245,"conditions":3285,"interventions":3286},[68],[3247],[3230,3249,3250],{"trials":3288,"activeCount":76},[],{"trials":3290,"activeCount":76},[],{"intervention":3292,"totalTrials":106,"cells":3293},"palivizumab",{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3300,"PHASE4":3313,"NA":3315},{"trials":3295,"activeCount":76},[],{"trials":3297,"activeCount":76},[],{"trials":3299,"activeCount":76},[],{"trials":3301,"activeCount":76},[3302],{"nctId":3303,"briefTitle":3304,"status":86,"phases":3305,"primaryCompletion":3306,"completion":254,"start":208,"enrollment":510,"conditions":3307,"interventions":3312},"NCT01006629","Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children",[67,68],"2010-04",[3308,3309,3310,3311],"Respiratory Syncytial Virus Infection","Premature Birth","Bronchopulmonary Dysplasia","Congenital Heart Disease",[3292],{"trials":3314,"activeCount":76},[],{"trials":3316,"activeCount":76},[],{"intervention":1469,"totalTrials":106,"cells":3318},{"EARLY_PHASE1":3319,"PHASE1":3321,"PHASE2":3323,"PHASE3":3325,"PHASE4":3331,"NA":3333},{"trials":3320,"activeCount":76},[],{"trials":3322,"activeCount":76},[],{"trials":3324,"activeCount":76},[],{"trials":3326,"activeCount":76},[3327],{"nctId":1459,"briefTitle":1460,"status":86,"phases":3328,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":3329,"interventions":3330},[68],[1438],[1398,1467,1468,1469],{"trials":3332,"activeCount":76},[],{"trials":3334,"activeCount":76},[],{"intervention":2334,"totalTrials":106,"cells":3336},{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3349,"NA":3351},{"trials":3338,"activeCount":76},[],{"trials":3340,"activeCount":76},[],{"trials":3342,"activeCount":76},[],{"trials":3344,"activeCount":76},[3345],{"nctId":2325,"briefTitle":2326,"status":86,"phases":3346,"primaryCompletion":2328,"completion":2328,"start":2329,"enrollment":2330,"conditions":3347,"interventions":3348},[68],[2332],[2314,2334],{"trials":3350,"activeCount":76},[],{"trials":3352,"activeCount":76},[],{"intervention":3354,"totalTrials":106,"cells":3355},"Eprosartan",{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3360,"PHASE3":3362,"PHASE4":3373,"NA":3375},{"trials":3357,"activeCount":76},[],{"trials":3359,"activeCount":76},[],{"trials":3361,"activeCount":76},[],{"trials":3363,"activeCount":76},[3364],{"nctId":3365,"briefTitle":3366,"status":86,"phases":3367,"primaryCompletion":997,"completion":997,"start":2372,"enrollment":3368,"conditions":3369,"interventions":3371},"NCT01631227","Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension",[68],665,[3370],"Essential Hypertension",[3354,3372],"Eprosartan Mesylate",{"trials":3374,"activeCount":76},[],{"trials":3376,"activeCount":76},[],{"intervention":3372,"totalTrials":106,"cells":3378},{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3391,"NA":3393},{"trials":3380,"activeCount":76},[],{"trials":3382,"activeCount":76},[],{"trials":3384,"activeCount":76},[],{"trials":3386,"activeCount":76},[3387],{"nctId":3365,"briefTitle":3366,"status":86,"phases":3388,"primaryCompletion":997,"completion":997,"start":2372,"enrollment":3368,"conditions":3389,"interventions":3390},[68],[3370],[3354,3372],{"trials":3392,"activeCount":76},[],{"trials":3394,"activeCount":76},[],{"intervention":3396,"totalTrials":106,"cells":3397},"emtricitabine\u002Ftenofovir disoproxil fumarate",{"EARLY_PHASE1":3398,"PHASE1":3400,"PHASE2":3402,"PHASE3":3404,"PHASE4":3416,"NA":3418},{"trials":3399,"activeCount":76},[],{"trials":3401,"activeCount":76},[],{"trials":3403,"activeCount":76},[],{"trials":3405,"activeCount":76},[3406],{"nctId":3407,"briefTitle":3408,"status":86,"phases":3409,"primaryCompletion":208,"completion":3410,"start":188,"enrollment":3411,"conditions":3412,"interventions":3414},"NCT00711009","Study Comparing Lopinavir\u002FRitonavir (LPV\u002Fr) + Emtricitabine\u002FTenofovir Disoproxil Fumarate (FTC\u002FTDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir\u002FRitonavir + Raltegravir (RAL)",[68],"2010-10",206,[3413],"Human Immunodeficiency Virus Infection",[2198,3396,3415],"raltegravir",{"trials":3417,"activeCount":76},[],{"trials":3419,"activeCount":76},[],{"intervention":3415,"totalTrials":106,"cells":3421},{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3428,"PHASE4":3434,"NA":3436},{"trials":3423,"activeCount":76},[],{"trials":3425,"activeCount":76},[],{"trials":3427,"activeCount":76},[],{"trials":3429,"activeCount":76},[3430],{"nctId":3407,"briefTitle":3408,"status":86,"phases":3431,"primaryCompletion":208,"completion":3410,"start":188,"enrollment":3411,"conditions":3432,"interventions":3433},[68],[3413],[2198,3396,3415],{"trials":3435,"activeCount":76},[],{"trials":3437,"activeCount":76},[],{"intervention":3439,"totalTrials":106,"cells":3440},"clarithromycin extended-release",{"EARLY_PHASE1":3441,"PHASE1":3443,"PHASE2":3445,"PHASE3":3447,"PHASE4":3458,"NA":3460},{"trials":3442,"activeCount":76},[],{"trials":3444,"activeCount":76},[],{"trials":3446,"activeCount":76},[],{"trials":3448,"activeCount":76},[3449],{"nctId":3450,"briefTitle":3451,"status":86,"phases":3452,"primaryCompletion":1389,"start":1305,"enrollment":3453,"conditions":3454,"interventions":3456},"NCT00645086","Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis",[68],465,[3455],"Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).",[3439,3457],"clarithromycin immediate-release",{"trials":3459,"activeCount":76},[],{"trials":3461,"activeCount":76},[],{"intervention":3457,"totalTrials":106,"cells":3463},{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3468,"PHASE3":3470,"PHASE4":3476,"NA":3478},{"trials":3465,"activeCount":76},[],{"trials":3467,"activeCount":76},[],{"trials":3469,"activeCount":76},[],{"trials":3471,"activeCount":76},[3472],{"nctId":3450,"briefTitle":3451,"status":86,"phases":3473,"primaryCompletion":1389,"start":1305,"enrollment":3453,"conditions":3474,"interventions":3475},[68],[3455],[3439,3457],{"trials":3477,"activeCount":76},[],{"trials":3479,"activeCount":76},[],{"intervention":1833,"totalTrials":106,"cells":3481},{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3486,"PHASE3":3488,"PHASE4":3494,"NA":3496},{"trials":3483,"activeCount":76},[],{"trials":3485,"activeCount":76},[],{"trials":3487,"activeCount":76},[],{"trials":3489,"activeCount":76},[3490],{"nctId":1826,"briefTitle":1827,"status":86,"phases":3491,"primaryCompletion":1463,"completion":1417,"start":1365,"enrollment":1829,"conditions":3492,"interventions":3493},[68],[1831],[1735,1833],{"trials":3495,"activeCount":76},[],{"trials":3497,"activeCount":76},[],{"intervention":3499,"totalTrials":106,"cells":3500},"Adalimumab 40 mg subcutaneous",{"EARLY_PHASE1":3501,"PHASE1":3503,"PHASE2":3505,"PHASE3":3507,"PHASE4":3517,"NA":3519},{"trials":3502,"activeCount":76},[],{"trials":3504,"activeCount":76},[],{"trials":3506,"activeCount":76},[],{"trials":3508,"activeCount":76},[3509],{"nctId":3510,"briefTitle":3511,"status":86,"phases":3512,"primaryCompletion":1070,"completion":1070,"start":3513,"enrollment":3514,"conditions":3515,"interventions":3516},"NCT00233571","A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis",[68],"2000-06",796,[39],[3499],{"trials":3518,"activeCount":76},[],{"trials":3520,"activeCount":76},[],{"intervention":3522,"totalTrials":106,"cells":3523},"ABT-335 and rosuvastatin calcium",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3528,"PHASE3":3530,"PHASE4":3543,"NA":3545},{"trials":3525,"activeCount":76},[],{"trials":3527,"activeCount":76},[],{"trials":3529,"activeCount":76},[],{"trials":3531,"activeCount":76},[3532],{"nctId":3533,"briefTitle":3534,"status":86,"phases":3535,"primaryCompletion":3536,"start":3537,"enrollment":3538,"conditions":3539,"interventions":3540},"NCT00300430","Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",[68],"2008-03","2006-09",1911,[1436,1437,1438],[3522,3541,3542],"ABT-335 and atorvastatin calcium","ABT-335 and simvastatin",{"trials":3544,"activeCount":76},[],{"trials":3546,"activeCount":76},[],{"intervention":3541,"totalTrials":106,"cells":3548},{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3561,"NA":3563},{"trials":3550,"activeCount":76},[],{"trials":3552,"activeCount":76},[],{"trials":3554,"activeCount":76},[],{"trials":3556,"activeCount":76},[3557],{"nctId":3533,"briefTitle":3534,"status":86,"phases":3558,"primaryCompletion":3536,"start":3537,"enrollment":3538,"conditions":3559,"interventions":3560},[68],[1436,1437,1438],[3522,3541,3542],{"trials":3562,"activeCount":76},[],{"trials":3564,"activeCount":76},[],{"intervention":3542,"totalTrials":106,"cells":3566},{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3573,"PHASE4":3579,"NA":3581},{"trials":3568,"activeCount":76},[],{"trials":3570,"activeCount":76},[],{"trials":3572,"activeCount":76},[],{"trials":3574,"activeCount":76},[3575],{"nctId":3533,"briefTitle":3534,"status":86,"phases":3576,"primaryCompletion":3536,"start":3537,"enrollment":3538,"conditions":3577,"interventions":3578},[68],[1436,1437,1438],[3522,3541,3542],{"trials":3580,"activeCount":76},[],{"trials":3582,"activeCount":76},[],{"intervention":3584,"totalTrials":106,"cells":3585},"Itopride Hydrochloride 150 mg extended release",{"EARLY_PHASE1":3586,"PHASE1":3588,"PHASE2":3590,"PHASE3":3592,"PHASE4":3605,"NA":3607},{"trials":3587,"activeCount":76},[],{"trials":3589,"activeCount":76},[],{"trials":3591,"activeCount":76},[],{"trials":3593,"activeCount":76},[3594],{"nctId":3595,"briefTitle":3596,"status":86,"phases":3597,"primaryCompletion":3598,"completion":3598,"start":3599,"enrollment":3600,"conditions":3601,"interventions":3603},"NCT06217393","Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia",[68],"2025-02-28","2024-02-28",564,[3602],"Functional Dyspepsia",[3584,3604],"Itopride Hydrochloride 50 mg film coated",{"trials":3606,"activeCount":76},[],{"trials":3608,"activeCount":76},[],{"intervention":3604,"totalTrials":106,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3617,"PHASE4":3623,"NA":3625},{"trials":3612,"activeCount":76},[],{"trials":3614,"activeCount":76},[],{"trials":3616,"activeCount":76},[],{"trials":3618,"activeCount":76},[3619],{"nctId":3595,"briefTitle":3596,"status":86,"phases":3620,"primaryCompletion":3598,"completion":3598,"start":3599,"enrollment":3600,"conditions":3621,"interventions":3622},[68],[3602],[3584,3604],{"trials":3624,"activeCount":76},[],{"trials":3626,"activeCount":76},[],{"intervention":3628,"totalTrials":106,"cells":3629},"hydrocodone \u002F acetaminophen extended release",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3636,"PHASE4":3646,"NA":3648},{"trials":3631,"activeCount":76},[],{"trials":3633,"activeCount":76},[],{"trials":3635,"activeCount":76},[],{"trials":3637,"activeCount":76},[3638],{"nctId":3639,"briefTitle":3640,"status":86,"phases":3641,"primaryCompletion":1792,"completion":1792,"start":2215,"enrollment":3642,"conditions":3643,"interventions":3645},"NCT00298974","A Study of Pain Relief in Osteoarthritis",[68],873,[3644],"Osteoarthritis",[3628],{"trials":3647,"activeCount":76},[],{"trials":3649,"activeCount":76},[],{"intervention":3651,"totalTrials":106,"cells":3652},"Testosterone (T) Gel 1.62%",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3659,"PHASE4":3669,"NA":3671},{"trials":3654,"activeCount":76},[],{"trials":3656,"activeCount":76},[],{"trials":3658,"activeCount":76},[],{"trials":3660,"activeCount":76},[3661],{"nctId":3662,"briefTitle":3663,"status":86,"phases":3664,"primaryCompletion":3665,"completion":167,"start":157,"enrollment":2079,"conditions":3666,"interventions":3668},"NCT00433199","Testosterone Treatment for Hypogonadal Men",[68],"2007-10",[3667],"Hypogonadism",[3651],{"trials":3670,"activeCount":76},[],{"trials":3672,"activeCount":76},[],{"intervention":3674,"totalTrials":106,"cells":3675},"Creon® 25000",{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3696,"NA":3698},{"trials":3677,"activeCount":76},[],{"trials":3679,"activeCount":76},[],{"trials":3681,"activeCount":76},[],{"trials":3683,"activeCount":76},[3684],{"nctId":3685,"briefTitle":3686,"status":3687,"phases":3688,"primaryCompletion":3689,"completion":3690,"start":3691,"enrollment":3692,"conditions":3693,"interventions":3694},"NCT03450772","Equivalence Study to Compare Two Strengths of Creon in China","UNKNOWN",[68],"2022-04","2022-04-30","2017-08-31",60,[744],[3674,3695],"Creon® 10000",{"trials":3697,"activeCount":76},[],{"trials":3699,"activeCount":76},[],{"intervention":3695,"totalTrials":106,"cells":3701},{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3708,"PHASE4":3714,"NA":3716},{"trials":3703,"activeCount":76},[],{"trials":3705,"activeCount":76},[],{"trials":3707,"activeCount":76},[],{"trials":3709,"activeCount":76},[3710],{"nctId":3685,"briefTitle":3686,"status":3687,"phases":3711,"primaryCompletion":3689,"completion":3690,"start":3691,"enrollment":3692,"conditions":3712,"interventions":3713},[68],[744],[3674,3695],{"trials":3715,"activeCount":76},[],{"trials":3717,"activeCount":76},[],{"intervention":3719,"totalTrials":106,"cells":3720},"Double-blind adalimumab",{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3727,"PHASE4":3740,"NA":3742},{"trials":3722,"activeCount":76},[],{"trials":3724,"activeCount":76},[],{"trials":3726,"activeCount":76},[],{"trials":3728,"activeCount":76},[3729],{"nctId":3730,"briefTitle":3731,"status":86,"phases":3732,"primaryCompletion":1216,"completion":3733,"start":166,"enrollment":3734,"conditions":3735,"interventions":3736},"NCT00870467","A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis",[68],"2011-08",334,[39],[3719,3737,3738,3739],"Double-blind Placebo","Open-label Adalimumab","Open-labelAdalimumabRescue",{"trials":3741,"activeCount":76},[],{"trials":3743,"activeCount":76},[],{"intervention":3737,"totalTrials":106,"cells":3745},{"EARLY_PHASE1":3746,"PHASE1":3748,"PHASE2":3750,"PHASE3":3752,"PHASE4":3758,"NA":3760},{"trials":3747,"activeCount":76},[],{"trials":3749,"activeCount":76},[],{"trials":3751,"activeCount":76},[],{"trials":3753,"activeCount":76},[3754],{"nctId":3730,"briefTitle":3731,"status":86,"phases":3755,"primaryCompletion":1216,"completion":3733,"start":166,"enrollment":3734,"conditions":3756,"interventions":3757},[68],[39],[3719,3737,3738,3739],{"trials":3759,"activeCount":76},[],{"trials":3761,"activeCount":76},[],{"intervention":3738,"totalTrials":106,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3770,"PHASE4":3776,"NA":3778},{"trials":3765,"activeCount":76},[],{"trials":3767,"activeCount":76},[],{"trials":3769,"activeCount":76},[],{"trials":3771,"activeCount":76},[3772],{"nctId":3730,"briefTitle":3731,"status":86,"phases":3773,"primaryCompletion":1216,"completion":3733,"start":166,"enrollment":3734,"conditions":3774,"interventions":3775},[68],[39],[3719,3737,3738,3739],{"trials":3777,"activeCount":76},[],{"trials":3779,"activeCount":76},[],{"intervention":3739,"totalTrials":106,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3788,"PHASE4":3794,"NA":3796},{"trials":3783,"activeCount":76},[],{"trials":3785,"activeCount":76},[],{"trials":3787,"activeCount":76},[],{"trials":3789,"activeCount":76},[3790],{"nctId":3730,"briefTitle":3731,"status":86,"phases":3791,"primaryCompletion":1216,"completion":3733,"start":166,"enrollment":3734,"conditions":3792,"interventions":3793},[68],[39],[3719,3737,3738,3739],{"trials":3795,"activeCount":76},[],{"trials":3797,"activeCount":76},[],{"intervention":3799,"totalTrials":106,"cells":3800},"Hydrocodone\u002FAcetaminophen on Extended Release",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3807,"PHASE4":3817,"NA":3819},{"trials":3802,"activeCount":76},[],{"trials":3804,"activeCount":76},[],{"trials":3806,"activeCount":76},[],{"trials":3808,"activeCount":76},[3809],{"nctId":3810,"briefTitle":3811,"status":86,"phases":3812,"primaryCompletion":466,"completion":466,"start":569,"enrollment":3813,"conditions":3814,"interventions":3816},"NCT00195728","Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain",[68],431,[3815],"Moderate to Severe Chronic, Non-malignant Pain",[3799],{"trials":3818,"activeCount":76},[],{"trials":3820,"activeCount":76},[],{"intervention":3822,"totalTrials":106,"cells":3823},"Mitizax",{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3828,"PHASE3":3830,"PHASE4":3843,"NA":3845},{"trials":3825,"activeCount":76},[],{"trials":3827,"activeCount":76},[],{"trials":3829,"activeCount":76},[],{"trials":3831,"activeCount":76},[3832],{"nctId":3833,"briefTitle":3834,"status":86,"phases":3835,"primaryCompletion":3836,"completion":3836,"start":3837,"enrollment":3838,"conditions":3839,"interventions":3842},"NCT02596321","A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and\u002For Atopic Asthma",[68],"2016-06","2015-10",112,[3840,691,3841],"Allergy","Rhinitis",[3822],{"trials":3844,"activeCount":76},[],{"trials":3846,"activeCount":76},[],{"intervention":3848,"totalTrials":106,"cells":3849},"Lupron",{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3856,"PHASE4":3867,"NA":3869},{"trials":3851,"activeCount":76},[],{"trials":3853,"activeCount":76},[],{"trials":3855,"activeCount":76},[],{"trials":3857,"activeCount":76},[3858],{"nctId":3859,"briefTitle":3860,"status":86,"phases":3861,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":3864,"conditions":3865,"interventions":3866},"NCT00660010","Study of Lupron Depot In The Treatment of Central Precocious Puberty",[68],"2009-04","1991-01",55,[2883],[3848],{"trials":3868,"activeCount":76},[],{"trials":3870,"activeCount":76},[],{"intervention":3872,"totalTrials":106,"cells":3873},"Human anti-TNF monoclonal antibody adalimumab\u002F up to 24 weeks",{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3880,"PHASE4":3888,"NA":3890},{"trials":3875,"activeCount":76},[],{"trials":3877,"activeCount":76},[],{"trials":3879,"activeCount":76},[],{"trials":3881,"activeCount":76},[3882],{"nctId":3883,"briefTitle":3884,"status":86,"phases":3885,"start":158,"enrollment":570,"conditions":3886,"interventions":3887},"NCT00338754","Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis",[67,68],[702],[3872],{"trials":3889,"activeCount":76},[],{"trials":3891,"activeCount":76},[],{"intervention":3893,"totalTrials":106,"cells":3894},"Creon 25000",{"EARLY_PHASE1":3895,"PHASE1":3897,"PHASE2":3899,"PHASE3":3901,"PHASE4":3911,"NA":3913},{"trials":3896,"activeCount":76},[],{"trials":3898,"activeCount":76},[],{"trials":3900,"activeCount":76},[],{"trials":3902,"activeCount":76},[3903],{"nctId":3904,"briefTitle":3905,"status":263,"phases":3906,"primaryCompletion":1042,"completion":1042,"start":266,"enrollment":3907,"conditions":3908,"interventions":3910},"NCT00623025","Creon in HIV Patients With Steatorrhea",[68],34,[3909],"Steatorrhea",[3893],{"trials":3912,"activeCount":76},[],{"trials":3914,"activeCount":76},[],{"intervention":3916,"totalTrials":106,"cells":3917},"Mebeverine+Simethicone",{"EARLY_PHASE1":3918,"PHASE1":3920,"PHASE2":3922,"PHASE3":3924,"PHASE4":3937,"NA":3939},{"trials":3919,"activeCount":76},[],{"trials":3921,"activeCount":76},[],{"trials":3923,"activeCount":76},[],{"trials":3925,"activeCount":76},[3926],{"nctId":3927,"briefTitle":3928,"status":86,"phases":3929,"primaryCompletion":3930,"completion":3930,"start":3931,"enrollment":3453,"conditions":3932,"interventions":3934},"NCT05175131","Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders",[68],"2021-05-18","2020-11-27",[3933],"Functional Bowel Disorder",[3916,3935,3936],"Mebeverine","Simethicone",{"trials":3938,"activeCount":76},[],{"trials":3940,"activeCount":76},[],{"intervention":3936,"totalTrials":106,"cells":3942},{"EARLY_PHASE1":3943,"PHASE1":3945,"PHASE2":3947,"PHASE3":3949,"PHASE4":3955,"NA":3957},{"trials":3944,"activeCount":76},[],{"trials":3946,"activeCount":76},[],{"trials":3948,"activeCount":76},[],{"trials":3950,"activeCount":76},[3951],{"nctId":3927,"briefTitle":3928,"status":86,"phases":3952,"primaryCompletion":3930,"completion":3930,"start":3931,"enrollment":3453,"conditions":3953,"interventions":3954},[68],[3933],[3916,3935,3936],{"trials":3956,"activeCount":76},[],{"trials":3958,"activeCount":76},[],{"intervention":2286,"totalTrials":106,"cells":3960},{"EARLY_PHASE1":3961,"PHASE1":3963,"PHASE2":3965,"PHASE3":3967,"PHASE4":3973,"NA":3975},{"trials":3962,"activeCount":76},[],{"trials":3964,"activeCount":76},[],{"trials":3966,"activeCount":76},[],{"trials":3968,"activeCount":76},[3969],{"nctId":2278,"briefTitle":2279,"status":86,"phases":3970,"completion":569,"start":559,"enrollment":2281,"conditions":3971,"interventions":3972},[68],[2283],[2285,2286],{"trials":3974,"activeCount":76},[],{"trials":3976,"activeCount":76},[],{"intervention":3978,"totalTrials":106,"cells":3979},"Adalimumab 80 mg",{"EARLY_PHASE1":3980,"PHASE1":3982,"PHASE2":3984,"PHASE3":3986,"PHASE4":3996,"NA":3998},{"trials":3981,"activeCount":76},[],{"trials":3983,"activeCount":76},[],{"trials":3985,"activeCount":76},[],{"trials":3987,"activeCount":76},[3988],{"nctId":3989,"briefTitle":3990,"status":86,"phases":3991,"primaryCompletion":188,"completion":187,"start":689,"enrollment":3992,"conditions":3993,"interventions":3994},"NCT00538902","Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate",[67,68],302,[39],[3978,3995],"Adalimumab 40 mg",{"trials":3997,"activeCount":76},[],{"trials":3999,"activeCount":76},[],{"intervention":3995,"totalTrials":106,"cells":4001},{"EARLY_PHASE1":4002,"PHASE1":4004,"PHASE2":4006,"PHASE3":4008,"PHASE4":4014,"NA":4016},{"trials":4003,"activeCount":76},[],{"trials":4005,"activeCount":76},[],{"trials":4007,"activeCount":76},[],{"trials":4009,"activeCount":76},[4010],{"nctId":3989,"briefTitle":3990,"status":86,"phases":4011,"primaryCompletion":188,"completion":187,"start":689,"enrollment":3992,"conditions":4012,"interventions":4013},[67,68],[39],[3978,3995],{"trials":4015,"activeCount":76},[],{"trials":4017,"activeCount":76},[],{"intervention":1894,"totalTrials":106,"cells":4019},{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4026,"PHASE4":4032,"NA":4034},{"trials":4021,"activeCount":76},[],{"trials":4023,"activeCount":76},[],{"trials":4025,"activeCount":76},[],{"trials":4027,"activeCount":76},[4028],{"nctId":1886,"briefTitle":1887,"status":86,"phases":4029,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":1891,"conditions":4030,"interventions":4031},[68],[1882],[1865,1894],{"trials":4033,"activeCount":76},[],{"trials":4035,"activeCount":76},[],{"intervention":4037,"totalTrials":527,"cells":4038},"ABT-751",{"EARLY_PHASE1":4039,"PHASE1":4041,"PHASE2":4043,"PHASE3":4081,"PHASE4":4083,"NA":4085},{"trials":4040,"activeCount":76},[],{"trials":4042,"activeCount":76},[],{"trials":4044,"activeCount":76},[4045,4054,4061,4068,4075],{"nctId":4046,"briefTitle":4047,"status":263,"phases":4048,"primaryCompletion":1453,"start":157,"enrollment":223,"conditions":4049,"interventions":4052},"NCT00354562","A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer",[66,67],[4050,4051],"Lung Cancer","Non-Small Cell Lung Cancer",[4037,4053],"Docetaxel",{"nctId":4055,"briefTitle":4056,"status":86,"phases":4057,"completion":308,"start":2194,"enrollment":1729,"conditions":4058,"interventions":4060},"NCT00073138","A Study of ABT-751 in Patients With Colorectal Cancer",[67],[4059],"Colorectal Cancer",[4037],{"nctId":4062,"briefTitle":4063,"status":86,"phases":4064,"completion":479,"start":222,"enrollment":1729,"conditions":4065,"interventions":4067},"NCT00063102","A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.",[67],[4066],"Breast Cancer",[4037],{"nctId":4069,"briefTitle":4070,"status":86,"phases":4071,"completion":3537,"start":2194,"enrollment":3692,"conditions":4072,"interventions":4074},"NCT00073112","A Study of ABT-751 in Patients With Renal Cell Cancer",[67],[4073],"Renal Cell Cancer",[4037],{"nctId":4076,"briefTitle":4077,"status":86,"phases":4078,"completion":619,"start":89,"enrollment":520,"conditions":4079,"interventions":4080},"NCT00073151","A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer",[67],[4051],[4037],{"trials":4082,"activeCount":76},[],{"trials":4084,"activeCount":76},[],{"trials":4086,"activeCount":76},[],{"intervention":4088,"totalTrials":527,"cells":4089},"ABT-263",{"EARLY_PHASE1":4090,"PHASE1":4092,"PHASE2":4126,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4091,"activeCount":76},[],{"trials":4093,"activeCount":76},[4094,4101,4108,4117],{"nctId":4095,"briefTitle":4096,"status":86,"phases":4097,"primaryCompletion":187,"completion":1695,"start":146,"enrollment":1285,"conditions":4098,"interventions":4100},"NCT01053520","Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects",[66],[4099],"Healthy Female Subjects",[4088,4088,4088],{"nctId":4102,"briefTitle":4103,"status":86,"phases":4104,"primaryCompletion":2537,"completion":2537,"start":88,"enrollment":1071,"conditions":4105,"interventions":4107},"NCT00888108","Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer",[66],[4106],"Solid Tumor",[4088,4053],{"nctId":4109,"briefTitle":4110,"status":86,"phases":4111,"primaryCompletion":3410,"start":1695,"enrollment":1285,"conditions":4112,"interventions":4115},"NCT01021358","A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).",[66],[4113,4114,1676],"Lymphoma","Chronic Lymphocytic Leukemia",[4088,4116],"Ketoconazole",{"nctId":4118,"briefTitle":4119,"status":86,"phases":4120,"primaryCompletion":2163,"start":710,"enrollment":4121,"conditions":4122,"interventions":4125},"NCT00743028","Assess the Oral Bioavailability of New ABT-263 Formulations",[66],36,[4114,4123,4124],"Lymphomas","Leukemias",[4088,4088,4088],{"trials":4127,"activeCount":76},[4128],{"nctId":4129,"briefTitle":4130,"status":687,"phases":4131,"primaryCompletion":2371,"start":4132,"enrollment":326,"conditions":4133,"interventions":4135},"NCT00918450","Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen",[67],"2010-03",[4134],"B-cell Chronic Lymphocytic Leukemia",[4088],{"trials":4137,"activeCount":76},[],{"trials":4139,"activeCount":76},[],{"trials":4141,"activeCount":76},[],{"intervention":4143,"totalTrials":527,"cells":4144},"ABT-089",{"EARLY_PHASE1":4145,"PHASE1":4147,"PHASE2":4149,"PHASE3":4188,"PHASE4":4190,"NA":4192},{"trials":4146,"activeCount":76},[],{"trials":4148,"activeCount":76},[],{"trials":4150,"activeCount":76},[4151,4159,4166,4173,4181],{"nctId":4152,"briefTitle":4153,"status":263,"phases":4154,"primaryCompletion":265,"start":2661,"enrollment":4155,"conditions":4156,"interventions":4158},"NCT00555204","Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease",[67],337,[4157],"Alzheimer's Disease",[4143,4143,4143,4143,4143,4143],{"nctId":4160,"briefTitle":4161,"status":263,"phases":4162,"primaryCompletion":265,"start":266,"enrollment":4163,"conditions":4164,"interventions":4165},"NCT00809510","A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study",[67],63,[4157],[4143],{"nctId":4167,"briefTitle":4168,"status":263,"phases":4169,"start":342,"enrollment":4170,"conditions":4171,"interventions":4172},"NCT00069849","A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease",[67],64,[4157],[4143],{"nctId":4174,"briefTitle":4175,"status":86,"phases":4176,"primaryCompletion":1463,"completion":1463,"start":901,"enrollment":4177,"conditions":4178,"interventions":4180},"NCT00391729","A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[67],221,[4179],"Attention-Deficit\u002FHyperactivity Disorder",[4143],{"nctId":4182,"briefTitle":4183,"status":263,"phases":4184,"primaryCompletion":710,"start":2661,"enrollment":4185,"conditions":4186,"interventions":4187},"NCT00554385","A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[67],283,[4179],[4143],{"trials":4189,"activeCount":76},[],{"trials":4191,"activeCount":76},[],{"trials":4193,"activeCount":76},[],{"intervention":1734,"totalTrials":26,"cells":4195},{"EARLY_PHASE1":4196,"PHASE1":4198,"PHASE2":4200,"PHASE3":4210,"PHASE4":4212,"NA":4214},{"trials":4197,"activeCount":76},[],{"trials":4199,"activeCount":76},[],{"trials":4201,"activeCount":76},[4202,4206],{"nctId":2023,"briefTitle":2024,"status":86,"phases":4203,"start":1322,"enrollment":49,"conditions":4204,"interventions":4205},[67],[1731],[2014,2028,1734],{"nctId":1726,"briefTitle":1727,"status":86,"phases":4207,"start":1583,"enrollment":1729,"conditions":4208,"interventions":4209},[67],[1731],[1733,1734,1717,1735],{"trials":4211,"activeCount":76},[],{"trials":4213,"activeCount":76},[],{"trials":4215,"activeCount":76},[],{"intervention":4053,"totalTrials":26,"cells":4217},{"EARLY_PHASE1":4218,"PHASE1":4220,"PHASE2":4226,"PHASE3":4232,"PHASE4":4234,"NA":4236},{"trials":4219,"activeCount":76},[],{"trials":4221,"activeCount":76},[4222],{"nctId":4102,"briefTitle":4103,"status":86,"phases":4223,"primaryCompletion":2537,"completion":2537,"start":88,"enrollment":1071,"conditions":4224,"interventions":4225},[66],[4106],[4088,4053],{"trials":4227,"activeCount":76},[4228],{"nctId":4046,"briefTitle":4047,"status":263,"phases":4229,"primaryCompletion":1453,"start":157,"enrollment":223,"conditions":4230,"interventions":4231},[66,67],[4050,4051],[4037,4053],{"trials":4233,"activeCount":76},[],{"trials":4235,"activeCount":76},[],{"trials":4237,"activeCount":76},[],{"intervention":4239,"totalTrials":26,"cells":4240},"volociximab",{"EARLY_PHASE1":4241,"PHASE1":4243,"PHASE2":4245,"PHASE3":4266,"PHASE4":4268,"NA":4270},{"trials":4242,"activeCount":76},[],{"trials":4244,"activeCount":76},[],{"trials":4246,"activeCount":76},[4247,4255],{"nctId":4248,"briefTitle":4249,"status":263,"phases":4250,"primaryCompletion":3536,"completion":3536,"start":466,"enrollment":4251,"conditions":4252,"interventions":4254},"NCT00369395","A Study of Volociximab in Metastatic Melanoma",[67],19,[4253],"Stage IV Melanoma",[4239],{"nctId":4256,"briefTitle":4257,"status":263,"phases":4258,"primaryCompletion":4259,"completion":4259,"start":1365,"enrollment":4260,"conditions":4261,"interventions":4264},"NCT00100685","Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)",[67],"2007-12",48,[4262,4263],"Renal Cell Carcinoma","Metastases",[4265],"Volociximab",{"trials":4267,"activeCount":76},[],{"trials":4269,"activeCount":76},[],{"trials":4271,"activeCount":76},[],{"intervention":4273,"totalTrials":26,"cells":4274},"Asoprisnil\u002FPremarin",{"EARLY_PHASE1":4275,"PHASE1":4277,"PHASE2":4279,"PHASE3":4298,"PHASE4":4300,"NA":4302},{"trials":4276,"activeCount":76},[],{"trials":4278,"activeCount":76},[],{"trials":4280,"activeCount":76},[4281,4288],{"nctId":4282,"briefTitle":4283,"status":86,"phases":4284,"primaryCompletion":1321,"completion":1321,"start":1322,"enrollment":1418,"conditions":4285,"interventions":4287},"NCT00152295","A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women",[67],[4286],"Postmenopause",[4273],{"nctId":4289,"briefTitle":4290,"status":86,"phases":4291,"primaryCompletion":4292,"completion":4292,"start":4293,"enrollment":4294,"conditions":4295,"interventions":4297},"NCT00152282","A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women",[67],"2001-08","2000-09",105,[4296,4286],"Amenorrhea",[4273,4273,4273],{"trials":4299,"activeCount":76},[],{"trials":4301,"activeCount":76},[],{"trials":4303,"activeCount":76},[],{"intervention":152,"totalTrials":26,"cells":4305},{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4320,"PHASE4":4322,"NA":4324},{"trials":4307,"activeCount":76},[],{"trials":4309,"activeCount":76},[],{"trials":4311,"activeCount":76},[4312,4316],{"nctId":142,"briefTitle":143,"status":86,"phases":4313,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":4314,"interventions":4315},[67],[149,150],[132,152],{"nctId":163,"briefTitle":164,"status":86,"phases":4317,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":4318,"interventions":4319},[67],[170,149],[172,173],{"trials":4321,"activeCount":76},[],{"trials":4323,"activeCount":76},[],{"trials":4325,"activeCount":76},[],{"intervention":4327,"totalTrials":26,"cells":4328},"ABT-874",{"EARLY_PHASE1":4329,"PHASE1":4331,"PHASE2":4339,"PHASE3":4348,"PHASE4":4350,"NA":4352},{"trials":4330,"activeCount":76},[],{"trials":4332,"activeCount":76},[4333],{"nctId":4334,"briefTitle":4335,"status":86,"phases":4336,"primaryCompletion":3862,"start":266,"enrollment":223,"conditions":4337,"interventions":4338},"NCT00870948","Phase 1 BA Study, Single Center With Healthy Volunteers",[66],[415],[4327],{"trials":4340,"activeCount":76},[4341],{"nctId":4342,"briefTitle":4343,"status":263,"phases":4344,"primaryCompletion":3306,"start":2661,"enrollment":4345,"conditions":4346,"interventions":4347},"NCT00562887","Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease",[67],246,[2457],[4327,4327],{"trials":4349,"activeCount":76},[],{"trials":4351,"activeCount":76},[],{"trials":4353,"activeCount":76},[],{"intervention":4355,"totalTrials":26,"cells":4356},"SLV337",{"EARLY_PHASE1":4357,"PHASE1":4359,"PHASE2":4369,"PHASE3":4380,"PHASE4":4382,"NA":4384},{"trials":4358,"activeCount":76},[],{"trials":4360,"activeCount":76},[4361],{"nctId":4362,"briefTitle":4363,"status":86,"phases":4364,"primaryCompletion":3410,"completion":3410,"start":254,"enrollment":1285,"conditions":4365,"interventions":4367},"NCT01176201","14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man",[66],[4366],"Healthy Subjects",[4368,4355],"SLV337 suspension",{"trials":4370,"activeCount":76},[4371],{"nctId":4372,"briefTitle":4373,"status":86,"phases":4374,"primaryCompletion":4375,"completion":4375,"start":187,"enrollment":4376,"conditions":4377,"interventions":4379},"NCT00924534","A Safety PK\u002FPD Study of SLV337 in Patients With Type 2 Diabetes",[67],"2010-12",61,[4378],"Type 2 Diabetes",[4355,4355,4355],{"trials":4381,"activeCount":76},[],{"trials":4383,"activeCount":76},[],{"trials":4385,"activeCount":76},[],{"intervention":4387,"totalTrials":26,"cells":4388},"ABT-510\u002FThrombospondin-1 mimetic",{"EARLY_PHASE1":4389,"PHASE1":4391,"PHASE2":4393,"PHASE3":4410,"PHASE4":4412,"NA":4414},{"trials":4390,"activeCount":76},[],{"trials":4392,"activeCount":76},[],{"trials":4394,"activeCount":76},[4395,4402],{"nctId":4396,"briefTitle":4397,"status":86,"phases":4398,"start":298,"enrollment":1601,"conditions":4399,"interventions":4401},"NCT00073125","Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma",[67],[4400],"Carcinoma, Renal Cell",[4387],{"nctId":4403,"briefTitle":4404,"status":263,"phases":4405,"start":559,"enrollment":46,"conditions":4406,"interventions":4408},"NCT00061646","Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)",[67],[4407],"Carcinoma, Non-Small-Cell Lung",[4387,4409],"Carboplatin\u002FTaxol",{"trials":4411,"activeCount":76},[],{"trials":4413,"activeCount":76},[],{"trials":4415,"activeCount":76},[],{"intervention":4417,"totalTrials":26,"cells":4418},"ABT-510 - Thrombospondin-1 mimetic",{"EARLY_PHASE1":4419,"PHASE1":4421,"PHASE2":4423,"PHASE3":4443,"PHASE4":4445,"NA":4447},{"trials":4420,"activeCount":76},[],{"trials":4422,"activeCount":76},[],{"trials":4424,"activeCount":76},[4425,4433],{"nctId":4426,"briefTitle":4427,"status":86,"phases":4428,"completion":630,"start":298,"enrollment":4429,"conditions":4430,"interventions":4432},"NCT00061659","Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma",[67],88,[4431],"Sarcoma, Soft Tissue",[4417],{"nctId":4434,"briefTitle":4435,"status":86,"phases":4436,"start":381,"enrollment":4437,"conditions":4438,"interventions":4441},"NCT00061672","Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma",[67],67,[4439,4440],"Lymphoma, Non-Hodgkin","Hodgkin's Lymphoma",[4442],"ABT-510 - Thrombospondin-1 Mimetic",{"trials":4444,"activeCount":76},[],{"trials":4446,"activeCount":76},[],{"trials":4448,"activeCount":76},[],{"intervention":4450,"totalTrials":106,"cells":4451},"Kaletra",{"EARLY_PHASE1":4452,"PHASE1":4454,"PHASE2":4456,"PHASE3":4467,"PHASE4":4469,"NA":4471},{"trials":4453,"activeCount":76},[],{"trials":4455,"activeCount":76},[],{"trials":4457,"activeCount":76},[4458],{"nctId":4459,"briefTitle":4460,"status":687,"phases":4461,"enrollment":542,"conditions":4462,"interventions":4464},"NCT00121017","A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1\u002FHCV Co-Infected Subjects",[67],[1831,4463],"Hepatitis C",[4450,4465,4466],"Sustiva","Truvada",{"trials":4468,"activeCount":76},[],{"trials":4470,"activeCount":76},[],{"trials":4472,"activeCount":76},[],{"intervention":4465,"totalTrials":106,"cells":4474},{"EARLY_PHASE1":4475,"PHASE1":4477,"PHASE2":4479,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4476,"activeCount":76},[],{"trials":4478,"activeCount":76},[],{"trials":4480,"activeCount":76},[4481],{"nctId":4459,"briefTitle":4460,"status":687,"phases":4482,"enrollment":542,"conditions":4483,"interventions":4484},[67],[1831,4463],[4450,4465,4466],{"trials":4486,"activeCount":76},[],{"trials":4488,"activeCount":76},[],{"trials":4490,"activeCount":76},[],{"intervention":4466,"totalTrials":106,"cells":4492},{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4497,"PHASE3":4503,"PHASE4":4505,"NA":4507},{"trials":4494,"activeCount":76},[],{"trials":4496,"activeCount":76},[],{"trials":4498,"activeCount":76},[4499],{"nctId":4459,"briefTitle":4460,"status":687,"phases":4500,"enrollment":542,"conditions":4501,"interventions":4502},[67],[1831,4463],[4450,4465,4466],{"trials":4504,"activeCount":76},[],{"trials":4506,"activeCount":76},[],{"trials":4508,"activeCount":76},[],{"intervention":1916,"totalTrials":106,"cells":4510},{"EARLY_PHASE1":4511,"PHASE1":4513,"PHASE2":4515,"PHASE3":4521,"PHASE4":4523,"NA":4525},{"trials":4512,"activeCount":76},[],{"trials":4514,"activeCount":76},[],{"trials":4516,"activeCount":76},[4517],{"nctId":1909,"briefTitle":1910,"status":86,"phases":4518,"primaryCompletion":1041,"completion":1041,"start":1656,"enrollment":1912,"conditions":4519,"interventions":4520},[67],[1914],[1916,1900],{"trials":4522,"activeCount":76},[],{"trials":4524,"activeCount":76},[],{"trials":4526,"activeCount":76},[],{"intervention":4528,"totalTrials":106,"cells":4529},"Itopride HCI 50 mg",{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4545,"PHASE4":4547,"NA":4549},{"trials":4531,"activeCount":76},[],{"trials":4533,"activeCount":76},[],{"trials":4535,"activeCount":76},[4536],{"nctId":4537,"briefTitle":4538,"status":86,"phases":4539,"primaryCompletion":2163,"completion":508,"start":1417,"enrollment":4540,"conditions":4541,"interventions":4543},"NCT01027260","Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation",[67],268,[4542],"Irritable Bowel Syndrome",[4528,4544],"Itopride HCI 100 mg",{"trials":4546,"activeCount":76},[],{"trials":4548,"activeCount":76},[],{"trials":4550,"activeCount":76},[],{"intervention":4544,"totalTrials":106,"cells":4552},{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4563,"PHASE4":4565,"NA":4567},{"trials":4554,"activeCount":76},[],{"trials":4556,"activeCount":76},[],{"trials":4558,"activeCount":76},[4559],{"nctId":4537,"briefTitle":4538,"status":86,"phases":4560,"primaryCompletion":2163,"completion":508,"start":1417,"enrollment":4540,"conditions":4561,"interventions":4562},[67],[4542],[4528,4544],{"trials":4564,"activeCount":76},[],{"trials":4566,"activeCount":76},[],{"trials":4568,"activeCount":76},[],{"intervention":4570,"totalTrials":106,"cells":4571},"Visilizumab",{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4576,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4573,"activeCount":76},[],{"trials":4575,"activeCount":76},[],{"trials":4577,"activeCount":76},[4578],{"nctId":4579,"briefTitle":4580,"status":263,"phases":4581,"primaryCompletion":2661,"completion":2661,"start":630,"enrollment":1323,"conditions":4582,"interventions":4584},"NCT00307827","Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)",[67],[4583],"Ulcerative Colitis",[4570],{"trials":4586,"activeCount":76},[],{"trials":4588,"activeCount":76},[],{"trials":4590,"activeCount":76},[],{"intervention":4592,"totalTrials":106,"cells":4593},"Extended-Release Hydrocodone\u002FAcetaminophen",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4606,"PHASE4":4608,"NA":4610},{"trials":4595,"activeCount":76},[],{"trials":4597,"activeCount":76},[],{"trials":4599,"activeCount":76},[4600],{"nctId":4601,"briefTitle":4602,"status":86,"phases":4603,"primaryCompletion":444,"start":479,"enrollment":612,"conditions":4604,"interventions":4605},"NCT00404183","A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone\u002FAcetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis",[67],[1777],[4592],{"trials":4607,"activeCount":76},[],{"trials":4609,"activeCount":76},[],{"trials":4611,"activeCount":76},[],{"intervention":4613,"totalTrials":106,"cells":4614},"(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400",{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4630,"PHASE4":4632,"NA":4634},{"trials":4616,"activeCount":76},[],{"trials":4618,"activeCount":76},[],{"trials":4620,"activeCount":76},[4621],{"nctId":4622,"briefTitle":4623,"status":86,"phases":4624,"completion":1504,"start":1348,"enrollment":4625,"conditions":4626,"interventions":4628},"NCT00607776","Artificial Tears Study in Mild to Moderate Dry Eye Patients",[67],110,[4627],"Dry Eye",[4613,4629],"Systane",{"trials":4631,"activeCount":76},[],{"trials":4633,"activeCount":76},[],{"trials":4635,"activeCount":76},[],{"intervention":4629,"totalTrials":106,"cells":4637},{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4648,"PHASE4":4650,"NA":4652},{"trials":4639,"activeCount":76},[],{"trials":4641,"activeCount":76},[],{"trials":4643,"activeCount":76},[4644],{"nctId":4622,"briefTitle":4623,"status":86,"phases":4645,"completion":1504,"start":1348,"enrollment":4625,"conditions":4646,"interventions":4647},[67],[4627],[4613,4629],{"trials":4649,"activeCount":76},[],{"trials":4651,"activeCount":76},[],{"trials":4653,"activeCount":76},[],{"intervention":4655,"totalTrials":106,"cells":4656},"SLV334",{"EARLY_PHASE1":4657,"PHASE1":4659,"PHASE2":4661,"PHASE3":4671,"PHASE4":4673,"NA":4675},{"trials":4658,"activeCount":76},[],{"trials":4660,"activeCount":76},[],{"trials":4662,"activeCount":76},[4663],{"nctId":4664,"briefTitle":4665,"status":263,"phases":4666,"primaryCompletion":2163,"completion":2163,"start":3862,"enrollment":4667,"conditions":4668,"interventions":4670},"NCT00735085","A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.",[67],57,[4669],"Traumatic Brain Injury",[4655,4655,4655,4655],{"trials":4672,"activeCount":76},[],{"trials":4674,"activeCount":76},[],{"trials":4676,"activeCount":76},[],{"intervention":4678,"totalTrials":106,"cells":4679},"Kaletra®",{"EARLY_PHASE1":4680,"PHASE1":4682,"PHASE2":4684,"PHASE3":4694,"PHASE4":4696,"NA":4698},{"trials":4681,"activeCount":76},[],{"trials":4683,"activeCount":76},[],{"trials":4685,"activeCount":76},[4686],{"nctId":4687,"briefTitle":4688,"status":86,"phases":4689,"start":541,"enrollment":326,"conditions":4690,"interventions":4691},"NCT00075231","A Simplified Kaletra® (Lopinavir\u002FRitonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects",[67],[1731],[4678,4692,4693],"Combivir®","Sustiva®",{"trials":4695,"activeCount":76},[],{"trials":4697,"activeCount":76},[],{"trials":4699,"activeCount":76},[],{"intervention":4692,"totalTrials":106,"cells":4701},{"EARLY_PHASE1":4702,"PHASE1":4704,"PHASE2":4706,"PHASE3":4712,"PHASE4":4714,"NA":4716},{"trials":4703,"activeCount":76},[],{"trials":4705,"activeCount":76},[],{"trials":4707,"activeCount":76},[4708],{"nctId":4687,"briefTitle":4688,"status":86,"phases":4709,"start":541,"enrollment":326,"conditions":4710,"interventions":4711},[67],[1731],[4678,4692,4693],{"trials":4713,"activeCount":76},[],{"trials":4715,"activeCount":76},[],{"trials":4717,"activeCount":76},[],{"intervention":4693,"totalTrials":106,"cells":4719},{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4724,"PHASE3":4730,"PHASE4":4732,"NA":4734},{"trials":4721,"activeCount":76},[],{"trials":4723,"activeCount":76},[],{"trials":4725,"activeCount":76},[4726],{"nctId":4687,"briefTitle":4688,"status":86,"phases":4727,"start":541,"enrollment":326,"conditions":4728,"interventions":4729},[67],[1731],[4678,4692,4693],{"trials":4731,"activeCount":76},[],{"trials":4733,"activeCount":76},[],{"trials":4735,"activeCount":76},[],{"intervention":4737,"totalTrials":106,"cells":4738},"Choline Fenofibrate",{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4743,"PHASE3":4752,"PHASE4":4754,"NA":4756},{"trials":4740,"activeCount":76},[],{"trials":4742,"activeCount":76},[],{"trials":4744,"activeCount":76},[4745],{"nctId":4746,"briefTitle":4747,"status":86,"phases":4748,"primaryCompletion":1216,"completion":1216,"start":699,"enrollment":4625,"conditions":4749,"interventions":4751},"NCT00683176","Effect of Choline Fenofibrate (SLV348) on Macular Edema",[67],[4750],"Diabetic Macular Edema",[4737],{"trials":4753,"activeCount":76},[],{"trials":4755,"activeCount":76},[],{"trials":4757,"activeCount":76},[],{"intervention":4759,"totalTrials":106,"cells":4760},"Cell-Derived Trivalent Subunit Influenza Vaccine",{"EARLY_PHASE1":4761,"PHASE1":4763,"PHASE2":4765,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4762,"activeCount":76},[],{"trials":4764,"activeCount":76},[],{"trials":4766,"activeCount":76},[4767],{"nctId":4768,"briefTitle":4769,"status":86,"phases":4770,"primaryCompletion":4771,"completion":4771,"start":509,"enrollment":4772,"conditions":4773,"interventions":4774},"NCT00889889","Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and \u003C= 64, Plus Revaccination",[67],"2011-01",1270,[1634],[4759],{"trials":4776,"activeCount":76},[],{"trials":4778,"activeCount":76},[],{"trials":4780,"activeCount":76},[],{"intervention":2186,"totalTrials":106,"cells":4782},{"EARLY_PHASE1":4783,"PHASE1":4785,"PHASE2":4787,"PHASE3":4793,"PHASE4":4795,"NA":4797},{"trials":4784,"activeCount":76},[],{"trials":4786,"activeCount":76},[],{"trials":4788,"activeCount":76},[4789],{"nctId":2181,"briefTitle":2182,"status":86,"phases":4790,"start":1313,"enrollment":520,"conditions":4791,"interventions":4792},[67],[1731],[1733,2186,2187],{"trials":4794,"activeCount":76},[],{"trials":4796,"activeCount":76},[],{"trials":4798,"activeCount":76},[],{"intervention":4800,"totalTrials":106,"cells":4801},"veliparib",{"EARLY_PHASE1":4802,"PHASE1":4804,"PHASE2":4806,"PHASE3":4817,"PHASE4":4819,"NA":4821},{"trials":4803,"activeCount":76},[],{"trials":4805,"activeCount":76},[],{"trials":4807,"activeCount":76},[4808],{"nctId":4809,"briefTitle":4810,"status":86,"phases":4811,"primaryCompletion":4812,"completion":4812,"start":254,"enrollment":49,"conditions":4813,"interventions":4815},"NCT01193140","To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors",[67],"2011-11",[4814],"Solid Tumor Cancers",[4800,4816],"Temozolomide",{"trials":4818,"activeCount":76},[],{"trials":4820,"activeCount":76},[],{"trials":4822,"activeCount":76},[],{"intervention":4816,"totalTrials":106,"cells":4824},{"EARLY_PHASE1":4825,"PHASE1":4827,"PHASE2":4829,"PHASE3":4835,"PHASE4":4837,"NA":4839},{"trials":4826,"activeCount":76},[],{"trials":4828,"activeCount":76},[],{"trials":4830,"activeCount":76},[4831],{"nctId":4809,"briefTitle":4810,"status":86,"phases":4832,"primaryCompletion":4812,"completion":4812,"start":254,"enrollment":49,"conditions":4833,"interventions":4834},[67],[4814],[4800,4816],{"trials":4836,"activeCount":76},[],{"trials":4838,"activeCount":76},[],{"trials":4840,"activeCount":76},[],{"intervention":4842,"totalTrials":106,"cells":4843},"Leuprolide acetate depot (LAD) 11.25 mg 3 Month",{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4860,"PHASE4":4862,"NA":4864},{"trials":4845,"activeCount":76},[],{"trials":4847,"activeCount":76},[],{"trials":4849,"activeCount":76},[4850],{"nctId":4851,"briefTitle":4852,"status":263,"phases":4853,"primaryCompletion":1409,"start":2215,"enrollment":46,"conditions":4854,"interventions":4858},"NCT00275262","A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation",[67],[4855,4439,4856,4857],"Hodgkin Disease","Multiple Myeloma","Mantle Cell Lymphoma",[4842,4859],"Matched placebo",{"trials":4861,"activeCount":76},[],{"trials":4863,"activeCount":76},[],{"trials":4865,"activeCount":76},[],{"intervention":4859,"totalTrials":106,"cells":4867},{"EARLY_PHASE1":4868,"PHASE1":4870,"PHASE2":4872,"PHASE3":4878,"PHASE4":4880,"NA":4882},{"trials":4869,"activeCount":76},[],{"trials":4871,"activeCount":76},[],{"trials":4873,"activeCount":76},[4874],{"nctId":4851,"briefTitle":4852,"status":263,"phases":4875,"primaryCompletion":1409,"start":2215,"enrollment":46,"conditions":4876,"interventions":4877},[67],[4855,4439,4856,4857],[4842,4859],{"trials":4879,"activeCount":76},[],{"trials":4881,"activeCount":76},[],{"trials":4883,"activeCount":76},[],{"intervention":4885,"totalTrials":106,"cells":4886},"NBI-56418",{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4891,"PHASE3":4900,"PHASE4":4902,"NA":4904},{"trials":4888,"activeCount":76},[],{"trials":4890,"activeCount":76},[],{"trials":4892,"activeCount":76},[4893],{"nctId":4894,"briefTitle":4895,"status":86,"phases":4896,"primaryCompletion":1070,"completion":1070,"start":1740,"enrollment":4897,"conditions":4898,"interventions":4899},"NCT00109512","Endometriosis Trial: Study of NBI-56418 in Endometriosis",[67],76,[104],[4885],{"trials":4901,"activeCount":76},[],{"trials":4903,"activeCount":76},[],{"trials":4905,"activeCount":76},[],{"intervention":809,"totalTrials":106,"cells":4907},{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4912,"PHASE3":4918,"PHASE4":4920,"NA":4922},{"trials":4909,"activeCount":76},[],{"trials":4911,"activeCount":76},[],{"trials":4913,"activeCount":76},[4914],{"nctId":801,"briefTitle":802,"status":86,"phases":4915,"start":342,"enrollment":804,"conditions":4916,"interventions":4917},[67],[806],[808,362,809],{"trials":4919,"activeCount":76},[],{"trials":4921,"activeCount":76},[],{"trials":4923,"activeCount":76},[],{"intervention":4925,"totalTrials":106,"cells":4926},"ABT-925",{"EARLY_PHASE1":4927,"PHASE1":4929,"PHASE2":4931,"PHASE3":4940,"PHASE4":4942,"NA":4944},{"trials":4928,"activeCount":76},[],{"trials":4930,"activeCount":76},[],{"trials":4932,"activeCount":76},[4933],{"nctId":4934,"briefTitle":4935,"status":263,"phases":4936,"primaryCompletion":3665,"completion":3665,"start":466,"enrollment":4937,"conditions":4938,"interventions":4939},"NCT00412620","An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia",[67],156,[806],[4925],{"trials":4941,"activeCount":76},[],{"trials":4943,"activeCount":76},[],{"trials":4945,"activeCount":76},[],{"intervention":4947,"totalTrials":106,"cells":4948},"pardoprunox",{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4953,"PHASE3":4964,"PHASE4":4966,"NA":4968},{"trials":4950,"activeCount":76},[],{"trials":4952,"activeCount":76},[],{"trials":4954,"activeCount":76},[4955],{"nctId":4956,"briefTitle":4957,"status":263,"phases":4958,"primaryCompletion":245,"completion":245,"start":2496,"enrollment":4959,"conditions":4960,"interventions":4962},"NCT00903838","A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.",[67],37,[4961],"Advanced Stage Parkinson's Disease",[4947,4963],"pramipexole",{"trials":4965,"activeCount":76},[],{"trials":4967,"activeCount":76},[],{"trials":4969,"activeCount":76},[],{"intervention":4963,"totalTrials":106,"cells":4971},{"EARLY_PHASE1":4972,"PHASE1":4974,"PHASE2":4976,"PHASE3":4982,"PHASE4":4984,"NA":4986},{"trials":4973,"activeCount":76},[],{"trials":4975,"activeCount":76},[],{"trials":4977,"activeCount":76},[4978],{"nctId":4956,"briefTitle":4957,"status":263,"phases":4979,"primaryCompletion":245,"completion":245,"start":2496,"enrollment":4959,"conditions":4980,"interventions":4981},[67],[4961],[4947,4963],{"trials":4983,"activeCount":76},[],{"trials":4985,"activeCount":76},[],{"trials":4987,"activeCount":76},[],{"intervention":2219,"totalTrials":106,"cells":4989},{"EARLY_PHASE1":4990,"PHASE1":4992,"PHASE2":4994,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4991,"activeCount":76},[],{"trials":4993,"activeCount":76},[],{"trials":4995,"activeCount":76},[4996],{"nctId":2212,"briefTitle":2213,"status":86,"phases":4997,"primaryCompletion":2215,"completion":2215,"start":158,"enrollment":2216,"conditions":4998,"interventions":4999},[67],[1777],[1787,2219],{"trials":5001,"activeCount":76},[],{"trials":5003,"activeCount":76},[],{"trials":5005,"activeCount":76},[],{"intervention":4409,"totalTrials":106,"cells":5007},{"EARLY_PHASE1":5008,"PHASE1":5010,"PHASE2":5012,"PHASE3":5018,"PHASE4":5020,"NA":5022},{"trials":5009,"activeCount":76},[],{"trials":5011,"activeCount":76},[],{"trials":5013,"activeCount":76},[5014],{"nctId":4403,"briefTitle":4404,"status":263,"phases":5015,"start":559,"enrollment":46,"conditions":5016,"interventions":5017},[67],[4407],[4387,4409],{"trials":5019,"activeCount":76},[],{"trials":5021,"activeCount":76},[],{"trials":5023,"activeCount":76},[],{"intervention":5025,"totalTrials":106,"cells":5026},"Depakote Delayed-Release\u002FDepakote Sprinkle",{"EARLY_PHASE1":5027,"PHASE1":5029,"PHASE2":5031,"PHASE3":5041,"PHASE4":5043,"NA":5045},{"trials":5028,"activeCount":76},[],{"trials":5030,"activeCount":76},[],{"trials":5032,"activeCount":76},[5033],{"nctId":5034,"briefTitle":5035,"status":86,"phases":5036,"primaryCompletion":541,"completion":541,"start":422,"enrollment":2035,"conditions":5037,"interventions":5039},"NCT00646711","Pediatric Switch Study for Children and Adolescent Patients With Epilepsy",[67],[5038],"Pediatric Epilepsy",[5025,5040],"Depakote ER",{"trials":5042,"activeCount":76},[],{"trials":5044,"activeCount":76},[],{"trials":5046,"activeCount":76},[],{"intervention":5040,"totalTrials":106,"cells":5048},{"EARLY_PHASE1":5049,"PHASE1":5051,"PHASE2":5053,"PHASE3":5059,"PHASE4":5061,"NA":5063},{"trials":5050,"activeCount":76},[],{"trials":5052,"activeCount":76},[],{"trials":5054,"activeCount":76},[5055],{"nctId":5034,"briefTitle":5035,"status":86,"phases":5056,"primaryCompletion":541,"completion":541,"start":422,"enrollment":2035,"conditions":5057,"interventions":5058},[67],[5038],[5025,5040],{"trials":5060,"activeCount":76},[],{"trials":5062,"activeCount":76},[],{"trials":5064,"activeCount":76},[],{"intervention":5066,"totalTrials":106,"cells":5067},"ABT-894",{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5072,"PHASE3":5083,"PHASE4":5085,"NA":5087},{"trials":5069,"activeCount":76},[],{"trials":5071,"activeCount":76},[],{"trials":5073,"activeCount":76},[5074],{"nctId":5075,"briefTitle":5076,"status":86,"phases":5077,"primaryCompletion":689,"start":1348,"enrollment":5078,"conditions":5079,"interventions":5081},"NCT00429091","A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[67],243,[4179,5080],"ADHD",[5066,5082],"atomoxetine",{"trials":5084,"activeCount":76},[],{"trials":5086,"activeCount":76},[],{"trials":5088,"activeCount":76},[],{"intervention":5082,"totalTrials":106,"cells":5090},{"EARLY_PHASE1":5091,"PHASE1":5093,"PHASE2":5095,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5092,"activeCount":76},[],{"trials":5094,"activeCount":76},[],{"trials":5096,"activeCount":76},[5097],{"nctId":5075,"briefTitle":5076,"status":86,"phases":5098,"primaryCompletion":689,"start":1348,"enrollment":5078,"conditions":5099,"interventions":5100},[67],[4179,5080],[5066,5082],{"trials":5102,"activeCount":76},[],{"trials":5104,"activeCount":76},[],{"trials":5106,"activeCount":76},[],{"intervention":5108,"totalTrials":527,"cells":5109},"ABT-072",{"EARLY_PHASE1":5110,"PHASE1":5112,"PHASE2":5146,"PHASE3":5148,"PHASE4":5150,"NA":5152},{"trials":5111,"activeCount":76},[],{"trials":5113,"activeCount":76},[5114,5121,5127,5133,5140],{"nctId":5115,"briefTitle":5116,"status":86,"phases":5117,"primaryCompletion":187,"completion":1695,"start":2496,"enrollment":5118,"conditions":5119,"interventions":5120},"NCT00982826","Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072",[66],52,[4463],[5108],{"nctId":5122,"briefTitle":5123,"status":86,"phases":5124,"primaryCompletion":1640,"start":4132,"enrollment":49,"conditions":5125,"interventions":5126},"NCT01081483","A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults",[66],[4463],[5108],{"nctId":5128,"briefTitle":5129,"status":86,"phases":5130,"primaryCompletion":509,"start":699,"enrollment":510,"conditions":5131,"interventions":5132},"NCT00752687","A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults",[66],[4463],[5108],{"nctId":5134,"briefTitle":5135,"status":86,"phases":5136,"primaryCompletion":88,"start":3862,"enrollment":1410,"conditions":5137,"interventions":5139},"NCT00890318","A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C",[66],[5138],"HCV Infection",[5108],{"nctId":5141,"briefTitle":5142,"status":86,"phases":5143,"primaryCompletion":1042,"start":88,"enrollment":1418,"conditions":5144,"interventions":5145},"NCT00947440","Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation",[66],[4463],[5108],{"trials":5147,"activeCount":76},[],{"trials":5149,"activeCount":76},[],{"trials":5151,"activeCount":76},[],{"trials":5153,"activeCount":76},[],{"intervention":5155,"totalTrials":527,"cells":5156},"ABT-126",{"EARLY_PHASE1":5157,"PHASE1":5159,"PHASE2":5194,"PHASE3":5196,"PHASE4":5198,"NA":5200},{"trials":5158,"activeCount":76},[],{"trials":5160,"activeCount":76},[5161,5168,5175,5181,5187],{"nctId":5162,"briefTitle":5163,"status":86,"phases":5164,"primaryCompletion":2537,"completion":2537,"start":4812,"enrollment":5165,"conditions":5166,"interventions":5167},"NCT01482845","A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease",[66],20,[4157],[5155],{"nctId":5169,"briefTitle":5170,"status":86,"phases":5171,"primaryCompletion":2496,"start":1042,"enrollment":5165,"conditions":5172,"interventions":5174},"NCT00959634","Pharmacokinetic Study of ABT-126 in Healthy Volunteers",[66],[5173],"Healthy Volunteers",[5155],{"nctId":5176,"briefTitle":5177,"status":86,"phases":5178,"primaryCompletion":509,"start":166,"enrollment":520,"conditions":5179,"interventions":5180},"NCT00867399","A Safety and Tolerability Study of ABT-126 in Elderly",[66],[4157],[5155],{"nctId":5182,"briefTitle":5183,"status":86,"phases":5184,"primaryCompletion":1695,"start":208,"enrollment":2035,"conditions":5185,"interventions":5186},"NCT01043458","Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia",[66],[806],[5155],{"nctId":5188,"briefTitle":5189,"status":86,"phases":5190,"primaryCompletion":1042,"start":265,"enrollment":5191,"conditions":5192,"interventions":5193},"NCT00912431","Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers",[66],10,[415],[5155],{"trials":5195,"activeCount":76},[],{"trials":5197,"activeCount":76},[],{"trials":5199,"activeCount":76},[],{"trials":5201,"activeCount":76},[],{"intervention":5203,"totalTrials":584,"cells":5204},"ABT-333",{"EARLY_PHASE1":5205,"PHASE1":5207,"PHASE2":5235,"PHASE3":5237,"PHASE4":5239,"NA":5241},{"trials":5206,"activeCount":76},[],{"trials":5208,"activeCount":76},[5209,5215,5221,5229],{"nctId":5210,"briefTitle":5211,"status":86,"phases":5212,"primaryCompletion":265,"start":3862,"enrollment":3907,"conditions":5213,"interventions":5214},"NCT00895102","Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers",[66],[5138],[5203,5203],{"nctId":5216,"briefTitle":5217,"status":86,"phases":5218,"primaryCompletion":88,"start":509,"enrollment":49,"conditions":5219,"interventions":5220},"NCT00909636","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet",[66],[5138],[5203],{"nctId":5222,"briefTitle":5223,"status":86,"phases":5224,"primaryCompletion":1042,"start":265,"enrollment":5225,"conditions":5226,"interventions":5228},"NCT00919490","A Study of Single Dose of ABT-333 in Healthy Male Adults",[66],39,[5227],"HCV Infections",[5203],{"nctId":5230,"briefTitle":5231,"status":86,"phases":5232,"primaryCompletion":1409,"start":1452,"enrollment":179,"conditions":5233,"interventions":5234},"NCT00768690","A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333",[66],[5138],[5203,1678],{"trials":5236,"activeCount":76},[],{"trials":5238,"activeCount":76},[],{"trials":5240,"activeCount":76},[],{"trials":5242,"activeCount":76},[],{"intervention":5244,"totalTrials":676,"cells":5245},"ABT-450",{"EARLY_PHASE1":5246,"PHASE1":5248,"PHASE2":5270,"PHASE3":5272,"PHASE4":5274,"NA":5276},{"trials":5247,"activeCount":76},[],{"trials":5249,"activeCount":76},[5250,5257,5263],{"nctId":5251,"briefTitle":5252,"status":86,"phases":5253,"primaryCompletion":88,"start":509,"enrollment":367,"conditions":5254,"interventions":5255},"NCT00909311","Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir",[66],[5138],[5244,5256],"ritonavir",{"nctId":5258,"briefTitle":5259,"status":86,"phases":5260,"primaryCompletion":2496,"start":265,"enrollment":1323,"conditions":5261,"interventions":5262},"NCT00931281","Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir",[66],[5138],[5244,5256],{"nctId":5264,"briefTitle":5265,"status":86,"phases":5266,"primaryCompletion":3306,"completion":3306,"start":5267,"enrollment":1729,"conditions":5268,"interventions":5269},"NCT01091649","Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450",[66],"2010-02",[415],[5244,5256,5244],{"trials":5271,"activeCount":76},[],{"trials":5273,"activeCount":76},[],{"trials":5275,"activeCount":76},[],{"trials":5277,"activeCount":76},[],{"intervention":1678,"totalTrials":676,"cells":5279},{"EARLY_PHASE1":5280,"PHASE1":5282,"PHASE2":5296,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5281,"activeCount":76},[],{"trials":5283,"activeCount":76},[5284,5288,5292],{"nctId":1671,"briefTitle":1672,"status":86,"phases":5285,"primaryCompletion":1674,"completion":1674,"start":145,"enrollment":1285,"conditions":5286,"interventions":5287},[66],[1676],[1664,1678],{"nctId":4109,"briefTitle":4110,"status":86,"phases":5289,"primaryCompletion":3410,"start":1695,"enrollment":1285,"conditions":5290,"interventions":5291},[66],[4113,4114,1676],[4088,4116],{"nctId":5230,"briefTitle":5231,"status":86,"phases":5293,"primaryCompletion":1409,"start":1452,"enrollment":179,"conditions":5294,"interventions":5295},[66],[5138],[5203,1678],{"trials":5297,"activeCount":76},[],{"trials":5299,"activeCount":76},[],{"trials":5301,"activeCount":76},[],{"trials":5303,"activeCount":76},[],{"intervention":5305,"totalTrials":676,"cells":5306},"ABT-614",{"EARLY_PHASE1":5307,"PHASE1":5309,"PHASE2":5332,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5308,"activeCount":76},[],{"trials":5310,"activeCount":76},[5311,5319,5325],{"nctId":5312,"briefTitle":5313,"status":86,"phases":5314,"primaryCompletion":5315,"completion":5315,"start":4812,"enrollment":2035,"conditions":5316,"interventions":5318},"NCT01464320","A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.",[66],"2012-04",[5317],"Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine",[5305],{"nctId":5320,"briefTitle":5321,"status":86,"phases":5322,"primaryCompletion":1042,"start":1042,"enrollment":367,"conditions":5323,"interventions":5324},"NCT00959816","A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans",[66],[415],[5305],{"nctId":5326,"briefTitle":5327,"status":86,"phases":5328,"primaryCompletion":166,"start":1683,"enrollment":5329,"conditions":5330,"interventions":5331},"NCT00788801","Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain",[66],11,[5173],[5305],{"trials":5333,"activeCount":76},[],{"trials":5335,"activeCount":76},[],{"trials":5337,"activeCount":76},[],{"trials":5339,"activeCount":76},[],{"intervention":5341,"totalTrials":676,"cells":5342},"linifanib",{"EARLY_PHASE1":5343,"PHASE1":5345,"PHASE2":5371,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5344,"activeCount":76},[],{"trials":5346,"activeCount":76},[5347,5355,5363],{"nctId":5348,"briefTitle":5349,"status":86,"phases":5350,"primaryCompletion":5351,"completion":5351,"start":245,"enrollment":267,"conditions":5352,"interventions":5354},"NCT01381341","To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.",[66],"2011-12",[5353],"Advanced Solid Tumors",[5341],{"nctId":5356,"briefTitle":5357,"status":86,"phases":5358,"primaryCompletion":875,"completion":875,"start":245,"enrollment":133,"conditions":5359,"interventions":5360},"NCT01401933","Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors",[66],[5353],[5361,5362],"Linifanib","Rifampin",{"nctId":5364,"briefTitle":5365,"status":263,"phases":5366,"primaryCompletion":5351,"completion":5367,"start":875,"enrollment":133,"conditions":5368,"interventions":5370},"NCT01506934","A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors",[66],"2012-01",[5369],"Advanced or Metastatic Solid Tumors",[5341],{"trials":5372,"activeCount":76},[],{"trials":5374,"activeCount":76},[],{"trials":5376,"activeCount":76},[],{"trials":5378,"activeCount":76},[],{"intervention":5380,"totalTrials":26,"cells":5381},"ABT-384",{"EARLY_PHASE1":5382,"PHASE1":5384,"PHASE2":5398,"PHASE3":5400,"PHASE4":5402,"NA":5404},{"trials":5383,"activeCount":76},[],{"trials":5385,"activeCount":76},[5386,5392],{"nctId":5387,"briefTitle":5388,"status":86,"phases":5389,"primaryCompletion":1695,"start":1042,"enrollment":43,"conditions":5390,"interventions":5391},"NCT00968422","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects",[66],[415],[5380],{"nctId":5393,"briefTitle":5394,"status":86,"phases":5395,"primaryCompletion":207,"completion":207,"start":146,"enrollment":1285,"conditions":5396,"interventions":5397},"NCT01009216","A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid",[66],[415],[5380],{"trials":5399,"activeCount":76},[],{"trials":5401,"activeCount":76},[],{"trials":5403,"activeCount":76},[],{"trials":5405,"activeCount":76},[],{"intervention":5407,"totalTrials":26,"cells":5408},"SLV354",{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5426,"PHASE3":5428,"PHASE4":5430,"NA":5432},{"trials":5410,"activeCount":76},[],{"trials":5412,"activeCount":76},[5413,5420],{"nctId":5414,"briefTitle":5415,"status":263,"phases":5416,"primaryCompletion":254,"completion":254,"start":5267,"enrollment":147,"conditions":5417,"interventions":5419},"NCT01133574","This is a Single Ascending Dose Tolerance Study",[66],[5418],"Cognition Disorders",[5407,5407,5407,5407,5407,5407,5407,5407,5407,5407,5407,5407],{"nctId":5421,"briefTitle":5422,"status":86,"phases":5423,"primaryCompletion":1648,"completion":1648,"start":245,"enrollment":1418,"conditions":5424,"interventions":5425},"NCT01545310","A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia",[66],[806],[5407],{"trials":5427,"activeCount":76},[],{"trials":5429,"activeCount":76},[],{"trials":5431,"activeCount":76},[],{"trials":5433,"activeCount":76},[],{"intervention":5435,"totalTrials":106,"cells":5436},"Cortiment",{"EARLY_PHASE1":5437,"PHASE1":5439,"PHASE2":5455,"PHASE3":5457,"PHASE4":5459,"NA":5461},{"trials":5438,"activeCount":76},[],{"trials":5440,"activeCount":76},[5441],{"nctId":5442,"briefTitle":5443,"status":86,"phases":5444,"primaryCompletion":5445,"completion":5446,"start":5447,"enrollment":5448,"conditions":5449,"interventions":5453},"NCT05519514","Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects",[66],"2021-08-08","2021-11-15","2021-07-12",56,[4366,5450,5451,5452],"Human Volunteers","Healthy Participants","Bioequivalence",[5435,5454],"Budesonide",{"trials":5456,"activeCount":76},[],{"trials":5458,"activeCount":76},[],{"trials":5460,"activeCount":76},[],{"trials":5462,"activeCount":76},[],{"intervention":5454,"totalTrials":106,"cells":5464},{"EARLY_PHASE1":5465,"PHASE1":5467,"PHASE2":5473,"PHASE3":5475,"PHASE4":5477,"NA":5479},{"trials":5466,"activeCount":76},[],{"trials":5468,"activeCount":76},[5469],{"nctId":5442,"briefTitle":5443,"status":86,"phases":5470,"primaryCompletion":5445,"completion":5446,"start":5447,"enrollment":5448,"conditions":5471,"interventions":5472},[66],[4366,5450,5451,5452],[5435,5454],{"trials":5474,"activeCount":76},[],{"trials":5476,"activeCount":76},[],{"trials":5478,"activeCount":76},[],{"trials":5480,"activeCount":76},[],{"intervention":5482,"totalTrials":106,"cells":5483},"Moksi® 400mg",{"EARLY_PHASE1":5484,"PHASE1":5486,"PHASE2":5498,"PHASE3":5500,"PHASE4":5502,"NA":5504},{"trials":5485,"activeCount":76},[],{"trials":5487,"activeCount":76},[5488],{"nctId":5489,"briefTitle":5490,"status":86,"phases":5491,"primaryCompletion":5492,"completion":5493,"start":5494,"enrollment":1323,"conditions":5495,"interventions":5496},"NCT05307614","Bioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects",[66],"2019-04-23","2019-04-27","2019-03-27",[5452],[5482,5497],"Drug: Avelox® 400Mg",{"trials":5499,"activeCount":76},[],{"trials":5501,"activeCount":76},[],{"trials":5503,"activeCount":76},[],{"trials":5505,"activeCount":76},[],{"intervention":5497,"totalTrials":106,"cells":5507},{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5516,"PHASE3":5518,"PHASE4":5520,"NA":5522},{"trials":5509,"activeCount":76},[],{"trials":5511,"activeCount":76},[5512],{"nctId":5489,"briefTitle":5490,"status":86,"phases":5513,"primaryCompletion":5492,"completion":5493,"start":5494,"enrollment":1323,"conditions":5514,"interventions":5515},[66],[5452],[5482,5497],{"trials":5517,"activeCount":76},[],{"trials":5519,"activeCount":76},[],{"trials":5521,"activeCount":76},[],{"trials":5523,"activeCount":76},[],{"intervention":5525,"totalTrials":106,"cells":5526},"Anti-HIV Immune Serum Globulin",{"EARLY_PHASE1":5527,"PHASE1":5529,"PHASE2":5537,"PHASE3":5539,"PHASE4":5541,"NA":5543},{"trials":5528,"activeCount":76},[],{"trials":5530,"activeCount":76},[5531],{"nctId":5532,"briefTitle":5533,"status":86,"phases":5534,"enrollment":1285,"conditions":5535,"interventions":5536},"NCT00002036","Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)",[66],[1731],[5525],{"trials":5538,"activeCount":76},[],{"trials":5540,"activeCount":76},[],{"trials":5542,"activeCount":76},[],{"trials":5544,"activeCount":76},[],{"intervention":5546,"totalTrials":106,"cells":5547},"M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab",{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5559,"PHASE3":5561,"PHASE4":5563,"NA":5565},{"trials":5549,"activeCount":76},[],{"trials":5551,"activeCount":76},[5552],{"nctId":5553,"briefTitle":5554,"status":86,"phases":5555,"primaryCompletion":1452,"completion":1452,"start":167,"enrollment":1399,"conditions":5556,"interventions":5558},"NCT00666692","A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)",[66],[5557],"Non-small Cell Lung Cancer",[5546],{"trials":5560,"activeCount":76},[],{"trials":5562,"activeCount":76},[],{"trials":5564,"activeCount":76},[],{"trials":5566,"activeCount":76},[],{"intervention":5568,"totalTrials":106,"cells":5569},"PG110",{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5581,"PHASE3":5583,"PHASE4":5585,"NA":5587},{"trials":5571,"activeCount":76},[],{"trials":5573,"activeCount":76},[5574],{"nctId":5575,"briefTitle":5576,"status":86,"phases":5577,"primaryCompletion":4771,"completion":4771,"start":1042,"enrollment":5448,"conditions":5578,"interventions":5580},"NCT00941746","Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain",[66],[5579],"Osteoarthritis, Knee",[5568,5568,5568,5568,5568,5568,5568,5568],{"trials":5582,"activeCount":76},[],{"trials":5584,"activeCount":76},[],{"trials":5586,"activeCount":76},[],{"trials":5588,"activeCount":76},[],{"intervention":5590,"totalTrials":106,"cells":5591},"ABT-267",{"EARLY_PHASE1":5592,"PHASE1":5594,"PHASE2":5604,"PHASE3":5606,"PHASE4":5608,"NA":5610},{"trials":5593,"activeCount":76},[],{"trials":5595,"activeCount":76},[5596],{"nctId":5597,"briefTitle":5598,"status":86,"phases":5599,"primaryCompletion":1216,"completion":5367,"start":2163,"enrollment":5600,"conditions":5601,"interventions":5602},"NCT01181427","Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects",[66],137,[5138],[5590,5603],"Cytochrome P450 inhibitor",{"trials":5605,"activeCount":76},[],{"trials":5607,"activeCount":76},[],{"trials":5609,"activeCount":76},[],{"trials":5611,"activeCount":76},[],{"intervention":5603,"totalTrials":106,"cells":5613},{"EARLY_PHASE1":5614,"PHASE1":5616,"PHASE2":5622,"PHASE3":5624,"PHASE4":5626,"NA":5628},{"trials":5615,"activeCount":76},[],{"trials":5617,"activeCount":76},[5618],{"nctId":5597,"briefTitle":5598,"status":86,"phases":5619,"primaryCompletion":1216,"completion":5367,"start":2163,"enrollment":5600,"conditions":5620,"interventions":5621},[66],[5138],[5590,5603],{"trials":5623,"activeCount":76},[],{"trials":5625,"activeCount":76},[],{"trials":5627,"activeCount":76},[],{"trials":5629,"activeCount":76},[],{"intervention":5631,"totalTrials":106,"cells":5632},"Elotuzumab",{"EARLY_PHASE1":5633,"PHASE1":5635,"PHASE2":5644,"PHASE3":5646,"PHASE4":5648,"NA":5650},{"trials":5634,"activeCount":76},[],{"trials":5636,"activeCount":76},[5637],{"nctId":5638,"briefTitle":5639,"status":263,"phases":5640,"primaryCompletion":2537,"completion":2537,"start":5641,"enrollment":43,"conditions":5642,"interventions":5643},"NCT00726869","A Phase 1\u002F2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.",[66],"2008-05",[4856],[5631],{"trials":5645,"activeCount":76},[],{"trials":5647,"activeCount":76},[],{"trials":5649,"activeCount":76},[],{"trials":5651,"activeCount":76},[],{"intervention":5653,"totalTrials":106,"cells":5654},"SLV342",{"EARLY_PHASE1":5655,"PHASE1":5657,"PHASE2":5665,"PHASE3":5667,"PHASE4":5669,"NA":5671},{"trials":5656,"activeCount":76},[],{"trials":5658,"activeCount":76},[5659],{"nctId":5660,"briefTitle":5661,"status":263,"phases":5662,"primaryCompletion":1640,"completion":1640,"start":1695,"enrollment":4260,"conditions":5663,"interventions":5664},"NCT00985478","First in Man Study With SLV342",[66],[1420],[5653],{"trials":5666,"activeCount":76},[],{"trials":5668,"activeCount":76},[],{"trials":5670,"activeCount":76},[],{"trials":5672,"activeCount":76},[],{"intervention":5674,"totalTrials":106,"cells":5675},"briakinumab",{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5687,"PHASE3":5689,"PHASE4":5691,"NA":5693},{"trials":5677,"activeCount":76},[],{"trials":5679,"activeCount":76},[5680],{"nctId":5681,"briefTitle":5682,"status":687,"phases":5683,"start":2152,"enrollment":1285,"conditions":5684,"interventions":5686},"NCT01260844","Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.",[66],[5685],"Moderate to Severe Plaque Psoriasis",[5674],{"trials":5688,"activeCount":76},[],{"trials":5690,"activeCount":76},[],{"trials":5692,"activeCount":76},[],{"trials":5694,"activeCount":76},[],{"intervention":5696,"totalTrials":106,"cells":5697},"Vicodin® CR",{"EARLY_PHASE1":5698,"PHASE1":5700,"PHASE2":5709,"PHASE3":5711,"PHASE4":5713,"NA":5715},{"trials":5699,"activeCount":76},[],{"trials":5701,"activeCount":76},[5702],{"nctId":5703,"briefTitle":5704,"status":86,"phases":5705,"start":1348,"enrollment":46,"conditions":5706,"interventions":5708},"NCT00429468","A Study to Evaluate the Interaction Between Vicodin® CR and Ethanol in Healthy Male and Female Moderate Alcohol Drinkers",[66],[5707],"Drug Interactions",[5696],{"trials":5710,"activeCount":76},[],{"trials":5712,"activeCount":76},[],{"trials":5714,"activeCount":76},[],{"trials":5716,"activeCount":76},[],{"intervention":5718,"totalTrials":106,"cells":5719},"[14C]linifanib",{"EARLY_PHASE1":5720,"PHASE1":5722,"PHASE2":5733,"PHASE3":5735,"PHASE4":5737,"NA":5739},{"trials":5721,"activeCount":76},[],{"trials":5723,"activeCount":76},[5724],{"nctId":5725,"briefTitle":5726,"status":263,"phases":5727,"primaryCompletion":5728,"completion":5729,"start":3733,"enrollment":676,"conditions":5730,"interventions":5731},"NCT01286974","A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.",[66],"2012-08","2012-09",[5353],[5718,5732],"ABT-869, linifanib",{"trials":5734,"activeCount":76},[],{"trials":5736,"activeCount":76},[],{"trials":5738,"activeCount":76},[],{"trials":5740,"activeCount":76},[],{"intervention":5732,"totalTrials":106,"cells":5742},{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5751,"PHASE3":5753,"PHASE4":5755,"NA":5757},{"trials":5744,"activeCount":76},[],{"trials":5746,"activeCount":76},[5747],{"nctId":5725,"briefTitle":5726,"status":263,"phases":5748,"primaryCompletion":5728,"completion":5729,"start":3733,"enrollment":676,"conditions":5749,"interventions":5750},[66],[5353],[5718,5732],{"trials":5752,"activeCount":76},[],{"trials":5754,"activeCount":76},[],{"trials":5756,"activeCount":76},[],{"trials":5758,"activeCount":76},[],{"intervention":5760,"totalTrials":106,"cells":5761},"Zidovudine",{"EARLY_PHASE1":5762,"PHASE1":5764,"PHASE2":5774,"PHASE3":5776,"PHASE4":5778,"NA":5780},{"trials":5763,"activeCount":76},[],{"trials":5765,"activeCount":76},[5766],{"nctId":5767,"briefTitle":5768,"status":86,"phases":5769,"enrollment":49,"conditions":5770,"interventions":5772},"NCT00000971","The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS",[66],[5771,1731],"Mycobacterium Avium-intracellulare Infection",[656,5760,5773],"Didanosine",{"trials":5775,"activeCount":76},[],{"trials":5777,"activeCount":76},[],{"trials":5779,"activeCount":76},[],{"trials":5781,"activeCount":76},[],{"intervention":5773,"totalTrials":106,"cells":5783},{"EARLY_PHASE1":5784,"PHASE1":5786,"PHASE2":5792,"PHASE3":5794,"PHASE4":5796,"NA":5798},{"trials":5785,"activeCount":76},[],{"trials":5787,"activeCount":76},[5788],{"nctId":5767,"briefTitle":5768,"status":86,"phases":5789,"enrollment":49,"conditions":5790,"interventions":5791},[66],[5771,1731],[656,5760,5773],{"trials":5793,"activeCount":76},[],{"trials":5795,"activeCount":76},[],{"trials":5797,"activeCount":76},[],{"trials":5799,"activeCount":76},[],{"intervention":5801,"totalTrials":106,"cells":5802},"rifabutin",{"EARLY_PHASE1":5803,"PHASE1":5805,"PHASE2":5816,"PHASE3":5818,"PHASE4":5820,"NA":5822},{"trials":5804,"activeCount":76},[],{"trials":5806,"activeCount":76},[5807],{"nctId":5808,"briefTitle":5809,"status":263,"phases":5810,"primaryCompletion":1452,"start":710,"enrollment":5811,"conditions":5812,"interventions":5815},"NCT00743470","A Bioavailability Study of Rifabutin and Lopinavir\u002FRitonavir in Healthy Adult Subjects",[66],15,[5813,5814],"HIV","Tuberculosis",[2198,5801],{"trials":5817,"activeCount":76},[],{"trials":5819,"activeCount":76},[],{"trials":5821,"activeCount":76},[],{"trials":5823,"activeCount":76},[],{"intervention":5825,"totalTrials":106,"cells":5826},"ABT-652",{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5838,"PHASE3":5840,"PHASE4":5842,"NA":5844},{"trials":5828,"activeCount":76},[],{"trials":5830,"activeCount":76},[5831],{"nctId":5832,"briefTitle":5833,"status":86,"phases":5834,"primaryCompletion":2152,"completion":2152,"start":2163,"enrollment":4121,"conditions":5835,"interventions":5837},"NCT01124851","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness",[66],[5836],"Sleep Disorder",[5825],{"trials":5839,"activeCount":76},[],{"trials":5841,"activeCount":76},[],{"trials":5843,"activeCount":76},[],{"trials":5845,"activeCount":76},[],{"intervention":5362,"totalTrials":106,"cells":5847},{"EARLY_PHASE1":5848,"PHASE1":5850,"PHASE2":5856,"PHASE3":5858,"PHASE4":5860,"NA":5862},{"trials":5849,"activeCount":76},[],{"trials":5851,"activeCount":76},[5852],{"nctId":5356,"briefTitle":5357,"status":86,"phases":5853,"primaryCompletion":875,"completion":875,"start":245,"enrollment":133,"conditions":5854,"interventions":5855},[66],[5353],[5361,5362],{"trials":5857,"activeCount":76},[],{"trials":5859,"activeCount":76},[],{"trials":5861,"activeCount":76},[],{"trials":5863,"activeCount":76},[],{"intervention":5865,"totalTrials":106,"cells":5866},"PDL192",{"EARLY_PHASE1":5867,"PHASE1":5869,"PHASE2":5878,"PHASE3":5880,"PHASE4":5882,"NA":5884},{"trials":5868,"activeCount":76},[],{"trials":5870,"activeCount":76},[5871],{"nctId":5872,"briefTitle":5873,"status":86,"phases":5874,"primaryCompletion":875,"completion":875,"start":188,"enrollment":520,"conditions":5875,"interventions":5877},"NCT00738764","A Trial of PDL192 in Subjects With Advanced Solid Tumors",[66],[5876],"Cancer",[5865],{"trials":5879,"activeCount":76},[],{"trials":5881,"activeCount":76},[],{"trials":5883,"activeCount":76},[],{"trials":5885,"activeCount":76},[],{"intervention":5887,"totalTrials":106,"cells":5888},"ABT-102",{"EARLY_PHASE1":5889,"PHASE1":5891,"PHASE2":5899,"PHASE3":5901,"PHASE4":5903,"NA":5905},{"trials":5890,"activeCount":76},[],{"trials":5892,"activeCount":76},[5893],{"nctId":5894,"briefTitle":5895,"status":86,"phases":5896,"primaryCompletion":265,"start":166,"enrollment":4121,"conditions":5897,"interventions":5898},"NCT00854659","A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects",[66],[5173],[5887],{"trials":5900,"activeCount":76},[],{"trials":5902,"activeCount":76},[],{"trials":5904,"activeCount":76},[],{"trials":5906,"activeCount":76},[],{"intervention":4368,"totalTrials":106,"cells":5908},{"EARLY_PHASE1":5909,"PHASE1":5911,"PHASE2":5917,"PHASE3":5919,"PHASE4":5921,"NA":5923},{"trials":5910,"activeCount":76},[],{"trials":5912,"activeCount":76},[5913],{"nctId":4362,"briefTitle":4363,"status":86,"phases":5914,"primaryCompletion":3410,"completion":3410,"start":254,"enrollment":1285,"conditions":5915,"interventions":5916},[66],[4366],[4368,4355],{"trials":5918,"activeCount":76},[],{"trials":5920,"activeCount":76},[],{"trials":5922,"activeCount":76},[],{"trials":5924,"activeCount":76},[],{"intervention":1686,"totalTrials":106,"cells":5926},{"EARLY_PHASE1":5927,"PHASE1":5929,"PHASE2":5935,"PHASE3":5937,"PHASE4":5939,"NA":5941},{"trials":5928,"activeCount":76},[],{"trials":5930,"activeCount":76},[5931],{"nctId":1680,"briefTitle":1681,"status":687,"phases":5932,"primaryCompletion":1683,"start":699,"enrollment":76,"conditions":5933,"interventions":5934},[66],[1676],[1664,1686],{"trials":5936,"activeCount":76},[],{"trials":5938,"activeCount":76},[],{"trials":5940,"activeCount":76},[],{"trials":5942,"activeCount":76},[],{"intervention":5944,"totalTrials":106,"cells":5945},"ABT-436",{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5956,"PHASE3":5958,"PHASE4":5960,"NA":5962},{"trials":5947,"activeCount":76},[],{"trials":5949,"activeCount":76},[5950],{"nctId":5951,"briefTitle":5952,"status":86,"phases":5953,"primaryCompletion":5267,"start":187,"enrollment":4121,"conditions":5954,"interventions":5955},"NCT01050127","A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults",[66],[415],[5944],{"trials":5957,"activeCount":76},[],{"trials":5959,"activeCount":76},[],{"trials":5961,"activeCount":76},[],{"trials":5963,"activeCount":76},[],{"intervention":5965,"totalTrials":106,"cells":5966},"ABT-SLV361",{"EARLY_PHASE1":5967,"PHASE1":5969,"PHASE2":5979,"PHASE3":5981,"PHASE4":5983,"NA":5985},{"trials":5968,"activeCount":76},[],{"trials":5970,"activeCount":76},[5971],{"nctId":5972,"briefTitle":5973,"status":86,"phases":5974,"primaryCompletion":5975,"completion":5975,"start":2152,"enrollment":76,"conditions":5976,"interventions":5978},"NCT01346319","Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.",[66],"2011-09",[5977],"Hypogonadal Males",[5965],{"trials":5980,"activeCount":76},[],{"trials":5982,"activeCount":76},[],{"trials":5984,"activeCount":76},[],{"trials":5986,"activeCount":76},[],{"intervention":554,"totalTrials":5988,"cells":5989},59,{"EARLY_PHASE1":5990,"PHASE1":5992,"PHASE2":5994,"PHASE3":6049,"PHASE4":6309,"NA":6340},{"trials":5991,"activeCount":76},[],{"trials":5993,"activeCount":76},[],{"trials":5995,"activeCount":76},[5996,6002,6009,6015,6022,6028,6036,6042],{"nctId":5997,"briefTitle":5998,"status":86,"phases":5999,"primaryCompletion":444,"start":499,"enrollment":560,"conditions":6000,"interventions":6001},"NCT00645905","Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[67],[702],[554],{"nctId":6003,"briefTitle":6004,"status":86,"phases":6005,"primaryCompletion":6006,"start":499,"enrollment":46,"conditions":6007,"interventions":6008},"NCT00235833","Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis",[67],"2004-10",[39],[554],{"nctId":6010,"briefTitle":6011,"status":86,"phases":6012,"primaryCompletion":611,"start":559,"enrollment":5600,"conditions":6013,"interventions":6014},"NCT00646191","Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[67],[702],[554,554,554],{"nctId":6016,"briefTitle":6017,"status":86,"phases":6018,"start":6019,"enrollment":299,"conditions":6020,"interventions":6021},"NCT00055523","A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease",[67],"2002-04",[2457],[545],{"nctId":6023,"briefTitle":6024,"status":86,"phases":6025,"primaryCompletion":519,"start":394,"enrollment":1410,"conditions":6026,"interventions":6027},"NCT00645892","Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[67],[702],[554],{"nctId":6029,"briefTitle":6030,"status":86,"phases":6031,"primaryCompletion":1389,"start":559,"enrollment":350,"conditions":6032,"interventions":6035},"NCT00646386","Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis",[67],[6033,6034],"Arthritis","Psoriatic",[554],{"nctId":6037,"briefTitle":6038,"status":86,"phases":6039,"primaryCompletion":89,"start":559,"enrollment":560,"conditions":6040,"interventions":6041},"NCT00645814","Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[67],[702],[554,554],{"nctId":6043,"briefTitle":6044,"status":86,"phases":6045,"primaryCompletion":4132,"completion":207,"start":3862,"enrollment":430,"conditions":6046,"interventions":6048},"NCT00918255","Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa",[67],[6047],"Hidradenitis Suppurativa",[554],{"trials":6050,"activeCount":76},[6051,6058,6065,6071,6078,6085,6089,6096,6103,6111,6115,6121,6128,6135,6143,6150,6157,6164,6171,6180,6184,6188,6192,6198,6205,6211,6219,6225,6231,6237,6243,6249,6255,6262,6268,6274,6281,6288,6295,6302],{"nctId":6052,"briefTitle":6053,"status":86,"phases":6054,"primaryCompletion":166,"completion":207,"start":1432,"enrollment":6055,"conditions":6056,"interventions":6057},"NCT00445432","A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease",[67,68],82,[2457],[554],{"nctId":6059,"briefTitle":6060,"status":86,"phases":6061,"primaryCompletion":4132,"completion":5975,"start":5641,"enrollment":46,"conditions":6062,"interventions":6064},"NCT00690573","Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis",[68],[6063],"Juvenile Rheumatoid Arthritis",[545],{"nctId":6066,"briefTitle":6067,"status":86,"phases":6068,"completion":1792,"start":1070,"enrollment":1553,"conditions":6069,"interventions":6070},"NCT00338650","Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)",[68],[2457],[554],{"nctId":6072,"briefTitle":6073,"status":86,"phases":6074,"primaryCompletion":3862,"completion":3862,"start":4259,"enrollment":6075,"conditions":6076,"interventions":6077},"NCT00647270","Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing",[68],420,[39],[554,554],{"nctId":6079,"briefTitle":6080,"status":86,"phases":6081,"primaryCompletion":6006,"completion":265,"start":541,"enrollment":6055,"conditions":6082,"interventions":6084},"NCT00195819","Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis",[68],[6083],"Ankylosing Spondylitis",[554],{"nctId":538,"briefTitle":539,"status":86,"phases":6086,"start":541,"enrollment":542,"conditions":6087,"interventions":6088},[68],[39],[545,546],{"nctId":6090,"briefTitle":6091,"status":86,"phases":6092,"primaryCompletion":1374,"start":1366,"enrollment":6093,"conditions":6094,"interventions":6095},"NCT00448383","A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis",[68],6610,[39],[554],{"nctId":6097,"briefTitle":6098,"status":86,"phases":6099,"start":342,"enrollment":6100,"conditions":6101,"interventions":6102},"NCT00077779","Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease",[68],854,[2457],[545],{"nctId":6104,"briefTitle":6105,"status":86,"phases":6106,"primaryCompletion":146,"completion":146,"start":6107,"enrollment":6108,"conditions":6109,"interventions":6110},"NCT00195676","Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis",[68],"2004-05",1469,[702],[554],{"nctId":2658,"briefTitle":2659,"status":86,"phases":6112,"primaryCompletion":1452,"start":2661,"enrollment":2662,"conditions":6113,"interventions":6114},[68],[2664],[554,2647],{"nctId":6116,"briefTitle":6117,"status":86,"phases":6118,"primaryCompletion":509,"completion":4771,"start":1453,"enrollment":1071,"conditions":6119,"interventions":6120},"NCT00667355","A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis",[68],[6083],[554],{"nctId":6122,"briefTitle":6123,"status":86,"phases":6124,"primaryCompletion":3862,"completion":4132,"start":610,"enrollment":6125,"conditions":6126,"interventions":6127},"NCT00385736","Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis",[68],576,[4583],[554,554],{"nctId":6129,"briefTitle":6130,"status":86,"phases":6131,"primaryCompletion":4132,"completion":4132,"start":610,"enrollment":6132,"conditions":6133,"interventions":6134},"NCT00408629","Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis",[68],518,[4583],[554],{"nctId":6136,"briefTitle":6137,"status":86,"phases":6138,"primaryCompletion":699,"start":6139,"enrollment":6140,"conditions":6141,"interventions":6142},"NCT00348283","Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon",[68],"2006-08",135,[2457],[554,554],{"nctId":6144,"briefTitle":6145,"status":86,"phases":6146,"primaryCompletion":145,"completion":145,"start":1504,"enrollment":6147,"conditions":6148,"interventions":6149},"NCT00409682","Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease",[68],192,[2457],[545,545,545],{"nctId":6151,"briefTitle":6152,"status":86,"phases":6153,"start":3156,"enrollment":6154,"conditions":6155,"interventions":6156},"NCT00235885","Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)",[68],445,[3223],[554],{"nctId":6158,"briefTitle":6159,"status":86,"phases":6160,"primaryCompletion":245,"completion":245,"start":1583,"enrollment":6161,"conditions":6162,"interventions":6163},"NCT00195650","Long Term Open Label Continuation Study",[68],846,[39],[545],{"nctId":6165,"briefTitle":6166,"status":86,"phases":6167,"primaryCompletion":1433,"completion":1683,"start":519,"enrollment":6168,"conditions":6169,"interventions":6170},"NCT00195715","Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease",[68],777,[2457],[545],{"nctId":6172,"briefTitle":6173,"status":86,"phases":6174,"primaryCompletion":569,"completion":6175,"start":6176,"enrollment":6177,"conditions":6178,"interventions":6179},"NCT00647491","A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis",[67,68],"2005-08","2004-02",352,[39],[554,554,554],{"nctId":548,"briefTitle":549,"status":86,"phases":6181,"start":342,"enrollment":551,"conditions":6182,"interventions":6183},[68],[39],[554,526],{"nctId":556,"briefTitle":557,"status":86,"phases":6185,"start":559,"enrollment":560,"conditions":6186,"interventions":6187},[68],[39],[554,526],{"nctId":3153,"briefTitle":3154,"status":86,"phases":6189,"primaryCompletion":1793,"start":3156,"enrollment":404,"conditions":6190,"interventions":6191},[68],[702],[554,3142],{"nctId":6193,"briefTitle":6194,"status":86,"phases":6195,"start":6006,"enrollment":299,"conditions":6196,"interventions":6197},"NCT00105300","Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease",[68],[2457],[545],{"nctId":6199,"briefTitle":6200,"status":86,"phases":6201,"primaryCompletion":1792,"start":1793,"enrollment":6202,"conditions":6203,"interventions":6204},"NCT00427362","A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)",[68],127,[3223],[545],{"nctId":6206,"briefTitle":6207,"status":86,"phases":6208,"primaryCompletion":5267,"completion":5267,"start":4259,"enrollment":510,"conditions":6209,"interventions":6210},"NCT01231321","A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis",[68],[39],[554],{"nctId":6212,"briefTitle":6213,"status":86,"phases":6214,"primaryCompletion":1366,"completion":2163,"start":6215,"enrollment":6216,"conditions":6217,"interventions":6218},"NCT00195702","Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.",[68],"2000-02",619,[39],[545,545,545,545,545],{"nctId":6220,"briefTitle":6221,"status":86,"phases":6222,"primaryCompletion":610,"start":1433,"enrollment":4429,"conditions":6223,"interventions":6224},"NCT00603993","Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis",[68],[39],[545],{"nctId":6226,"briefTitle":6227,"status":86,"phases":6228,"primaryCompletion":1740,"start":342,"enrollment":147,"conditions":6229,"interventions":6230},"NCT00647920","Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate",[68],[39],[554],{"nctId":6232,"briefTitle":6233,"status":86,"phases":6234,"primaryCompletion":255,"completion":3306,"start":630,"enrollment":256,"conditions":6235,"interventions":6236},"NCT00647400","Adalimumab in Adult Japanese Subjects With Psoriasis",[67,68],[702],[554,554],{"nctId":6238,"briefTitle":6105,"status":86,"phases":6239,"start":2272,"enrollment":6240,"conditions":6241,"interventions":6242},"NCT00237887",[68],1212,[702],[554],{"nctId":6244,"briefTitle":6245,"status":86,"phases":6246,"primaryCompletion":1069,"completion":1069,"start":1348,"enrollment":1610,"conditions":6247,"interventions":6248},"NCT00427921","Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)",[68],[2457],[554],{"nctId":6250,"briefTitle":6251,"status":86,"phases":6252,"primaryCompletion":3862,"completion":3862,"start":1069,"enrollment":1829,"conditions":6253,"interventions":6254},"NCT00566722","Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy",[68],[702],[554],{"nctId":6256,"briefTitle":6257,"status":86,"phases":6258,"primaryCompletion":188,"completion":188,"start":466,"enrollment":6259,"conditions":6260,"interventions":6261},"NCT00409617","Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease",[68],945,[2457],[554,554],{"nctId":6263,"briefTitle":6264,"status":86,"phases":6265,"primaryCompletion":4259,"start":157,"enrollment":2216,"conditions":6266,"interventions":6267},"NCT00445939","A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease",[67,68],[2457],[554,554],{"nctId":6269,"briefTitle":6270,"status":86,"phases":6271,"primaryCompletion":2272,"completion":88,"start":393,"enrollment":350,"conditions":6272,"interventions":6273},"NCT00085644","Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis",[68],[6083],[554],{"nctId":6275,"briefTitle":6004,"status":86,"phases":6276,"primaryCompletion":6277,"start":479,"enrollment":6278,"conditions":6279,"interventions":6280},"NCT00235872",[68],"2006-07",309,[39],[554],{"nctId":6282,"briefTitle":6283,"status":86,"phases":6284,"primaryCompletion":508,"completion":1674,"start":1695,"enrollment":6285,"conditions":6286,"interventions":6287},"NCT01114880","Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis",[68],344,[6083],[554],{"nctId":6289,"briefTitle":6290,"status":86,"phases":6291,"start":2215,"enrollment":6292,"conditions":6293,"interventions":6294},"NCT00478660","An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)",[68],1250,[6083],[554],{"nctId":6296,"briefTitle":6297,"status":86,"phases":6298,"start":1366,"enrollment":6299,"conditions":6300,"interventions":6301},"NCT00049751","Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis",[68],3000,[39],[545],{"nctId":6303,"briefTitle":6304,"status":86,"phases":6305,"primaryCompletion":403,"start":499,"enrollment":6306,"conditions":6307,"interventions":6308},"NCT00646178","Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy",[68],102,[6033,6034],[554],{"trials":6310,"activeCount":76},[6311,6315,6322,6326,6333],{"nctId":566,"briefTitle":567,"status":263,"phases":6312,"start":569,"enrollment":570,"conditions":6313,"interventions":6314},[69],[39],[554,526],{"nctId":6316,"briefTitle":6317,"status":86,"phases":6318,"start":479,"enrollment":6319,"conditions":6320,"interventions":6321},"NCT00234897","Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis",[69],1938,[39],[554],{"nctId":574,"briefTitle":575,"status":86,"phases":6323,"primaryCompletion":254,"completion":254,"start":466,"enrollment":577,"conditions":6324,"interventions":6325},[69],[39],[554,526],{"nctId":6327,"briefTitle":6328,"status":86,"phases":6329,"primaryCompletion":2496,"completion":2496,"start":710,"enrollment":6330,"conditions":6331,"interventions":6332},"NCT00735787","Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and\u002For Feet",[69],81,[702],[545],{"nctId":6334,"briefTitle":6335,"status":86,"phases":6336,"primaryCompletion":2272,"completion":308,"start":1774,"enrollment":6337,"conditions":6338,"interventions":6339},"NCT00649922","Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis",[69],226,[39],[554,554],{"trials":6341,"activeCount":76},[6342,6349,6356,6362,6369,6375],{"nctId":6343,"briefTitle":6344,"status":86,"phases":6345,"primaryCompletion":254,"completion":254,"start":89,"enrollment":6346,"conditions":6347,"interventions":6348},"NCT00234884","Post-marketing Observational Study in Subjects With Rheumatoid Arthritis",[],3435,[39],[554],{"nctId":6350,"briefTitle":6351,"status":6352,"phases":6353,"conditions":6354,"interventions":6355},"NCT00649545","Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis","APPROVED_FOR_MARKETING",[],[39],[554],{"nctId":6357,"briefTitle":6358,"status":6352,"phases":6359,"conditions":6360,"interventions":6361},"NCT00650026","Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis",[],[39],[554],{"nctId":6363,"briefTitle":6364,"status":86,"phases":6365,"primaryCompletion":145,"completion":145,"start":1793,"enrollment":6366,"conditions":6367,"interventions":6368},"NCT01078571","Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis",[],705,[39],[554],{"nctId":6370,"briefTitle":6371,"status":687,"phases":6372,"enrollment":76,"conditions":6373,"interventions":6374},"NCT01078610","Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine",[],[3223],[554],{"nctId":6376,"briefTitle":6377,"status":6352,"phases":6378,"conditions":6379,"interventions":6380},"NCT00650390","Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab",[],[39],[554],{"intervention":1744,"totalTrials":4251,"cells":6382},{"EARLY_PHASE1":6383,"PHASE1":6385,"PHASE2":6395,"PHASE3":6409,"PHASE4":6453,"NA":6461},{"trials":6384,"activeCount":76},[],{"trials":6386,"activeCount":76},[6387,6391],{"nctId":2238,"briefTitle":2239,"status":86,"phases":6388,"conditions":6389,"interventions":6390},[66],[1731],[1744,2231],{"nctId":5808,"briefTitle":5809,"status":263,"phases":6392,"primaryCompletion":1452,"start":710,"enrollment":5811,"conditions":6393,"interventions":6394},[66],[5813,5814],[2198,5801],{"trials":6396,"activeCount":76},[6397,6401,6405],{"nctId":2181,"briefTitle":2182,"status":86,"phases":6398,"start":1313,"enrollment":520,"conditions":6399,"interventions":6400},[67],[1731],[1733,2186,2187],{"nctId":1726,"briefTitle":1727,"status":86,"phases":6402,"start":1583,"enrollment":1729,"conditions":6403,"interventions":6404},[67],[1731],[1733,1734,1717,1735],{"nctId":1737,"briefTitle":1738,"status":86,"phases":6406,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":510,"conditions":6407,"interventions":6408},[66,67],[1731],[1744,1717,1745],{"trials":6410,"activeCount":76},[6411,6415,6419,6423,6431,6435,6442,6446],{"nctId":1749,"briefTitle":1750,"status":86,"phases":6412,"start":1752,"enrollment":1753,"conditions":6413,"interventions":6414},[68],[1731],[1744,1756,1717,1745],{"nctId":2191,"briefTitle":2192,"status":86,"phases":6416,"primaryCompletion":157,"start":2194,"enrollment":2195,"conditions":6417,"interventions":6418},[68],[1831],[2198,2172],{"nctId":1819,"briefTitle":1820,"status":86,"phases":6420,"start":382,"enrollment":542,"conditions":6421,"interventions":6422},[68],[1731],[1733,1735,1824],{"nctId":6424,"briefTitle":6425,"status":86,"phases":6426,"primaryCompletion":1462,"completion":1462,"start":6139,"enrollment":6427,"conditions":6428,"interventions":6430},"NCT00358917","Study of Lopinavir\u002FRitonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside\u002FNucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects",[68],599,[6429],"Human Immunodeficiency Virus Infections",[2198,2198],{"nctId":2248,"briefTitle":2249,"status":86,"phases":6432,"enrollment":299,"conditions":6433,"interventions":6434},[68],[1731],[1744,2231],{"nctId":6436,"briefTitle":6437,"status":86,"phases":6438,"primaryCompletion":188,"completion":188,"start":158,"enrollment":6439,"conditions":6440,"interventions":6441},"NCT00262522","Study of Lopinavir\u002FRitonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects",[68],664,[6429],[2198,2198,2198,2198],{"nctId":3407,"briefTitle":3408,"status":86,"phases":6443,"primaryCompletion":208,"completion":3410,"start":188,"enrollment":3411,"conditions":6444,"interventions":6445},[68],[3413],[2198,3396,3415],{"nctId":6447,"briefTitle":6448,"status":86,"phases":6449,"start":4293,"enrollment":4121,"conditions":6450,"interventions":6451},"NCT00038636","A Study of Two Different Doses of ABT-378\u002FRitonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors",[68],[1731],[1733,6452],"Ritonavir",{"trials":6454,"activeCount":76},[6455],{"nctId":6456,"briefTitle":6457,"status":263,"phases":6458,"completion":157,"start":1313,"enrollment":542,"conditions":6459,"interventions":6460},"NCT00234962","Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy",[69],[1831],[1744],{"trials":6462,"activeCount":76},[6463,6470,6478,6487,6493],{"nctId":6464,"briefTitle":6465,"status":86,"phases":6466,"primaryCompletion":207,"completion":207,"start":1552,"enrollment":40,"conditions":6467,"interventions":6469},"NCT01153269","Long-term Effectiveness and Safety in Hepatitis-co-infected Patients",[],[6468],"Human Immunodeficiency Virus-Infection",[1744],{"nctId":6471,"briefTitle":6472,"status":86,"phases":6473,"primaryCompletion":145,"completion":1640,"start":167,"enrollment":6474,"conditions":6475,"interventions":6477},"NCT01074931","Clinical, Virological and Safety Outcomes of a Lopinavir\u002FRitonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China",[],98,[6476],"HIV-1 Infections",[1733],{"nctId":6479,"briefTitle":6480,"status":86,"phases":6481,"primaryCompletion":4375,"completion":4375,"start":6482,"enrollment":6483,"conditions":6484,"interventions":6486},"NCT01076972","Drug Use Investigation of Kaletra",[],"2000-12",1184,[6485],"Human Immunodeficiency Virus",[1733],{"nctId":6488,"briefTitle":6489,"status":86,"phases":6490,"primaryCompletion":4375,"completion":4375,"start":6482,"enrollment":49,"conditions":6491,"interventions":6492},"NCT01076985","Special Investigation of Kaletra in Pregnant Women",[],[6485],[1733],{"nctId":6494,"briefTitle":6495,"status":86,"phases":6496,"primaryCompletion":1640,"completion":1640,"start":1544,"enrollment":6497,"conditions":6498,"interventions":6499},"NCT01083810","Evaluation of Kaletra Therapy Over the Long-term",[],284,[6485],[1744],{"intervention":6452,"totalTrials":1399,"cells":6501},{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6518,"PHASE3":6527,"PHASE4":6533,"NA":6535},{"trials":6503,"activeCount":76},[],{"trials":6505,"activeCount":76},[6506,6510,6514],{"nctId":5251,"briefTitle":5252,"status":86,"phases":6507,"primaryCompletion":88,"start":509,"enrollment":367,"conditions":6508,"interventions":6509},[66],[5138],[5244,5256],{"nctId":5258,"briefTitle":5259,"status":86,"phases":6511,"primaryCompletion":2496,"start":265,"enrollment":1323,"conditions":6512,"interventions":6513},[66],[5138],[5244,5256],{"nctId":5264,"briefTitle":5265,"status":86,"phases":6515,"primaryCompletion":3306,"completion":3306,"start":5267,"enrollment":1729,"conditions":6516,"interventions":6517},[66],[415],[5244,5256,5244],{"trials":6519,"activeCount":76},[6520],{"nctId":6521,"briefTitle":6522,"status":86,"phases":6523,"conditions":6524,"interventions":6526},"NCT00002366","The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma",[67],[6525,1731],"Sarcoma, Kaposi",[6452],{"trials":6528,"activeCount":76},[6529],{"nctId":6447,"briefTitle":6448,"status":86,"phases":6530,"start":4293,"enrollment":4121,"conditions":6531,"interventions":6532},[68],[1731],[1733,6452],{"trials":6534,"activeCount":76},[],{"trials":6536,"activeCount":76},[6537,6543],{"nctId":6538,"briefTitle":6539,"status":86,"phases":6540,"conditions":6541,"interventions":6542},"NCT00002201","A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients",[70],[1731],[6452,1756],{"nctId":6544,"briefTitle":6545,"status":86,"phases":6546,"conditions":6547,"interventions":6548},"NCT00002223","A Study of Ritonavir\u002FIndinavir Combination in HIV-Infected Patients",[70],[1731],[6549,6452],"Indinavir sulfate",{"intervention":656,"totalTrials":454,"cells":6551},{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6560,"PHASE3":6562,"PHASE4":6568,"NA":6570},{"trials":6553,"activeCount":76},[],{"trials":6555,"activeCount":76},[6556],{"nctId":5767,"briefTitle":5768,"status":86,"phases":6557,"enrollment":49,"conditions":6558,"interventions":6559},[66],[5771,1731],[656,5760,5773],{"trials":6561,"activeCount":76},[],{"trials":6563,"activeCount":76},[6564],{"nctId":649,"briefTitle":650,"status":86,"phases":6565,"primaryCompletion":403,"start":298,"enrollment":652,"conditions":6566,"interventions":6567},[68],[654],[656,657],{"trials":6569,"activeCount":76},[],{"trials":6571,"activeCount":76},[6572,6581,6589,6599],{"nctId":6573,"briefTitle":6574,"status":86,"phases":6575,"primaryCompletion":6576,"completion":6576,"start":6577,"conditions":6578,"interventions":6580},"NCT00002336","The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients",[70],"1994-11","1992-11",[6579,1731],"Mycobacterium Avium-intracellular Infection",[656],{"nctId":6582,"briefTitle":6583,"status":86,"phases":6584,"primaryCompletion":145,"completion":145,"start":1042,"enrollment":6585,"conditions":6586,"interventions":6588},"NCT01095978","Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine",[],2822,[6587],"Respiratory Tract Infections",[656],{"nctId":6590,"briefTitle":6591,"status":86,"phases":6592,"primaryCompletion":6593,"completion":6593,"start":6594,"conditions":6595,"interventions":6596},"NCT00002331","The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS",[70],"1995-03","1994-01",[6579,1731],[6597,656,6598],"Ethambutol hydrochloride","Clofazimine",{"nctId":6600,"briefTitle":6601,"status":86,"phases":6602,"primaryCompletion":3306,"completion":3306,"start":1683,"enrollment":6603,"conditions":6604,"interventions":6606},"NCT01076153","Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR",[],760,[6605],"Respiratory Tract Infection",[656],{"intervention":6608,"totalTrials":676,"cells":6609},"DAPT",{"EARLY_PHASE1":6610,"PHASE1":6612,"PHASE2":6614,"PHASE3":6616,"PHASE4":6618,"NA":6620},{"trials":6611,"activeCount":76},[],{"trials":6613,"activeCount":76},[],{"trials":6615,"activeCount":76},[],{"trials":6617,"activeCount":76},[],{"trials":6619,"activeCount":76},[],{"trials":6621,"activeCount":76},[6622,6640,6650],{"nctId":6623,"briefTitle":6624,"status":86,"phases":6625,"primaryCompletion":6626,"completion":6627,"start":6628,"enrollment":6629,"conditions":6630,"interventions":6639},"NCT03355742","XIENCE 28 Global Study",[70],"2019-10-24","2020-04-30","2018-02-09",963,[6631,6632,6633,6634,6635,6636,6637,6638,33],"Bleeding Disorder","Stroke, Ischemic","Stroke Hemorrhagic","Hematological Disease","Thrombocytopenia","Coagulation Disorder","Anemia","Renal Insufficiency",[6608],{"nctId":6641,"briefTitle":6642,"status":86,"phases":6643,"primaryCompletion":6644,"completion":6644,"start":6645,"enrollment":6646,"conditions":6647,"interventions":6649},"NCT03218787","XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.",[70],"2020-09-04","2017-07-19",2047,[6648],"Coronary Artery Lesions",[6608],{"nctId":6651,"briefTitle":6652,"status":86,"phases":6653,"primaryCompletion":6654,"completion":6655,"start":6656,"enrollment":6657,"conditions":6658,"interventions":6662},"NCT03815175","XIENCE 28 USA Study",[70],"2020-08-14","2021-02-04","2019-02-25",1605,[6631,6659,6660,6661,6635,6636,6637,6638,33],"Ischemic Stroke","Hemorrhagic Stroke","Hematological Diseases",[6608],{"intervention":1756,"totalTrials":26,"cells":6664},{"EARLY_PHASE1":6665,"PHASE1":6667,"PHASE2":6669,"PHASE3":6671,"PHASE4":6677,"NA":6679},{"trials":6666,"activeCount":76},[],{"trials":6668,"activeCount":76},[],{"trials":6670,"activeCount":76},[],{"trials":6672,"activeCount":76},[6673],{"nctId":1749,"briefTitle":1750,"status":86,"phases":6674,"start":1752,"enrollment":1753,"conditions":6675,"interventions":6676},[68],[1731],[1744,1756,1717,1745],{"trials":6678,"activeCount":76},[],{"trials":6680,"activeCount":76},[6681],{"nctId":6538,"briefTitle":6539,"status":86,"phases":6682,"conditions":6683,"interventions":6684},[70],[1731],[6452,1756],{"intervention":6686,"totalTrials":26,"cells":6687},"Duphaston®",{"EARLY_PHASE1":6688,"PHASE1":6690,"PHASE2":6692,"PHASE3":6694,"PHASE4":6696,"NA":6698},{"trials":6689,"activeCount":76},[],{"trials":6691,"activeCount":76},[],{"trials":6693,"activeCount":76},[],{"trials":6695,"activeCount":76},[],{"trials":6697,"activeCount":76},[],{"trials":6699,"activeCount":76},[6700,6710],{"nctId":6701,"briefTitle":6702,"status":86,"phases":6703,"primaryCompletion":6704,"completion":6705,"start":6706,"enrollment":6707,"conditions":6708,"interventions":6709},"NCT03690765","Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis",[],"2019-11-10","2020-05-29","2018-09-27",350,[104],[6686,6686],{"nctId":6711,"briefTitle":6712,"status":3687,"phases":6713,"primaryCompletion":6714,"completion":6715,"start":6716,"enrollment":6717,"conditions":6718,"interventions":6720},"NCT04249297","Predictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines",[],"2022-03","2022-12","2020-03-03",1150,[6719],"Infertility",[6686],{"intervention":6722,"totalTrials":26,"cells":6723},"Clarithromycin modified release 500 mg",{"EARLY_PHASE1":6724,"PHASE1":6726,"PHASE2":6728,"PHASE3":6730,"PHASE4":6732,"NA":6734},{"trials":6725,"activeCount":76},[],{"trials":6727,"activeCount":76},[],{"trials":6729,"activeCount":76},[],{"trials":6731,"activeCount":76},[],{"trials":6733,"activeCount":76},[],{"trials":6735,"activeCount":76},[6736,6744],{"nctId":6737,"briefTitle":6738,"status":86,"phases":6739,"primaryCompletion":5367,"completion":5367,"start":245,"enrollment":6740,"conditions":6741,"interventions":6743},"NCT01354938","Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis",[],220,[6742],"Bronchitis",[6722],{"nctId":6745,"briefTitle":6746,"status":86,"phases":6747,"primaryCompletion":5367,"completion":5367,"start":4771,"enrollment":6748,"conditions":6749,"interventions":6750},"NCT01075204","Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)",[],335,[6605],[6751],"clarithromycin modified release 500 mg",{"intervention":6753,"totalTrials":26,"cells":6754},"Fat Emulsion 2%",{"EARLY_PHASE1":6755,"PHASE1":6757,"PHASE2":6759,"PHASE3":6761,"PHASE4":6763,"NA":6765},{"trials":6756,"activeCount":76},[],{"trials":6758,"activeCount":76},[],{"trials":6760,"activeCount":76},[],{"trials":6762,"activeCount":76},[],{"trials":6764,"activeCount":76},[],{"trials":6766,"activeCount":76},[6767,6774],{"nctId":6768,"briefTitle":6769,"status":86,"phases":6770,"conditions":6771,"interventions":6772},"NCT00002275","A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)",[70],[1731],[6753,6773],"Fat Emulsion 20%",{"nctId":6775,"briefTitle":6776,"status":86,"phases":6777,"conditions":6778,"interventions":6779},"NCT00002029","Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent",[70],[1731],[6753,6773],{"intervention":6773,"totalTrials":26,"cells":6781},{"EARLY_PHASE1":6782,"PHASE1":6784,"PHASE2":6786,"PHASE3":6788,"PHASE4":6790,"NA":6792},{"trials":6783,"activeCount":76},[],{"trials":6785,"activeCount":76},[],{"trials":6787,"activeCount":76},[],{"trials":6789,"activeCount":76},[],{"trials":6791,"activeCount":76},[],{"trials":6793,"activeCount":76},[6794,6798],{"nctId":6768,"briefTitle":6769,"status":86,"phases":6795,"conditions":6796,"interventions":6797},[70],[1731],[6753,6773],{"nctId":6775,"briefTitle":6776,"status":86,"phases":6799,"conditions":6800,"interventions":6801},[70],[1731],[6753,6773],{"intervention":3935,"totalTrials":26,"cells":6803},{"EARLY_PHASE1":6804,"PHASE1":6806,"PHASE2":6808,"PHASE3":6810,"PHASE4":6816,"NA":6818},{"trials":6805,"activeCount":76},[],{"trials":6807,"activeCount":76},[],{"trials":6809,"activeCount":76},[],{"trials":6811,"activeCount":76},[6812],{"nctId":3927,"briefTitle":3928,"status":86,"phases":6813,"primaryCompletion":3930,"completion":3930,"start":3931,"enrollment":3453,"conditions":6814,"interventions":6815},[68],[3933],[3916,3935,3936],{"trials":6817,"activeCount":76},[],{"trials":6819,"activeCount":76},[6820],{"nctId":6821,"briefTitle":6822,"status":86,"phases":6823,"primaryCompletion":2432,"completion":2432,"start":1041,"enrollment":6740,"conditions":6824,"interventions":6826},"NCT02260154","Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm",[],[6825],"Post-cholecystectomy Gastrointestinal Spasms",[3935],{"intervention":6828,"totalTrials":106,"cells":6829},"clarithromycin (Klacid) granules for oral suspension",{"EARLY_PHASE1":6830,"PHASE1":6832,"PHASE2":6834,"PHASE3":6836,"PHASE4":6838,"NA":6840},{"trials":6831,"activeCount":76},[],{"trials":6833,"activeCount":76},[],{"trials":6835,"activeCount":76},[],{"trials":6837,"activeCount":76},[],{"trials":6839,"activeCount":76},[],{"trials":6841,"activeCount":76},[6842],{"nctId":6843,"briefTitle":6844,"status":86,"phases":6845,"primaryCompletion":1695,"completion":1695,"start":3862,"enrollment":4155,"conditions":6846,"interventions":6848},"NCT01076166","Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid® Granules for Oral Suspension.",[],[6847],"Lower Respiratory Tract Infection",[6828],{"intervention":6850,"totalTrials":106,"cells":6851},"Leuprolide acetate Depot Susp. 11.25 mg",{"EARLY_PHASE1":6852,"PHASE1":6854,"PHASE2":6856,"PHASE3":6858,"PHASE4":6860,"NA":6862},{"trials":6853,"activeCount":76},[],{"trials":6855,"activeCount":76},[],{"trials":6857,"activeCount":76},[],{"trials":6859,"activeCount":76},[],{"trials":6861,"activeCount":76},[],{"trials":6863,"activeCount":76},[6864],{"nctId":6865,"briefTitle":6866,"status":86,"phases":6867,"primaryCompletion":207,"completion":207,"start":699,"enrollment":6868,"conditions":6869,"interventions":6872},"NCT01078545","Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)",[],729,[6870,6871],"Advanced Prostate Cancer","Lower Urinary Tract Symptoms",[6850],{"intervention":6874,"totalTrials":106,"cells":6875},"Tricor (fenofibrate), 145 mg, film-coated",{"EARLY_PHASE1":6876,"PHASE1":6878,"PHASE2":6880,"PHASE3":6882,"PHASE4":6884,"NA":6886},{"trials":6877,"activeCount":76},[],{"trials":6879,"activeCount":76},[],{"trials":6881,"activeCount":76},[],{"trials":6883,"activeCount":76},[],{"trials":6885,"activeCount":76},[],{"trials":6887,"activeCount":76},[6888],{"nctId":6889,"briefTitle":6890,"status":86,"phases":6891,"primaryCompletion":6892,"completion":6892,"start":6893,"enrollment":1553,"conditions":6894,"interventions":6895},"NCT04650152","Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)",[],"2021-11-12","2020-10-27",[880,633],[6874],{"intervention":6897,"totalTrials":106,"cells":6898},"Amiodarone",{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6903,"PHASE3":6905,"PHASE4":6907,"NA":6909},{"trials":6900,"activeCount":76},[],{"trials":6902,"activeCount":76},[],{"trials":6904,"activeCount":76},[],{"trials":6906,"activeCount":76},[],{"trials":6908,"activeCount":76},[],{"trials":6910,"activeCount":76},[6911],{"nctId":6912,"briefTitle":6913,"status":263,"phases":6914,"primaryCompletion":6915,"completion":1889,"start":1215,"enrollment":5988,"conditions":6916,"interventions":6917},"NCT01276093","Pulmonary Vein Ablation Versus Amiodarone in the Elderly",[70],"2015-12",[36],[6897],{"intervention":6919,"totalTrials":106,"cells":6920},"Omacor",{"EARLY_PHASE1":6921,"PHASE1":6923,"PHASE2":6925,"PHASE3":6927,"PHASE4":6929,"NA":6931},{"trials":6922,"activeCount":76},[],{"trials":6924,"activeCount":76},[],{"trials":6926,"activeCount":76},[],{"trials":6928,"activeCount":76},[],{"trials":6930,"activeCount":76},[],{"trials":6932,"activeCount":76},[6933],{"nctId":6934,"briefTitle":6935,"status":86,"phases":6936,"primaryCompletion":6937,"completion":6937,"start":6938,"enrollment":6299,"conditions":6939,"interventions":6941},"NCT03415152","A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy",[],"2019-07-01","2018-01-24",[6940,880],"History of Myocardial Infarction",[6919],{"intervention":6943,"totalTrials":106,"cells":6944},"AndroGel (testosterone gel) 1%",{"EARLY_PHASE1":6945,"PHASE1":6947,"PHASE2":6949,"PHASE3":6951,"PHASE4":6953,"NA":6955},{"trials":6946,"activeCount":76},[],{"trials":6948,"activeCount":76},[],{"trials":6950,"activeCount":76},[],{"trials":6952,"activeCount":76},[],{"trials":6954,"activeCount":76},[],{"trials":6956,"activeCount":76},[6957],{"nctId":6958,"briefTitle":6959,"status":86,"phases":6960,"primaryCompletion":2163,"completion":2163,"start":4259,"enrollment":6961,"conditions":6962,"interventions":6963},"NCT01143818","ESPRIT Study in Hypogonadal Men",[],1053,[3667],[6943],{"intervention":6965,"totalTrials":106,"cells":6966},"Niacin",{"EARLY_PHASE1":6967,"PHASE1":6969,"PHASE2":6971,"PHASE3":6973,"PHASE4":6975,"NA":6977},{"trials":6968,"activeCount":76},[],{"trials":6970,"activeCount":76},[],{"trials":6972,"activeCount":76},[],{"trials":6974,"activeCount":76},[],{"trials":6976,"activeCount":76},[],{"trials":6978,"activeCount":76},[6979],{"nctId":6980,"briefTitle":6981,"status":86,"phases":6982,"primaryCompletion":6983,"completion":6983,"start":5267,"enrollment":551,"conditions":6984,"interventions":6985},"NCT01200160","Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America",[],"2012-05",[879],[6965],{"intervention":6987,"totalTrials":106,"cells":6988},"Zemplar iv",{"EARLY_PHASE1":6989,"PHASE1":6991,"PHASE2":6993,"PHASE3":6995,"PHASE4":6997,"NA":6999},{"trials":6990,"activeCount":76},[],{"trials":6992,"activeCount":76},[],{"trials":6994,"activeCount":76},[],{"trials":6996,"activeCount":76},[],{"trials":6998,"activeCount":76},[],{"trials":7000,"activeCount":76},[7001],{"nctId":7002,"briefTitle":7003,"status":86,"phases":7004,"primaryCompletion":1640,"completion":1640,"start":255,"enrollment":7005,"conditions":7006,"interventions":7007},"NCT01084538","Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis",[],181,[512],[6987],{"intervention":7009,"totalTrials":106,"cells":7010},"Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.",{"EARLY_PHASE1":7011,"PHASE1":7013,"PHASE2":7015,"PHASE3":7017,"PHASE4":7019,"NA":7021},{"trials":7012,"activeCount":76},[],{"trials":7014,"activeCount":76},[],{"trials":7016,"activeCount":76},[],{"trials":7018,"activeCount":76},[],{"trials":7020,"activeCount":76},[],{"trials":7022,"activeCount":76},[7023],{"nctId":7024,"briefTitle":7025,"status":86,"phases":7026,"primaryCompletion":1674,"completion":1674,"start":255,"enrollment":6055,"conditions":7027,"interventions":7028},"NCT01107535","Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection",[],[3308],[7009],{"intervention":7030,"totalTrials":106,"cells":7031},"Aspirin 100mg",{"EARLY_PHASE1":7032,"PHASE1":7034,"PHASE2":7036,"PHASE3":7038,"PHASE4":7040,"NA":7042},{"trials":7033,"activeCount":76},[],{"trials":7035,"activeCount":76},[],{"trials":7037,"activeCount":76},[],{"trials":7039,"activeCount":76},[],{"trials":7041,"activeCount":76},[],{"trials":7043,"activeCount":76},[7044],{"nctId":7045,"briefTitle":7046,"status":86,"phases":7047,"primaryCompletion":7048,"completion":7048,"start":7049,"enrollment":7050,"conditions":7051,"interventions":7052},"NCT04069156","The ARIES HeartMate 3 Pump IDE Study",[70],"2023-08-10","2020-07-14",628,[30],[7030],{"intervention":7054,"totalTrials":106,"cells":7055},"Leuprolide acetate",{"EARLY_PHASE1":7056,"PHASE1":7058,"PHASE2":7060,"PHASE3":7062,"PHASE4":7064,"NA":7066},{"trials":7057,"activeCount":76},[],{"trials":7059,"activeCount":76},[],{"trials":7061,"activeCount":76},[],{"trials":7063,"activeCount":76},[],{"trials":7065,"activeCount":76},[],{"trials":7067,"activeCount":76},[7068],{"nctId":7069,"briefTitle":7070,"status":86,"phases":7071,"primaryCompletion":317,"completion":317,"start":559,"enrollment":7072,"conditions":7073,"interventions":7074},"NCT00056654","Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer",[70],164,[1536],[7054],{"intervention":7076,"totalTrials":106,"cells":7077},"leuprolide",{"EARLY_PHASE1":7078,"PHASE1":7080,"PHASE2":7082,"PHASE3":7084,"PHASE4":7086,"NA":7088},{"trials":7079,"activeCount":76},[],{"trials":7081,"activeCount":76},[],{"trials":7083,"activeCount":76},[],{"trials":7085,"activeCount":76},[],{"trials":7087,"activeCount":76},[],{"trials":7089,"activeCount":76},[7090],{"nctId":7091,"briefTitle":7092,"status":86,"phases":7093,"primaryCompletion":4375,"completion":4375,"start":611,"enrollment":7094,"conditions":7095,"interventions":7097},"NCT01081873","Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer",[],2717,[7096],"Prostatic Neoplasm",[7076],{"intervention":6549,"totalTrials":106,"cells":7099},{"EARLY_PHASE1":7100,"PHASE1":7102,"PHASE2":7104,"PHASE3":7106,"PHASE4":7108,"NA":7110},{"trials":7101,"activeCount":76},[],{"trials":7103,"activeCount":76},[],{"trials":7105,"activeCount":76},[],{"trials":7107,"activeCount":76},[],{"trials":7109,"activeCount":76},[],{"trials":7111,"activeCount":76},[7112],{"nctId":6544,"briefTitle":6545,"status":86,"phases":7113,"conditions":7114,"interventions":7115},[70],[1731],[6549,6452],{"intervention":6597,"totalTrials":106,"cells":7117},{"EARLY_PHASE1":7118,"PHASE1":7120,"PHASE2":7122,"PHASE3":7124,"PHASE4":7126,"NA":7128},{"trials":7119,"activeCount":76},[],{"trials":7121,"activeCount":76},[],{"trials":7123,"activeCount":76},[],{"trials":7125,"activeCount":76},[],{"trials":7127,"activeCount":76},[],{"trials":7129,"activeCount":76},[7130],{"nctId":6590,"briefTitle":6591,"status":86,"phases":7131,"primaryCompletion":6593,"completion":6593,"start":6594,"conditions":7132,"interventions":7133},[70],[6579,1731],[6597,656,6598],{"intervention":6598,"totalTrials":106,"cells":7135},{"EARLY_PHASE1":7136,"PHASE1":7138,"PHASE2":7140,"PHASE3":7142,"PHASE4":7144,"NA":7146},{"trials":7137,"activeCount":76},[],{"trials":7139,"activeCount":76},[],{"trials":7141,"activeCount":76},[],{"trials":7143,"activeCount":76},[],{"trials":7145,"activeCount":76},[],{"trials":7147,"activeCount":76},[7148],{"nctId":6590,"briefTitle":6591,"status":86,"phases":7149,"primaryCompletion":6593,"completion":6593,"start":6594,"conditions":7150,"interventions":7151},[70],[6579,1731],[6597,656,6598],{"intervention":7153,"totalTrials":106,"cells":7154},"Medical Management",{"EARLY_PHASE1":7155,"PHASE1":7157,"PHASE2":7159,"PHASE3":7161,"PHASE4":7163,"NA":7165},{"trials":7156,"activeCount":76},[],{"trials":7158,"activeCount":76},[],{"trials":7160,"activeCount":76},[],{"trials":7162,"activeCount":76},[],{"trials":7164,"activeCount":76},[],{"trials":7166,"activeCount":76},[7167],{"nctId":7168,"briefTitle":7169,"status":86,"phases":7170,"primaryCompletion":2372,"completion":5728,"start":1452,"enrollment":7171,"conditions":7172,"interventions":7174},"NCT01288976","ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe",[],721,[7173],"Mitral Valve (MV) Regurgitation",[7153],{"intervention":7176,"totalTrials":106,"cells":7177},"OMM",{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7182,"PHASE3":7184,"PHASE4":7186,"NA":7188},{"trials":7179,"activeCount":76},[],{"trials":7181,"activeCount":76},[],{"trials":7183,"activeCount":76},[],{"trials":7185,"activeCount":76},[],{"trials":7187,"activeCount":76},[],{"trials":7189,"activeCount":76},[7190],{"nctId":7191,"briefTitle":7192,"status":86,"phases":7193,"primaryCompletion":1889,"completion":3836,"start":875,"enrollment":542,"conditions":7194,"interventions":7195},"NCT01452802","Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management",[],[30],[7176]]